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Abstract
HIV has disproportionately affected southern Africa. This region, which comprises 2% of the
worlds population, is home to an estimated 34% of all people living with HIV, 29% of new HIV
infections globally in 2010, and 30% of AIDS-related deaths. A strengthened response to the
epidemic by countries in southern Africa in recent years has brought life-prolonging antiretroviral
therapy to the majority of those in need of treatment, and declines from peak levels of HIV
incidence over the past decade are a reason for optimism. But, in 2010, 770,000 new HIV
infections occurred. A better understanding of why the epidemic has spread so severely in this
region is required to inform strategies to reduce and eventually eliminate new HIV infections.
This thesis uses data analysis and mathematical modelling to understand the interaction be-
tween behavioural and biological factors that may have contributed to the spread of HIV in
southern Africa, and the implications of these for controlling the epidemic. It focuses specif-
ically on two topics of recent attention for public health decision makers in southern Africa:
concurrent sexual partnerships and HIV treatment as prevention. Chapters explore the inter-
action between high HIV infectiousness during primary HIV infection and concurrent sexual
partnerships, describe and evaluate a consensus indicator for concurrency, develop a method to
adjust for high levels of missing data in sexual behaviour surveys and examine trends in sexual
behaviours in a high HIV prevalence population in South Africa, create a mathematical model
to examine the potential impact of antiretroviral therapy on HIV incidence in hyperendemic
settings, and systematically compare the predictions of twelve different mathematical models
of the impact of HIV treatment as prevention in South Africa. Taken together, through these
topics we come to understand more broadly the complexity of the epidemiological context in
which HIV spreads in southern Africa.
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1 Introduction
The condition now known as Acquired Immunodeficiency Syndrome (AIDS) was first identified
in a series of case reports of Kaposi’s sarcoma and pneumocystis pneumonia in homosexual
men in New York City and Los Angeles in 1981 [1]. Scientific progress into understanding the
syndrome was rapid in the early 1980s. Human Immunodeficiency Virus, Type-1 (HIV-1) was
isolated and determined to be the viral agent causing AIDS in 1983 [2, 3], and less than two years
later in March 1985 the United States Food and Drug Administration (FDA) approved the first
test for HIV antibodies in blood [4]. The identification of AIDS in homosexual men shaped the
initial public perception of the epidemic, but epidemiological analysis soon determined that the
virus was also transmitted heterosexually, that this was the most common mode of transmission
in sub-Saharan Africa [5–7], and that the emergence of the epidemic in central Africa predated
that in the West [8].
At the same time as much was being learnt about the the epidemiology, immunology, and
pathology of HIV and AIDS, HIV was silently and steadily spreading from central and eastern
Africa to southern Africa [9]. In the mid-1980s, central Africa was the most severely affected re-
gion, with uncertain indication of what would follow [8]. HIV transmission exploded in southern
Africa in the late 1980s and early 1990s. By the time that anonymous sentinel surveillance was
established in Zimbabwe in 1990, HIV prevalence amongst women attending antenatal clinics
in urban areas was estimated to be between 15% and 30% [10]. In South Africa, where the
epidemic occurred later, prevalence among pregnant women was estimated to be less than 1%
in 1990, but increased to 8% in 1994 and over 20% by 1998 [11]. This explosion was anticipated
by some [12], but opportunities to intervene early were missed and the severity was sobering. By
the mid-1990s it became clear that the countries of Botswana, Lesotho, South Africa, Swaziland,
Zambia, and Zimbabwe would comprise the most affected region in the world.
For high-income countries, 1996 marked a turning point in the epidemic. At the international
AIDS conference in Vancouver, preliminary positive results were presented about treatment
with combinations of three antiretroviral drugs [13]. The first antiretroviral for the treatment
of HIV, zidovudine or AZT, had been approved by the FDA in 1987 [4], but in 1993 the
Concorde trial found that immediate AZT treatment did not affect progression to AIDS after
three years, due to the rapid evolution of resistance to the monotherapy [14]. The year after the
Vancouver conference, the full trial results showed conclusively that the three drug combinations
including a protease inhibitor were more effective at long-term suppression of plasma HIV-RNA
levels below the detectable level and staving off AIDS and death than the combination of two
nucleoside analog reverse transcriptase inhibitors (NRTIs) that had been the standard of care
[15, 16]. AIDS mortality fell almost immediately in the United States and Europe [17, 18], and
was sustained [19].
In 1998, global attention was drawn to southern Africa, where prevalence continued to in-
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crease unabated and the expensive life-saving antiretrovirals were not available, by the recently
formed Joint United Nations Programme on HIV/AIDS [20]. At the turn of the millennium,
AIDS in sub-Saharan Africa was becoming recognised as a priority for global health, develop-
ment, and, importantly for the response to follow, security [21]. This recognition prompted
the establishment of the multilateral Global Fund to Fight AIDS, Tuberculosis, and Malaria in
2002 and unilateral United States President’s Emergency Plan for AIDS Relief (PEPFAR) in
2003, each with dual mandates to both treat and prevent HIV infections in the most severely
affected low- and middle-income countries. Led by these programmes, global spending on HIV
and AIDS in low- and middle-income countries increased from just US$1.4 billion in 2000 to an
estimated US$16.8 billion in 2011 [22]. As a result, nearly 6.2 million people in sub-Saharan
Africa were receiving antiretroviral therapy at the end of that year, representing coverage of
an estimated 56% of those in need of treatment according to the WHO recommendation that
individuals should receive treatment when their CD4 cell count, an indicator of the effect of
HIV on the immune system [23], falls below 350 cells/µl [22].
The repsonse to the epidemic in southern Africa varied from country to country. In Zimbabwe,
AIDS education and prevention curricula, mass-media campaigns focusing on partner reduction
and condom promotion, and community mobilisation around AIDS occurred in the early 1990s.
A comprehensive review of evidence concluded that these efforts “probably” contributed to
declining rates of HIV incidence from around 1990 and a commensurate steep decline in adult
HIV prevalence from an estimated 29% in 1997 to 16% in 2007 [24]. HIV incidence appears to
have stabilised now and may have increased slightly during the peak of the economic crisis in
2008, based on data from eastern Zimbabwe [25].
Botswana was the first country in the region to commit to universal access to antiretroviral
therapy, pledging in 2001 to provide treatment for all those in need. The initial scale-up
was relatively slow, but accelerated dramatically in 2004 to 2006, today achieving the highest
coverage of those in need of treatment of any country in sub-Saharan Africa, an estimated
93% at the end of 2010, with Namibia not far behind at an estimated 90% [26]. Lessons from
the Botswana experience have been studied and applied as other countries in the region have
scaled-up treatment [27, 28].
In South Africa, the response to the epidemic was hampered by misguided political leadership
that embraced fringe theories that HIV was not the cause of AIDS and that antiretrovirals
were toxic and harmful, prompting the Durban Declaration signed by over 5000 scientists and
doctors reaffirming that HIV is the cause of AIDS [29]. Public access to antiretrovirals for the
prevention of mother-to-child transmission was the result not of a political decision, but a legal
victory in the Constitutional Court by the activist group the Treatment Action Campaign over
the government [30]. The government committed to public sector provision of antiretroviral
therapy in 2003 [31], but the roll-out of this program was frustratingly slow for many years.
Coordinated HIV prevention efforts were similarly stagnant, but estimates suggest that the
adult HIV incidence rate in South Africa peaked sometime between 1997 and 2000 [32], largely
attributable to increases in condom usage [33]. Since 2009, the new administration has reversed
course and implemented an aggressive expansion of HIV testing and treatment [34], surpassing
targets defined in the 2006 National Strategic Plan [35].
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In spite of the positive increases in access to treatment and declines in incidence over the past
decade across the region, in 2010 an estimated 770,000 new HIV infections occurred in southern
Africa [36]. This underscores the need for improved strategies for preventing the spread of
HIV, supported by a better understanding of why HIV has spread so widely in the general
population in this region while it has remained mostly constrained to populations exhibiting
specific ‘high-risk’ behaviours elsewhere in the world.
1.1 Factors affecting the spread and control of HIV in southern
Africa
Returning to first principles, the necessary and sufficient condition for an epidemic to spread
is that on average each individual who becomes infected transmits the infection to at least
one more person. The average number of individuals that an infected person will infect in a
population where everyone is susceptible is referred to as R0 [37].
1 The key determinants of
R0 are the rate of contacts between infected and susceptible individuals, the probability that
transmission of the infection results from such a contact, and the duration of the infection
[39]. For a very simple model of the spread of an infectious agent in which all members of
the population mix randomly and the infectiousness of the pathogen is the same for the entire
duration of the infection, the product of these quantities is exactly R0. In more complicated
systems where patterns of contact are more complex and infectiousness varies, such as HIV,
translating these quantities into R0 is more complicated, but they remain the key ingredients
to the spread of the an epidemic. Controlling an epidemic requires affecting one or more of
these quantities so that, on average, each infected person transmits the infection to less than
one additional person [37].
The natural duration of HIV infection of between eleven and twelve years in sub-Saharan
Africa is remarkably similar to that which has been measured in other epidemic settings [40],
so differences in the duration of infection are unlikely to have been an important factor in
the differential spread of HIV. There are a number of factors that have been hypothesised to
increase the probability of HIV transmission during a sexual contact between a susceptible and
infectious individual in parts of sub-Saharan Africa, either by increasing the infectiousness of an
infected individual, or increasing the susceptibility of an uninfected individual. One of the first
epidemiological risk factors identified for heterosexual HIV acquisition in sub-Saharan Africa
was the presence of other sexually transmitted infections (STIs)[41, 42]. An extensive body
of research has supported that both ulcerative and non-ulcerative STIs increase both the risk
of HIV acquisition and transmission [43–45], the latter likely by increasing genital shedding of
HIV [46]. Observational, ecological, and randomised controlled trial data have found that lack
of male circumcision increases the risk of HIV acquisition in adult men [47–49]. Heterosexual
anal intercourse increases the risk of HIV transmission compared to vaginal intercourse [50],
and may be more common in parts of sub-Saharan Africa than other regions, but is a sensitive
topic about which to collect information [51]. Prospective studies have shown that bacterial
1The concept of a reproductive threshold has roots in ecological and demographic modelling, but the first
application of R0 in epidemiology is typically attributed to George MacDonald in the 1952 paper The analysis
of equlibrium in malaria [38]. This paper is not easily retrievable, however.
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vaginosis, which is common amongst women in southern and eastern Africa, increases the risk
of HIV acquisition [52, 53] and transmission [54]. Use of injectable hormonal contraceptives,
which are the most widely used form of contraception in southern Africa, has been associated
with increased risk of incident HIV infection in women [55, 56] and HIV transmission to men
[56]. Intravaginal practices practised in some regions of sub-Saharan Africa such as douching
and ‘dry sex’ are associated with increased risk of HIV acquisition, with the hypothesis that this
effect may be mediated by increased risk of bacterial vaginosis, but a causal pathway has not
been demonstrated [57, 58]. The presence of other infections endemic in southern and eastern
Africa such as malaria, tuberculosis, or schistosomiasis increase HIV viral load, facilitating HIV
transmission, or weaken the immune system, facilitating HIV acquisition, but prospective data
have not associated these factors with HIV incidence [59, 60]. Differences in viral subtype have
been hypothesised to also potentially enhance the spread of HIV in southern Africa [61].
While data suggest that in aggregate those in Africa do not have more sexual partners in
their lifetime than those in other regions of the world [62], there are also many behavioural
factors hypothesised to have increased the formation of sexual partnerships between susceptible
and infected individuals. Some of these include the presence of specific high-risk and highly
mobile populations such as female sex workers, truck drivers, and migrant labourers that allow
the virus to rapidly spread [41, 63, 64], large age differences between sexual partners [65–67],
gender power imbalances that compel or force young women into higher-risk sexual relationships
[68, 69], overall low levels of marriage, high rates of divorce and remarriage, and later age at first
marriage in southern Africa [70–73], and the practice of having ‘concurrent’ sexual partnerships
[74, 75].
Each of these biological and behavioural determinants generates a hypothesis for a poten-
tial avenue for intervening to reduce the further spread of HIV—for example, the increased
risk associated with sexually transmitted infections suggests treating sexually transmitted in-
fections could reduce HIV transmission, the risk associated with lack of circumcision suggests
a potential benefit of mass male circumcision programmes, and the finding that women are
forced into unwanted sexual relationships suggests that interventions to empower women could
reduce HIV incidence. There are other technologies that intend to reduce the probability of
HIV transmission, such as condoms, diaphragms, vaginal microbicide gels, antiretrovirals and
vaccines. But two decades of largely frustrating HIV prevention research has clarified that being
identified as a risk factor for HIV transmission does not necessarily translate into a successful
HIV prevention target [76–78]. After one early community-randomised trial of improved treat-
ment of sexually transmitted diseases reduced HIV incidence [79], two subsequent trials failed
to find any benefit [80, 81], and, in later trials, HSV-2 suppressive therapy did not reduce HIV
acquisition [82, 83], or HIV transmission in discordant couples [84]. Multiple co-formulations of
vaginal microbicides failed to reduce infections in women [85]. Through 2008, three randomised
controlled trials that estimated male circumcision reduces the risk of HIV acquisition for adult
men by around 60% [86–88] were the only example of an identified epidemiological risk factor
for adult heterosexual HIV transmission in southern Africa that had been translated into an
implementable HIV prevention intervention.
While changes in sexual behaviour have effected sharp reductions in HIV incidence and preva-
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lence in Uganda and Zimbabwe [89, 90], behavioural interventions, including HIV and sexual
health interventions amongst adolescents [91, 92] and peer-education and condom distribution
amongst sex-workers and male clients [93], have not been effective at catalysing behaviour
change to reduce HIV incidence in randomised controlled trials. Structural HIV interventions
also seek to reduce the spread of HIV through changing sexual behaviour or increasing the use
of prevention technologies, but rather than focusing on these behaviours themselves, they seek
to alter the socio-economic context that encourages risk behaviour, often by producing other
desireable social outcomes such as poverty alleviation, increased education, and reducing gen-
der power inequalities [78]. A structural intervention trial seeking to reduce gender inequalities
through a microfinance intervention for women reduced reports of domestic violence, but not
HIV incidence [94]. Other interventions that must be considered by policy makers lack sufficient
epidemiological and efficacy data to inform evidence-based decisions [95].
A priority for biomedical HIV prevention since the isolation of the virus has been, and re-
mains, a highly efficacious HIV vaccine [96, 97]. The development of vaccines for other infectious
diseases have been responsible for dramatic improvements in public health and life expectancy
over the past century, and historically vaccines have been attractive because they can be admin-
istered once or a few times to confer a high level of protection for many years or life-long [98].
In 1997, President Bill Clinton set a target to develop an HIV vaccine within ten years [99],
but development of a vaccine has been more challenging than expected because HIV does not
produce known natural immunity to be stimulated by a vaccine, the usual strategy for vaccine
development [100]. The reporting of a 31% efficacy in a modified intention-to-treat analysis
of the RV144 vaccine trial conducted in Thailand [101] testing a prime-boost vaccine strategy
combining a previously-tested inefficacious vaccine with a vaccine candidate not judged suffi-
ciently immunogenic to proceed to an efficacy trial [102] has produced new information about
correlates of HIV protection that will generate hypotheses for future vaccine development [103],
but is unlikely to lead directly to a vaccine candidate of sufficient efficacy to seek licensure [104].
Today, even vaccine optimists believe that we are ten to fifteen years from production of a vac-
cine [76], necessitating the development of other prevention strategies to stem new infections in
the meantime.
Since 2010, the toolbox of efficacious HIV prevention interventions has expanded due to
a series of successful trials using antiretrovirals to prevent HIV transmission by those already
infected or HIV acquisition of those not infected [76]. The HPTN 052 trial compared HIV trans-
mission in HIV serodiscordant couples in which the HIV infected partner was randomised to
either begin antiretroviral therapy immediately, at CD4 cell count between 350 and 550 cells/µl,
or delay treatment until the infected partner’s CD4 cell count fell below 250 cells/µl or developed
symptoms related to AIDS. In the delayed treatment arm, 27 linked HIV infections occurred
while only one linked transmission was observed in the immediate treatment arm, resulting in
an estimated 96% reduction in HIV transmission for those receiving ART [105]. The single
transmission in the immediate treatment arm was estimated to have occurred within days of
enrolment in the trial, before viral load suppression would have occurred. Using antiretrovirals
for the prevention of HIV acquisition, the CAPRISA 004 trial in South Africa demonstrated
39% efficacy for a vaginal microbicide gel formulated with antiretroviral compounds to pre-
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vent HIV infection in HIV uninfected women in KwaZulu-Natal province, South Africa [106].
Randomised controlled trials of oral pre-exposure prophylaxis (PrEP) have demonstrated that
oral antiretrovirals taken daily by uninfected individuals can prevent HIV acquisition in men
who have sex with men [107], heterosexual serodiscordant couples in Kenya and Uganda [108],
and sexually active adult men and women in Botswana [109]. These successes are contrasted
with the lack of efficacy of oral PrEP for African women in the FEM-PrEP trial [110] and the
discontinuation for reason of futility of two arms of the VOICE (MTN-003) trial testing an
antiretroviral based vaginal microbicide and single-drug oral PrEP [111]. These contradicting
results are mainly attributed to differences in adherence between the trials, emphasising the
importance of behaviour in biomedical HIV prevention [112]. As a result of the successful trials,
antiretrovirals have quickly become entrenched as a component of a comprehensive HIV pre-
vention strategy [113, 114], even while debate and research continue about the most effective
use of antiretrovirals for HIV prevention in southern Africa [114–117].
1.2 Data and methods for characterising generalised HIV
epidemics
The data and analytical methods that have been used to understand, estimate, and project
the AIDS epidemic have evolved as the epidemic progressed, scientific knowledge has improved,
and more resources have become available [118]. Coordinated international HIV surveillance
efforts undertaken as part of the global response to HIV and AIDS have resulted in HIV being
one of the more precisely characterised disease burdens globally [119]. Early data about HIV
and AIDS, both in high-income settings and sub-Saharan Africa, consisted of case reports
of AIDS in hospital patients and counts of AIDS mortality [5–7]. These data were used for
classical epidemiological analyses identifying characteristics of individuals acquiring AIDS and
comparing distributions with the general population to hypothesise risk factors for the spread
of the virus. Small-scale surveillance of at-risk groups in central and eastern Africa such as
attendees of sexually transmitted disease clinics and a cohort of female sex workers in Nairobi
allowed case-control studies to determine risk factors for HIV infection [42, 120–122].
In the United States, reliable population-level data on HIV and AIDS was available from
death registration which provided trends in mortality due to AIDS, and HIV diagnosis was
made notifiable in all 50 states [123]. In sub-Saharan Africa and elsewhere in low- and middle-
income settings, few countries had complete or reliable vital registration systems, necessitating
other strategies for HIV and AIDS surveillance. In 1989, the World Health Organization Global
Programme on AIDS issued the first international guidelines for HIV surveillance [124]. These
guidelines outlined a strategy for sentinel surveillance of HIV prevalence using unlinked anony-
mous testing of blood samples routinely collected for other purposes. The guidelines led to the
establishment of surveillance of HIV prevalence in pregnant women attending antenatal clinics
in every country in southern and eastern Africa [125]. These data remain the main source of
information about historical epidemic trends in generalised HIV epidemics. Antenatal surveil-
lance also has limitations though: they do not directly measure HIV prevalence in men, in many
countries the selection of sentinel sites was biased towards urban areas, and pregnant women
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are a selected population who are all sexually active, but could also under-represent women
with reduced fecundity due to AIDS [126–128].
Around the same time the WHO Global Programme on AIDS also undertook the first coor-
dinated effort to survey population-level data about sexual behaviour in response to the HIV
pandemic, drawing on the experience of surveillance of fertility and contracepting behaviour to
monitor progress of family planning programmes in the 1970s [129]. The indicators reported
in the results of this endeavour—age at first sex, patterns of marriage and polygyny, multiple
sexual partnerships, sexual behaviour before, within, and outside marriage, casual and commer-
cial sex, sex in exchange for goods or money, and condom use [130]—reflect many of the same
indicators that are used today to monitor sexual risk behaviour in the context of HIV epidemics
[131].
Shortly thereafter, the first of a number of population-based cohort studies that regularly con-
duct demographic, behavioural, and HIV surveillance of an entire population of a geographically
defined area were established. These longitudinal studies have provided information about the
patterns of HIV spread in the general population [132, 133], and importantly about HIV in men
about which data is not available from antenatal surveillance, the demographic and socioeco-
nomic consequences of generalised HIV epidemics [134–136], the natural history of HIV infection
[40, 137–139], and risk factors for HIV transmission [140–143], and served as a foundation for
the conduct of HIV intervention randomised trials [79–81, 93]. Collaborative and comparative
analyses of these data have identified aspects of HIV epidemiology that are generalisable across
epidemic settings in southern and eastern Africa and areas of variation that could be responsible
for different national and sub-national patterns of HIV spread [72, 144–146].
In 2000, the World Health Organization published guidelines for strengthened ‘second genera-
tion surveillance’ strategies for monitoring HIV epidemics [147]. Second generation surveillance
focused on tailoring HIV surveillance systems to different HIV epidemic types, linking surveil-
lance of HIV biomarkers with behavioural risk factor data, strengthening monitoring of epidemic
and behavioural trends, and improving the use of surveillance data to plan HIV prevention and
care services. The principles underlying second generation surveillance motivated the inclusion
of HIV serostatus testing and expansion of survey questions related to risks and consequences
of HIV infection in nationally-representative household surveys such as the Demographic and
Health Surveys [148, 149]. These surveys, for the first time, provided an estimate of HIV preva-
lence from in the adult population sampled to be statistically representative of the national
population in many countries in sub-Saharan Africa. There are concerns about biases in HIV
estimates from these data as well; concerns include that the household-based sampling frame
may systematically exclude populations at particularly high risk of infection, such as workers
living in hostels, army barracks, or institutionalised populations, and that highly mobile popula-
tions may be more likely to be unable to be contacted for the survey and hence underrepresented
[144]. In the household-based surveys, unlike antenatal clinic surveillance where HIV testing
is anonymous and unlinked, HIV status information is linked to behavioural data and requires
informed consent, which creates another potential bias if some groups are systematically more
likely to refuse to participate. For example, in some cases it has been shown that individu-
als who know that they are HIV infected are more likely to refuse in subsequent surveillance
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[150–152].
Other valuable sources of data are clinical cohorts that longitudinally monitor patients before
and after they initiate antiretroviral therapy, which provide information about the prognosis
of patients on ART, the effectiveness of ART programmes, and antiretroviral resistance and
switching to second-line therapies [153–155]. Consortia of cohorts that identify and follow HIV
seroconverters from the time they become infected have been particularly helpful for char-
acterising the natural history of HIV infection [156, 157]. HIV epidemiology and prevention
studies have also made use of designs for randomised trials such as cluster-randomised trials
that measure the effect of biomedical, behavioural, or structural interventions to reduce HIV
incidence in whole communities [79–81, 91, 93, 94, 158–161] and trials conducted amongst HIV
serodiscordant couples designed to specifically test the efficacy of technologies to prevent HIV
transmission [84, 105, 108]. Genetic methods to determine with high certainty whether an ob-
served HIV transmission event occurred in the couple enrolled in a trial have further increased
the power of this study design [162, 163].
Strategies for HIV surveillance are continuing to evolve. Antiretroviral therapy complicates
the use of HIV prevalence as the main metric for monitoring HIV epidemic trends because the
life-prolonging benefits of ART mean that overall increases in prevalence could either indicate
the success of antiretroviral therapy programmes, or the failure of HIV prevention programmes.
This makes the measurement of HIV incidence more essential for surveillance. The reason that
prevalence has been used thus far is that the measurement of incidence requires longitudinal
data which time consuming, expensive, and challenging to collect, and potentially subject to
greater bias than cross-sectional measures of HIV prevalence due to loss to follow-up. Model-
based estimates of HIV incidence using serial cross-sectional age-specific prevalence surveys
in the same population have been validated using longitudinal data [164], but these methods
also require adjustment to account for the effect of ART. Progress is being made toward the
development of reliable HIV incidence assays that can detect recent HIV infections [165, 166].
This would theoretically enable estimation of HIV incidence from a single cross-sectional survey,
such as nationally-representative household surveys. A final current innovation in surveillance
technology is the inclusion of phylogenetic data that reconstruct sequence and timing of HIV
transmissions by assessing the similarity between viruses and using information about the rate
of mutation of the virus [167, 168].
Mathematical modelling has been used since very early in the epidemic to interpret surveil-
lance data and project the course and impact of the epidemic [169, 170]. The approaches to
modelling the HIV epidemic have been guided by the available data [118]. In the early years of
the epidemic, surveillance data consisted mostly of data on AIDS case notifications and deaths.
This inspired the development of ‘back-calculation’ methods that combined reported numbers
of cases with information about the duration from infection to AIDS or death to estimate the
size of the epidemic and historical trends in incidence [171, 172]. The establishment of antenatal
clinic sentinel surveillance made HIV prevalence the preferred data source for monitoring HIV
epidemics, and mathematical modelling strategies were developed that dynamically simulated
HIV transmission to produce epidemic curves which could be calibrated to observed levels of
HIV prevalence [173].
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As knowledge about the natural history and epidemiology of HIV improved, mathematical
models have become more complex to reflect this, as it was predicted that they would and
should [172]. Some early examples include the understanding of the importance of heterogeneous
levels of sexual risk behaviour on the dynamics of the epidemic [174–176], and variation in the
infectiousness over the duration of infection [177, 178].
Mathematical modelling methodologies are often broadly classified as ‘deterministic’ models
that use differential equations to represent the transmission dynamics of HIV between infected
and susceptible individuals, and ‘individual-based’ or ‘microsimulation’ models that explicitly
simulate each individual, their infection status, sexual contacts, and probability of transmission.
This dichotomous classification obscures the many decisions that have to be made in choosing
a modelling strategy [179], which should ultimately be guided by the question to be asked of
the model and the data available to inform the model [180]. In addition to their arguably
most prominent and important use to synthesise surveillance data to create estimates and
projections of the burden of HIV [181–183], a very common use of mathematical models is to
simulate the potential impact of hypothetical HIV intervention strategies and policy decisions
[113, 184–189]. Models can elucidate surprising, counterintuitive, or complex empirical findings
[190, 191]. Models are also used in concert with surveillance and programmatic uptake data to
estimate the impact of previous changes intervention programmes or changes in epidemiological
context [32, 33, 192, 193]. The success of these efforts should be enhanced by the inclusion of
modelling in the initial design of evaluation strategies, as has been the case for a large multi-
sectoral HIV prevention strategy in India [194] and three upcoming randomised clinical trials
of combination HIV prevention programmes in southern and eastern Africa [116].
In recent years, developments in approaches to mathematical modelling of HIV epidemics have
followed two main directions. The first is statistically rigorous calibration of model parame-
ters based on observed epidemic data and prior parameter ranges informed from the literature,
often using a Bayesian statistical paradigm [192, 193, 195, 196]. Well calibrated models that
incorporate statistical uncertainty in the data and model inputs into their projections increase
confidence in the conclusions of model analyses, with the caveat that important factors could still
be omitted from the model altogether. The other prevailing trend in modelling of HIV epidemics
has been towards more detailed individual-based simulation models that include mechanistic
representations of the population-level and in vivo processes that determine HIV transmission,
progression, morbidity, and mortality [197–203]. Such models permit more flexibility in the
implementation of processes and allow investigation of complex interactions between interven-
tions and epidemic processes, for example the examination of different virological monitoring
guidelines on the transmission of HIV drug resistance [203, 204], but it can also be challenging
to comprehend, critique, and replicate these models due to the level of complexity.
1.3 Content of this thesis
Taken together, the conclusion of three decades of research is that the hyperendemic spread
of HIV in southern Africa is almost certainly the result of all of biological, behavioural, and
structural socio-economic factors [205, 206]. Historically, public health has relied the discovery
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of single highly-efficacious interventions such as clean water and sanitation, vaccines, and an-
tibiotics to control infectious diseases [207]. But, due to the diversity of factors that contribute
to the spread of HIV in southern Africa and the complexities these present for HIV prevention,
a single ‘silver bullet’ prevention strategy is unlikely to emerge in the immediate future, neces-
sitating a multifaceted ‘combination’ approach to HIV prevention to alleviate the spread of new
HIV infections [21, 113, 208].
This thesis uses mathematical modelling and data analysis to understand how these factors
interact to create these epidemics, how they affect the future course of the epidemic, and
the implications for efforts to control the epidemics. It focuses particularly on two topics of
recent attention for public health decision makers in southern Africa, and topics which stand
to benefit from further synthesis and quantitative analysis—concurrent sexual partnerships and
HIV treatment as prevention. Through these topics, we come to understand more broadly the
complexities that simultaneously make generalised HIV epidemics so riveting academically and
so challenging epidemiologically, and the breadth of lines of enquiry that must be pursued to
mitigate the epidemic.
1.3.1 The ‘concurrency hypothesis’
Higher levels of ‘concurrent sexual partnerships’, generally understood as multiple sexual part-
nerships that overlap in time, was first suggested as an explanation for the severe spread of
HIV in sub-Saharan Africa compared to elsewhere in the world almost 20 years ago [74]. The
origins of the purported acceptability of concurrency in many parts of sub-Saharan Africa lie
in the practice of polygynous marriage (men having multiple wives) that has been and remains
common in many cultures in sub-Saharan Africa and culturally specific notions of masculinity
[209]. Concurrency, compared to having multiple sexual partners sequentially—referred to as
‘serial monogamy’—is hypothesised to promote the spread of HIV through two mechanisms
[210]. First, it reduces the time between HIV acquisition and exposure of another potentially
susceptible individual because, when partnerships are concurrent, the partnership in which HIV
was acquired does not have to end before another partnership begins in which HIV can be trans-
mitted onward. The importance of this effect is expected to be exacerbated by the period of
increased infectiousness in the first few months after HIV infection occurs [75]. Second, when
partnerships are concurrent, a partner that is acquired later can indirectly infect a previously
acquired partner, thereby removing the ‘protective sequencing’ afforded by serial monogamy in
which only partners acquired after an individual has become infected will be at risk of infection.
The evidence for the concurrency hypothesis provided by ecological studies associating con-
currency with HIV infection has been mixed. A comparison of data from three settings—rural
Uganda, Thailand, and the United States—collected during the early 1990s found that levels of
concurrency at a point in time was higher in Uganda, where the HIV epidemic was most severe
[211]. Early global sexual behavioural surveillance in response to the HIV epidemic found that
respondents in sub-Saharan African countries were much more likely to report having more than
one regular partner or spouse than those in non-African countries [75, 130]. However, within
Africa, data from the ‘Four Cities study’ did not find differences in concurrency associated with
higher levels of HIV prevalence across the five cities of Dakar, Cotonou, Yaounde´, Kisumu,
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and Ndola [212]. An ecological study comparing levels of polygyny with HIV prevalence in
20 Demogrphic and Health Surveys (DHS) conducted in sub-Saharan Africa found that HIV
prevalence was lower in survey clusters with more polygyny [213], although at the individual
level those in polygynous marriages were more likely to be infected [214]. Comparisons of con-
currency across settings and empirical evaluations of the hypothesis have been hampered by
the proliferation of different measures and indicators of concurrency used in different studies
[209, 215], which vary in their sensitivity to the exposure of epidemiological risk of concurrency
[212, 216], and some of which are ‘proxy’ measures which do not actually measure any form of
partnership overlap.
A number of epidemiological studies have tested associations between reporting concurrency
and individual HIV infection [212, 217–219], sometimes finding positive associations. However,
such an association is at odds with the theory, which predicts that concurrency should increase
the risk of transmission of HIV, but all else being equal the number of lifetime partners should
predict the individual risk of acquiring HIV, so concurrency should not increase the likelihood
of being HIV infected when adequately controlling for the number of partners [210, 220–222].
Studies involving sexual contact tracing patients with syphilis and gonorrhoea in the United
States have associated concurrency with increased risk of STI transmission [223, 224]. Conduct-
ing such studies to test concurrency as a risk factor for HIV transmission in southern Africa is
more challenging because of the long duration of HIV infection, which means that transmission
could have occurred many years before sexual behaviour is being measured, and the egocentric
nature of most of the epidemiological data typically used to examine risk factors for infection.
Lopman and colleagues found that suspecting ones partner had other sexual partners was asso-
ciated with HIV incidence in females in eastern Zimbabwe, but the association did not persist
after controlling for other risk factors [143].
Because of the challenges inherent in empirically testing the effect of concurrency on HIV
spread in generalised epidemics, mathematical modelling has played a particularly prominent
role in evaluating and communicating the concurrency hypothesis [225, 226]. Concurrency
first arose in mathematical models of STI transmission as an extension of ‘pair models’ that
explicitly model sexual partnerships to allow infection to spread more quickly than would be
possible if partnerships were forced to dissolve before another partnership was formed [227, 228].
Watts and May created a model motivated by removal of the ‘protective sequencing’ aspect of
serial monogamy [229]. The relevance of concurrency for the rapid heterosexual spread of HIV
in sub-Saharan Africa was first considered by mathematical models in a series of papers by
Martina Morris and Mirjam Kretzschmar [230, 231]. The relevance of these early models has
been questioned recently due to assumptions and parameter values that now seem unrealistic
and their focus only on the initial outbreak of infection [215, 232].
The incomplete nature of each of these streams of evidence has resulted in a great deal of
debate about the extent to which concurrent partnerships have contributed to the growth and
maintenance of severe HIV epidemics in southern Africa, with a number of self-described ‘se-
lective’ literature reviews on the topic having argued alternately that the evidence is sufficient
for reducing concurrency to be a central plank of HIV prevention strategies [209], while other
have argued that more evidence is needed [215, 232]. Nonetheless, an expert think tank meeting
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hosted by the Southern African Development Community in Maseru, Lesotho in May 2006 iden-
tified “multiple concurrent partnerships by men and women with low consistent condom use,
and in the context of low levels of male circumcision” as the key drivers of the epidemic in the re-
gion [233]. National behaviour change communication campaigns aimed at reducing concurrent
sexual partnerships have been undertaken in Botswana, Kenya, Lesotho, Malawi, Mozambique,
Namibia, South Africa, Swaziland, Tanzania, Zambia, and Zimbabwe [234]. Broad support and
sustenance of these programmes, however, will require more robust epidemiological evidence and
solid indicators of the programmes’ success at reducing concurrency. This circumstance of calls
to action and scaling-up of behaviour change communication campaigns focusing on concurrent
sexual partnerships amidst debate and uncertainty about the epidemiological importance of
concurrency is the foundation from which the research in this thesis is pursued.
1.3.2 HIV ‘treatment as prevention’
The most prominent recent addition to the HIV prevention toolkit has been the knowledge
that provision of antiretroviral therapy to HIV infected individuals reduces the likelihood of
transmitting HIV to others—HIV ‘treatment as prevention’. The prospect of using therapy to
prevent HIV transmission in addition to delaying AIDS was first broached in a mathematical
model in 1991, only shortly after the approval of zidovudine for HIV therapy [235]. Success-
ful antiretroviral therapy prevents viral replication, reducing the amount of virus in blood to
undetectable levels, so the high efficacy of antiretroviral therapy for reducing HIV transmis-
sion was predicted by the demonstration of the strong association between heterosexual HIV
transmission and serum HIV-1 RNA levels in the infected partner [137]. Enthusiasm for the
strategy has been bolstered by several observational studies and one randomised-controlled trial
showing that ART reduces the rate of HIV transmission within HIV serodiscordant couples by
over 90% [105, 236–238] and a mathematical modelling study suggesting that an extremely
aggressive strategy of mass HIV testing with immediate treatment regardless of CD4 cell count
could eliminate HIV in South Africa [185]. The precipitous decline in the price of antiretrovi-
rals in low- and middle-income countries and the simultaneous increase in global funding for
HIV treatment and prevention in these settings [239, 240] have made treatment as prevention
strategies in generalised HIV epidemics more affordable and cost-effective than they might have
once been thought to be.
While most observational and trial data have been congruous about the high individual ef-
ficacy of treatment for preventing HIV transmission2, much like the concurrency hypothesis,
ecological data from epidemic settings that have achieved high levels of HIV treatment are less
conclusive about the promise of HIV treatment to contain HIV epidemics [243, 244]. Declines
in the numbers of new HIV diagnoses or estimated HIV incidence have coincided with the in-
creases in ART provision in Vancouver [245], San Francisco [246], and Taiwan [247], but HIV
diagnoses amongst men who have sex with men have been stable or increased during the era
2The one exception is a retrospective study of HIV transmission in heterosexual serodiscordant couples in China
in which the index partner was infected through plasma donation [241]. In this study there was no difference
in HIV transmission when the infected partner was taking antiretrovirals received through routine health
care. This study highlights the importance of continuing to study the real-world effectiveness and durability
of ART to prevent HIV transmission [242].
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of high coverage of ARVs in HIV epidemics in the United Kingdom [248], France [249], and
Australia [244]. In both cases, it is hard to make strong causal statements from ecological
trends, especially when incidence is only inferred or modelled from HIV diagnoses rather than
being directly measured. New HIV diagnoses might reflect HIV infections that occurred years
previously and so might not be temporally related with the trends in HIV treatment [250].
Campaigns to improve access to ART could be accompanied by increased investments in other
prevention modalities that would create a temporal correlation but not causal association be-
tween reductions in incidence and HIV treatment [251], but improvements in ART provision
might also be accompanied by greater HIV testing efforts, which could increase diagnoses but
not reflect a true change incidence [252]. In sub-Saharan Africa, where the most common indi-
cator of the epidemic remains estimates of HIV prevalence, disaggregating the therapeutic and
preventive benefits of treatment is likely to be even more challenging due to the countervailing
survival and transmission effects of ART on HIV prevalence [32].
Maximising the epidemiological impact of HIV treatment as prevention relies critically on
successes and improvements in many other areas, something which has been recognised by the
explosion of literature on the topic [253, 254] and the diverse streams of research underway
[255]. Not least of these challenges is how to actually achieve the high levels of HIV testing,
treatment initiation, and retention and viral suppression on treatment presumed by optimistic
mathematical model projections [256, 257] in settings where health systems and budgets are al-
ready stretched by providing treatment to those presenting with clinical need for treatment. But
perhaps the most fundamental question is how the high individual efficacy of treatment as pre-
vention will translate into population-level reductions in HIV incidence for different treatment
strategies, on different time scales, and in different settings. This will depend on the interac-
tion between biological and behavioural factors that determine the epidemiological context in
which HIV spreads [258]. These estimates of the epidemiological impact of HIV treatment as
prevention underlie calculations of the affordability, cost-effectiveness, and feasibility that will
inform public health policy.
1.3.3 Organisation of the thesis
The thesis is comprised of five chapters of original substantive research. The common thread
that runs throughout the thesis is understanding how biological and behavioural factors interact
in promoting the spread and control of HIV. Chapter 2 addresses this question most directly.
The chapter reviews the approaches that have been used to modelling the role of concurrency in
the spread of HIV and then extends the influential illustrative model of Morris and Kretzschmar
[230, 259] to incorporate recent epidemiological data about variation in HIV infectiousness over
the course of infection [260]. We explore how this variation, particularly high infectiousness
during the first few months after becoming infected, affects the predictions of the concurrency
hypothesis.
Having addressed the theoretical foundation of the concurrency hypothesis in chapter 2, chap-
ter 3 considers one of the key challenges that has hampered empirical research on the hypothesis:
the proliferation of different indicators of concurrency reported throughout the literature, mak-
ing it challenging to compare estimates of concurrency across studies. The chapter describes
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a process undertaken in collaboration with the UNAIDS Reference Group on Estimates, Mod-
elling, and Projections to review the existing approaches to measuring concurrency and their
relation to the theoretical importance of concurrency, and then to convene a meeting of expert
researchers and stakeholders to agree upon a consensus definition, indicator, and instrument
for measuring concurrent sexual partnerships in the context of HIV risk in sub-Saharan Africa.
We then use sexual behaviour survey data collected in a high HIV prevalence setting in ru-
ral KwaZulu-Natal province, South Africa to demonstrate the calculation of the recommended
consensus indicator and consider the robustness of the indicator to some decisions about the
calculation of the indicator.
The data used to estimate population levels of and changes over time in concurrency, other
sexual risk behaviours, and HIV prevalence are from household-based surveys constructed to be
statistically representative of the general adult population. These data, comprising both nation-
ally representative cross-sectional samples and longitudinal observation of the entire population
withing limited geographic areas, have been invaluable for improving our understanding of the
epidemiology of HIV in generalised epidemics [261]. However, participation is voluntary, some
eligible participants cannot be found, and sometimes survey questions are left unanswered. If
not accounted for, non-participation and missing data could lead to biases in population-level
inferences and trends over time estimated from these data. Existing approaches and software
for adjusting for missing data in surveys are not well-suited to the structure of sexual behaviour
questionnaires where responses to different outcomes are systematically related to each other. In
chapter 4 we propose an approach to adjusting for survey non-participation and missing data in
population-based sexual partner history surveys and apply this approach to estimating trends in
concurrency and other sexual behaviour indicators over seven years of sexual behaviour surveil-
lance data during the era of ART scale-up in a rural population in KwaZulu-Natal province
[262].
Chapter 5 turns attention to the topic of HIV treatment as prevention. It focuses on quanti-
fying the behavioural, biological, and programmatic factors that determine the impact of HIV
treatment on HIV incidence in generalised HIV epidemics. We review recent epidemiological
data about the natural history of HIV infection, HIV transmission, and transmissibility and
prognosis on antiretroviral therapy and create a mathematical model of the impact of ART on
the HIV epidemic in South Africa. The model is calibrated to national HIV prevalence and ART
scale-up surveillance data using a Bayesian statistical framework. We use the model to estimate
the potential impact of the current ART scale-up in South Africa and examine how different
combinations of behavioural and biological parameter values, all consistent with the observed
epidemic data, affect the long-term epidemiological impact of HIV treatment interventions.
The mathematical model described in chapter 5 is only one of many mathematical models that
have been employed to inform policy decisions about the use of antiretroviral therapy for HIV
prevention. Mathematical models vary widely in their structures and parameterisations, but
what is most important for decision making is whether mathematical models reach the same
policy-relevant conclusions. Comparing results across models is challenging though because
models have considered different interventions and reported different outcomes. Chapter 6
reviews different models that have examined the effect of ART on HIV incidence in South
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Africa, and systematically compares the predictions of twelve different models when simulating
the same stylised intervention scenarios and report the same measures of intervention impact.
The analysis does not make predictions about specific HIV treatment strategies for South Africa,
but rather helps to define the space of mathematical models applied to the question of ‘treatment
as prevention’. Although models were developed for different purposes and to answer different
questions, we find important areas of agreement and disagreement across models. Chapter 7
synthesises the conclusions across all chapters of the thesis for the future analysis and control of
the HIV epidemics in southern Africa and suggests lessons and directions for future quantitative
research to support HIV decision-making.
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2 The interaction between concurrent
sexual partnerships and primary HIV
infection: insights from a mathematical
model
2.1 Background
Mathematical modelling has had an especially prominent role in the development of the concur-
rency hypothesis. Concurrency first appeared in the HIV literature as a mechanism for creating
mathematical models that more realistically captured the rapid growth rate of observed HIV
epidemics [229], rather than as a hypothesis to explain the severity of HIV epidemics, which
only appeared in the literature a year later [74]. As a result of inconsistent definition and mea-
surement of concurrency in the literature [209, 215, 263] and the challenges inherent in designing
epidemiological studies to empirically test the hypothesis [230, 264], mathematical modelling
has comprised a substantial component of the ‘evidence’ base used to advocate for public health
attention for concurrent sexual partnerships [226].
Since the early modelling suggesting that concurrency could be an important factor in the
spread of HIV in sub-Saharan Africa [229–231, 259], we have learnt a great deal about other
factors that determine the transmission of HIV, including better estimates of the overall trans-
mission probability of HIV [265, 266] and the variation in HIV infectiousness over the natural
course of HIV infection [137, 138, 260]. High infectiousness during the first few weeks of ‘pri-
mary infection’ coupled with the low levels of HIV transmission by asymptomatic individuals
has often been cited as increasing the evidence that concurrency is crucial to the maintenance
of generalised HIV epidemics [75], but this has not been explored in models. This chapter first
reviews approaches to mathematically modelling concurrency, and then extends an influential
model of concurrency and HIV transmission to examine how HIV transmission estimates in-
formed by data and different stages of HIV infection affect model predictions about the influence
of concurrency on HIV spread.
2.1.1 Contributions and dissemination
Most of the results in this chapter appear as a peer-reviewed original paper in AIDS and Behav-
ior [267]. Computer code to reproduce the model and simulation results is available as online
supplementary material to that paper. We thank Dr. Peter Ghys, Professor Christophe Fraser,
and two anonymous reviewers for helpful feedback on earlier versions of this work. Computer
simulations presented here were carried out on the server demog.soc.washington.edu admin-
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istered by Professor Samuel J. Clark at the University of Washington and supported with the
NIH grant 1K01HD057246-01.
2.2 Review of mathematical models of concurrency and HIV
transmission
A number of approaches to modelling the spread of HIV and other STIs over networks of con-
current sexual partnerships have been pursued in the literature. Early models tended to use
deterministic differential equation models solved analytically. With the advent of modern com-
puting technology, more flexible individual-based simulation approaches have become popular,
which increasingly seek to represent mechanistic theories of sexual partnership formation or
replicate observed data about sexual partnering. At the same time, more sophisticated analyt-
ical approaches to modelling networks in infectious disease epidemiology have been applied to
concurrency and sexual network modelling.
2.2.1 Deterministic and analytical approaches
The inclusion of concurrent partnerships into models of the spread of sexually transmitted infec-
tion was a natural extension of the ‘pair models’ of sexually transmitted infections of Dietz [227],
Dietz and Hadeler [228], and Diekmann, Dietz, and Heesterbeek [268]. These authors observed
that previous models of STI transmission, which assumed that sexual contacts were instanta-
neous and did not model partnership duration, did not account for the ‘temporary immunity’
conferred for the duration of a partnership between two susceptible individuals, considerably
changing the transmission dynamics especially during the early growth of the epidemic. The
models developed by Dietz and colleagues incorporated partnership dynamics by extending clas-
sical differential equation models of susceptible-infected-susceptible (SIS ) infection dynamics to
explicitly model partnership (pair) formation and dissolution, and allowed for transmission of
infection within partnerships according to a fixed or random number of sexual contacts in the
partnership.
Dietz considered a pair formation model with a susceptible-infected (SI ) type infection sim-
ilar to HIV [227]. He demonstrated that in a model without pairing, allowing for a random
geometrically distributed number of contacts in a partnership, reduced the basic reproductive
number compared to a modelling a fixed number of sexual contacts per partnership. Incorpo-
rating pair formation into the model further decreased the equilibrium infection prevalence and
nearly tripled the time required to reach endemic equilibrium. This observation was particularly
relevant at the time as HIV epidemics were relatively young and a great deal of emphasis was
being placed on predicting the final epidemic size.
Dietz and Hadeler considered a slightly more general model for an SIS type infection more
similar to common bacterial STIs. This model allowed for multiple functional forms dictating
the balance of pair formation between males and females [228]. They proved the existence
of a solution to their model and derived thresholds for persistence of infection relating pair
formation, dissolution, transmission, and mortality rates.
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The first model of HIV/STI transmission to allow for concurrent sexual partnerships to in-
fluence transmission dynamics was published by Watts and May [229]. They noted that the
presence of concurrent partnerships makes it possible for a partner that is uninfected at the
beginning of a partnership to become infected and expose the other partner before the part-
nership ends, in contrast to the models of Dietz and colleagues where being in an uninfected
partnership conferred “temporary immunity” for the duration of the partnership.
Instead of explicitly modelling pair formation and dissolution as did the previous work by
Dietz and colleagues, Watts and May modelled concurrency by adjusting the force of infection
parameter in the standard SI model to account for additional potential infections acquired
through concurrent partnerships formed during an existing partnership. Based on an earlier
study of heterosexual transmission in a cohort of individuals infected through blood transfusion,
transmission is modelled as a per partnership rate rather than per sexual act rate [269]. The per
partnership specification of transmission probability conveniently allows the described approach
for adjusting the force of infection. One important implication of this is that the probability of
an infection acquired from a new partner will be transmitted to a previously acquired partner
is the same per partnership rate, regardless of how long the partnerships overlap.
HIV infection is modelled in three stages: a fixed-duration latent infection period lasting
for around one month in which an individual was infected but not infectious, an exponentially
distributed infectious period lasting a mean of eight years, and an exponentially distributed
AIDS stage before death of about 1.6 years in which the individual is not infectious. Aside from
AIDS mortality, their model does not include any other demography.
Watts and May derive an expression for the reproductive number, R0, as the sum of the
standard reproductive number for an SI model, cβ/ν, and another expression ρ0 = cβτ , where c
is the number of new partners per year and τ is the mean partnership duration. The parameter
ρ0 can be interpreted as the reproductive number for transmission on the static network of
existing partnerships. That is, if ρ0 > 1 then infection can persist on the static network of
partnerships without dissolution and formation of new partnerships. Model results are simulated
for scenarios with cβ/ν = 2, and ρ0 = 1, 2, and 3. When ρ0 = 1, the overall shape of the epidemic
looks similar to a standard SI model, but with a much faster growth rate. When ρ0 = 2 or 3 the
epidemic exhibits a clear two phased growth with a very fast initial spread and comparatively
slower subsequent spread, which the authors argue is consistent with empirically observed HIV
epidemics that had very rapid growth rates, but then slower spread than would be predicted by
the initial growth rates. This is an alternative explanation for this phenomenon, which is often
attributed to HIV spreading between high and low risk groups in the population [270].
The next compartmental model to consider the effect of concurrent partnerships on trans-
mission was by Altmann [271]. Altmann developed a continuous time stochastic SIR model for
transmission of an infection with concurrent partnerships by counting all possible dyads in the
population and their infection states, whether or not the dyad is formed. This was a different
approach from the pair formation models of Dietz in which individuals were counted and pairs
were only counted once they had formed [227]. Partnerships were formed at a homogeneous
rate between all possible pairs in the population. The resulting distribution for the number of
partnerships for a person was binomially distributed, converging to a Poisson distribution for
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sufficiently large population size. Because the model did not track the number of partnerships
for each individual, it was not possible to vary the rate of partnership formation based on the
existing number of partners, and hence not possible to vary the amount or configuration of
concurrency. Transmission within formed discordant partnerships occurred with probability
dependent on contacts distributed as a Poisson process over the duration of the partnership.
Altmann used a branching process approximation for the initial spread of infection in an
entirely susceptible population to derive an expression for R0 for the stochastic process. It was
shown that when the mean partnership duration becomes small and the population becomes
large, the expression for R0 converges to the classical expression for R0 in an SIR model,
while when the partnership duration becomes very long, the expression for R0 becomes the
same as percolation through a random graph. Altmann suggested that reality probably lies
somewhere between his random partnership model and Dietz’s pair formation models that limit
the number of partnerships to monogamy, which are two extreme models of realistic partner
formation mechanisms.
In a subsequent publication, Altmann considered the deterministic limit of the stochastic
model developed in his 1995 paper [272]. Here he derived the system of differential equations
corresponding to the model described earlier, and outlined a proof of the convergence. This
model was compared to a model based on the approximation of force of infection used by Watts
and May [229], which it was pointed out ignored the correlation between previous partnership
acquisition and infection status. The result of this is that Watts and May’s approximation
gives the correct value of R0 and initial growth rate because there is no dependence when
the entire population is susceptible, but that after the epidemic has spread, Watts and May’s
approximation over-estimates the risk of infection. Finally, Altmann generalised the model to
allow for partnership acquisition rates to depend on the number of partners that an individual
has, but requires that the contribution to the pair formation rate be independent for each
partner. Essentially this means that it is possible to model arbitrary degree distributions other
than Poisson, but does not allow for assortative mixing on the number of partnerships.
Bauch and Rand proposed a different solution to generalising the random partnership for-
mation model of concurrent partnerships that does allow for some dependence on the number
of partnerships [273].1 They analysed an SIS -type model similar to the random mixing model
developed by Kretzschmar and Morris [230, 259] (see section 2.2.2), in which there were differ-
ent formation rates for partnerships between two singles than for partnerships where at least
one partner had an additional partner. Specifying this model requires a moment closure for
higher order partner configurations in the model, which amounts to, in this case, approximat-
ing the number of infected partners of an individual in a susceptible-infected partnership, and
the number of infected partners of an individual in a susceptible-susceptible partnership. The
assumption that they made to derive their moment closure is that the infection status of one
partner is not affected by the infection status of another partner. In an appendix, they evalu-
ated the impact of this assumption by comparing a stochastic simulation of the system to the
deterministic system under various parameter values. They found that when the time scale of
1Bauch and Rand do not cite Altmann’s papers [271, 272] and may have been unaware of Altmann’s work at
the time of their 2000 paper [273].
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transmission of infection is on approximately the same time scale as partnership formation, the
results from the deterministic system are fairly close to the stochastic simulation, but, when
transmission is much faster than the partnership formation, the chosen moment closure does
not approximate the stochastic system well.
They derived an expression for R0 and the endemic prevalence for their system, and presented
the relationship between these values and the amount of concurrency, measured by the κ3
statistic (see [259]), when the total number of partnerships in the population is fixed. In
general, R0 and the endemic prevalence increases with the amount of concurrency, although
the rate of increase in both of these quantities is not, in general, exponentially related to κ3.
Interestingly, Bauch and Rand showed that when the recovery rate from infection is very slow
relative to the partnership dynamics, concurrency has little effect on the endemic prevalence,
and that in this situation increasing concurrency can even decrease the endemic prevalence.
In a subsequent paper, Bauch considered the effect of introducing both longer ‘steady’ part-
nerships and shorter concurrent ‘casual’ partnerships for SIS infection dynamics [274]. For this
exercise Bauch developed a triple approximation for the moment closure, in which the number
of triples of each type are explicitly modelled and the conditional independence assumption
used previously approximates higher order formations. It was demonstrated that the triple
approximation matches the infected equilibrium of the stochastic simulation nearly perfectly,
while the previously described pair approximation does poorly.
Ferguson and Garnett fully generalised the pair formation model for concurrent partnerships
in a random mixing heterosexual population by specifying a model that allows for different
partnership formation based on the current number of partners of both the potential partners
[275]. Of the approaches to introducing concurrency into pair models discussed thus far, theirs
was the first to explicitly model two sexes. To allow for flexibly specified partner formation rates,
it was necessary to count the number of partnerships where the male partner has i partners
and the female partner has j partners, and again to specify a moment closure for the number
of triples of each configuration. Ferguson and Garnett made a similar conditional independence
assumption as did Bauch and Rand [273], although they made no mention of the potential error
introduced by this approximation other than to mention that it requires further investigation.
Ferguson and Garnett used the model to present exploratory simulations into the potential
effect of concurrency on the spread of a SIS -type STI. They presented three scenarios of part-
nership formation where up to one (serial monogamy), two, or three partnerships are allowed
at a time. Parameters were chosen such that in all scenarios the average number of contacts
per year is around 1.1, and such that the rate of partner acquisition is very high for individuals
with no partnerships but much lower for individuals with one or two partners. The result was
that in each of the scenarios less than 15% of the population is single, and the proportion of the
population with more than one partner is 5.6% when two partners are allowed and 7.3% when
three partners are allowed. It should be noted that under Ferguson and Garnett’s parameterisa-
tions, the total number of partnerships in the population increased slightly and the proportion
of isolates decreased slightly as concurrency is increased. Each scenario was simulated for a
variety of transmission and recovery rates, demonstrating that concurrency makes it much eas-
ier for infection to take hold and increases endemic prevalence. When up to three partners
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were allowed, the prevalence of infection was much higher amongst those whose partners had
concurrent partners. The strong dependency between concurrency and prevalent infection in
this model is likely enhanced by the short duration of infection relative to the rate of partner
dissolution in this model.
2.2.2 Stochastic network simulation models
Advanced analysis has created elegant mathematical results showing how concurrency affects
fundamental epidemic thresholds such asR0 or endemic prevalence, but individual-based stochas-
tic simulation models that simulate dynamic sexual networks of individuals and partnerships
with transmission of infection have arguably been more persuasive in convincing the general
community of epidemiologists and public health experts of the potential importance of concur-
rency for HIV/STI transmission. Complexities of real world systems can be incorporated into
stochastic simulations more easily and they are often more accessible to non-mathematicians
because the model can be described as a set of rules and algorithms rather than mathematical
symbols and equations. Most of the stochastic simulation models published until recently have
focused on the impact of concurrency on the spread of curable sexually transmitted infections
rather than HIV.
The first stochastic simulation model to consider the effect of concurrent partnerships on
HIV/STI transmission was produced by Morris and Kretzschmar in a series of papers pub-
lished between 1995 and 1997 [230, 259, 276]. Morris and Kretzschmar’s model superimposed
transmission of infection on a simple model of heterosexual partner formation and dissolution.
The key feature of all of Morris and Kretzschmar’s simulations was that the mean number of
partnerships in the population is held constant, as is the duration of partnerships, while more
or less concurrency is created by changing how the partnerships are distributed in the pop-
ulation. To effect this, partner formation is done through an algorithm that first determines
that a partnership will be formed, then a candidate male and female are randomly selected and
form a partnership with probability according to some function φ. If the pair does not form a
partnership, then another pair is randomly chosen to form a partnership according to φ until a
the partnership is formed. By modifying φ they are able to alter the amount of concurrency,
assortativity, or disassortativity in the population. Partnerships were dissolved at a constant
probability σ per day and infection was transmitted between an infected and a susceptible
partner with a constant probability β per day. As they were principally concerned with the
initial growth rates of epidemics and their simulations were not run for very long simulated time
periods, there was no removal or recovery of infecteds in the model.
In their first paper [276], Morris and Kretzschmar explored the effect of concurrency and
degree homophily, the preference for a partner of similar or dissimilar degree to oneself, on
epidemic growth. They considered the case of serial monogamy as a baseline and compared this
with seven scenarios of assortativity ranging from strongly disassortative to strongly assortative.
The median scenario between these represented random partner selection as was considered in
the concurrency models of Watts and May [229] and Altmann [271]. This first paper considered
a system in which the mean number of partnerships per person was 0.91, the mean duration
of a partnership was 2.7 years (1000 days), the infection probability was 0.1 per day. The
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epidemic was seeded with a single infection after the partnering dynamics reached equilibrium
and simulations were run for three years. Each scenario was simulated 100 times. The results
showed that adding any form of concurrency increases the median outbreak size after three
years compared to serial monogamy, and that both disassortative and assortative mixing on
degree increase the median outbreak size compared to random mixing. However, in the serial
monogamy scenario, every seed infection produced at least one secondary infection, whereas
for the scenarios with homophily, between 38 and 89 out of the 100 scenarios did not generate
a secondary infection. Remembering that the average total number of partnerships in the
population is constant in all of the scenarios, and that the mean partnership duration is 2.7
years, which is not much shorter than the simulation duration of three years, this result is
not particularly surprising and is probably closely related to the probability that the epidemic
is seeded with someone that does not have a partnership [276]. Finally, the paper examined
the trajectory of epidemic growth when outbreaks do occur. When mixing was random, the
epidemic grew at a fairly constant rate, while both assortative and disassortative mixing could
create a short period of very rapid growth followed by slower growth.
In their second paper, Kretzschmar and Morris presented the details of their algorithm and the
forms of the function φ for creating assortative and disassortative mixing, and they introduced a
new form for φ that varies the amount of concurrency while retaining random mixing [259]. For
the simulation experiment presented in this paper, parameters were chosen such that the average
number of partnerships per person was 2/3, partnerships lasted for an mean of 6.6 months (200
days), and the probability of transmission in a discordant partnership was 0.05 per day. The
simulations lasted for five years and were again seeded with a single random infection. They
conducted simulations for a range of levels of concurrency for the random mixing scenario and
different degrees of assortative and disassortative mixing. They found that for approximately
the same value of κ3, assortative mixing led to faster rates of initial epidemic growth than did
disassortative mixing.
Morris and Kretzschmar’s third paper used the same simulation design and parameters as
the previous paper but focused only on the effect of varying concurrency within random mixing,
simulating an outbreak for ten years [230]. Here they showed that concurrency increases both
the mean and variance of the outbreak size after five years and they estimated that the log of
the mean outbreak size is linearly related to κ3, although they pointed out that this effect is
only expected to be valid during the exponential growth phase of the epidemic before saturation
effects alter the relationship. The largest connected component of the momentary partnership
network appeared to be linearly related to the value of κ3, which they argued is the reason for
the dramatic effect of concurrency on epidemic growth.
Morris and Kretzschmar were also very interested in how concurrency should be defined and
measured at the population level, and proposed and discussed the merits of several measures of
concurrency in a population [259, 276]. They finally recommended a measure that they term
the index of concurrency, defined as the mean number of concurrent partnerships per partner-
ship in the population where a single concurrent partnership is defined as two partnerships in
the network that share a node (an individual). Note that, in this way of counting, a single
partnership can be a part of a number of concurrent partnerships. They proved that when the
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number nodes in the contact graph is large, this measure, also referred to as κ3 in [259] or just
κ in [230], converges to
κ3 = σ
2/µ+ µ− 1
where µ is the mean number of partnerships in the population and σ2 is the variance of the
number of partnerships in the population. This identity offers an easy method for calculating
κ3 from empirical data on concurrent partnerships. Empirical studies have used κ3 to measure
concurrency in a population [212, 216], although none have found it effective for explaining
differences in infection prevalence between populations.
In 2000, Morris and Kretzschmar extended their model to consider two types of partnerships,
spousal and non-spousal pairs, that have a mean duration of 239.1 months and 28.4 months
respectively [231]. They reparameterised their model such that the resulting male and female
partnership degree distribution matched that observed in a local network survey conducted in
Rakai District, Uganda. Women were restricted to have only one spousal partnership at a time,
while men could have multiple spousal partners. HIV transmission was 0.05 per day as in their
previous models. The epidemic was seeded with 20 randomly selected individuals and run for
five years. They considered a variety of scenarios including a simulation based on the degree
distribution from Uganda, a scenario with the same number of partnerships, but all partnerships
are monogamous, increasing the number of monogamous partnerships without changing the
number of concurrent partnerships, increasing the proportion of concurrent partnerships keeping
the total number of partnerships in the population constant, and increasing both the overall
number of partnerships and the proportion of concurrent partnerships. They found that the
observed amount of concurrency produces on average 26% more infections after five years than
in the serial monogamy scenario. Each of the other scenarios further increased the size of the
outbreak, and redistributing partnerships to be concurrent increased the size of the outbreak
more than adding more monogamous partnerships.
Around the same time as Morris and Kretzschmar’s work, Ghani, Swinton, and Garnett [277]
considered a discrete-time stochastic network model of gonorrhoea in a heterosexual popula-
tion. In Ghani and colleagues’ model, individuals formed partnerships according to a ‘sexual
activity preference’, which is the maximum number of partnerships an individual is allowed to
have. Individuals’ levels of sexual activity preference were negative-binomially distributed. At
each time step, all males and females with less than their desired number of partnerships were
eligible to form a partnership with probability according to their respective desired number of
partnerships, allowing for assortative or disassortative mixing. The assortative and disassorta-
tive mixing modelled here is based on the desired number of partners, which differs from the
assortative and disassortative mixing patterns considered in Morris and Kretzschmar’s work
[276] that were based on the actual number of partners at the time of partnership formation.
Partnership durations were exponentially distributed with a mean duration that depended on
the sexual activity preference of both partners, allowing for lower activity partnerships to last
longer. The infection modelled was similar to gonorrhoea with a daily transmission probability
of between 0.05 and 0.2 per day and a mean duration of infection between 10 and 50 days in
different simulation scenarios.
Ghani and colleagues’ simulation study consisted of independently sampling forty sets of pa-
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rameters from specified reasonable ranges. Each set of parameters was simulated five times
in populations of size 200, 500, and 1,000 people. Pair formation was simulated for 20 days
before infection was introduced and simulated for 2 years. A variety of network statistics were
calculated on the static sexual network at the end of the simulation and for the cumulative
network over the final 90 days of simulation. Logistic regression was used to determine which
statistics were significantly associated with whether or not an outbreak occurred and, if an out-
break did occur, with the infection prevalence at the end of the simulation. Statistics measuring
individual network placement were calculated and used to predict individual risk of infection.
Their analysis found that the proportion of the population in mutually non-monogamous pairs
best predicted whether a gonorrhoea epidemic was established or not. This result makes sense
for the context of gonorrhoea, an infection with a relatively short duration, but it may not
necessarily generalise to HIV which has a much longer duration of infection. For predicting the
prevalence of infection, the pattern of partnerships amongst the highest sexual activity levels
was most important. Individual risk of infection was better predicted using measures of sexual
behaviour and network position over the previous 90 days than of the static sexual network
at the end of the simulation, arguing for cumulative rather than static sexual network mea-
sures to measure epidemiological risk in empirical studies. The total number of partners of an
individual’s partners was a significant predictor of whether and individual was infected.
In a subsequent paper, Ghani and Garnett repeated their simulation exercise to investigate
which network statistics best predicted the risk of gonorrhoea acquisition and transmission
[278]. This time they randomly sampled 2000 parameter combinations and simulated epidemics
in a population of 2000 individuals for 1000 days. Using logistic regression, they found that the
number of partners in a month was significantly associated with whether or not an individual
acquired infection in that month in all simulations. In 75% of simulations, including their
measure of individual concurrency in the month significantly improved the prediction, and
number of partners’ partners also improved model fit in 75% of simulations. For assessing the
risk of transmission, they used Poisson regression to model the number of transmissions in a
month as function of the network statistics. In the majority of networks, both the number of
partners in the month and the measure of concurrency in the month were highly significant.
The local network measures were in general less significant for predicting transmission than for
predicting acquisition.
Ghani and Garnett’s finding that concurrency improved the prediction of acquisition of infec-
tion merits attention considering that it contradicts the theoretical prediction that concurrency
is only a risk factor for transmitting infection, not for acquiring infection [210, 220, 221]. This
concept has been used to criticise empirical studies that have attempted to evaluate the im-
portance of concurrency by testing for an association between having concurrent partners and
being infected [209]. A recent network simulation paper demonstrated that individuals that had
at least one concurrent partner are at no more risk of acquiring infection than individuals with
no concurrent partners when controlling for total number of partners, but that individuals that
had concurrent partners are more likely to have transmitted infection when controlling for total
number of partners [222]. The reason for the apparently contradictory results may be explained
by more careful examination of the indicator of concurrency used by Ghani and Garnett, which
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did not simply measure whether an individual had concurrent partnerships in the month, but
is a continuous measure of the average number of partnerships they had while they were in a
partnership. This concurrency indicator probably includes information about the overall du-
ration of partnerships, and hence potential exposure to infection, that is not contained in the
number of partnerships in the month. This reinforces the point that, for both modelling and
empirical studies, it is important to be aware of how changing concurrency or other behaviours
affects the factor that actually matters—potentially infectious contacts.
Welch, Chick, and Koopman considered a continuous-time stochastic partnership formation
model similar to Ghani’s in that each individual is eligible to form up to a pre-specified number
of partnerships [279]. In Welch and colleagues’ model, different partnership ‘bins’ are created,
representing different types of partnerships, and individuals were eligible to form a certain
number of partnerships of each type. Partnerships were formed between eligible individuals at
a constant rate depending on the partnership type. Within partnerships, sex acts were modelled
at a rate of about three per week under two assumptions: the sex act rate does not depend on
the number of partnerships and that the sex act rate is proportional to the number of current
partnerships of both partners. The overall sex act rate was scaled such that the total number
of sex acts in the population per unit time is conserved between the two scenarios. Welch and
colleagues considered a variety of scenarios adjusting the amount of mixing between high and low
risk groups, the partnership formation rate, and the amount of concurrency in the population.
For each scenario, they simulated a population of 500 males and 500 females for 1,800 days with
a pathogen similar to gonorrhoea. They found that increasing the partnership formation rate,
increasing the amount of between group partnerships, and increasing the amount of concurrency
each increased the prevalence of infection. Increasing concurrency had the largest effect. The
fixed sex act rate led to between a 9% to 23% increase in prevalence compared to when the sex
act rate is proportional to the number of partnerships.
2.2.3 An illustrative model revisited
The most influential work, from the perspective of catalysing public health discussion about the
role of concurrency in generalised HIV epidemics, has been the 1997 paper in AIDS, “Concurrent
partnerships and the spread of HIV.” Morris and Kretzschmar used an intuitive and tractable
model to compare the spread of infection under sequential monogamy with varying levels of
concurrency to demonstrate how concurrency could increase the size and growth rate of an
outbreak.
This model, and earlier work by Watts and May, however, focused only on how concurrency
affects the initial growth of the epidemic, and used parameter values for HIV transmission,
a probability of 0.05 per day, that now seem unrealistically high in light of data [265, 266].
This has caused some to question the relevance of these models to understanding the role of
concurrency in the generalised HIV epidemics in southern Africa [215, 232].
Moreover, increasing data have supported that individuals are highly infectiousness during
‘primary infection’ for the first few months after they become infected [260, 266, 280]. It is
often presumed that the influence of concurrency is increased by this short period of high
infectiousness [75, 138, 220, 281, 282]. A brief period of high infectiousness following initial
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infection would make transmission more dependent on a newly infected individual having sex
with a susceptible individual shortly after his or her own infection [260, 280, 283]. A few
papers have attempted to quantify the proportion of transmissions due to primary infection
[283–285], but these models have not included overlapping sexual partnerships, and hence were
unable to examine the synergy between concurrency and primary infection for HIV transmission.
The remainder of this chapter extends Morris and Kretzschmar’s model to explore how this
new knowledge about HIV pathogenesis affect the relationship between concurrency and HIV
transmission.
2.3 Methods
We replicated and then extended the mathematical model of concurrency and HIV transmis-
sion developed by Morris and Kretzschmar [230, 259, 276] to include different stages of HIV
infectiousness and HIV mortality and replacement.
2.3.1 Mathematical model
The model simulates a population of Nm males and Nf females forming heterosexual partner-
ships. The key feature of the model is that it retains the same average number of total partner-
ships in the population while changing the distribution of the partnerships to vary the amount of
concurrency. This is achieved by forming partnerships at a rate of ρ[(Nm +Nf )/2−P ] per day,
where P is the total number of partnerships in the population. The amount of concurrency is
manipulated by changing the probability that an individual already having a partnership forms
another partnership. For each partnership determined to be formed, one male and female are
randomly chosen as candidates to form the partnership. The probability that this pair forms
the partnership depends on the male’s number of partnerships i and the female’s number of
partnerships j according to the function
φ(i, j) =
{
1 if i = j = 0
1− ε otherwise. (2.1)
If the partnership is not formed, another male and female are randomly chosen and this is
repeated until the partnership is formed. Inspection of this equation reveals that ε = 1 creates
only monogamous partnerships, reducing to Dietz’s heterosexual pair model [286], while ε = 0
corresponds to the purely random pair formation model considered by Watts and May [229] and
Altmann [271]. Partner selection in the model only depends on whether an individual already
has a partner, and there is no heterogeneity in the propensity to form sexual partnerships.
Each HIV discordant partnership is exposed to HIV transmission every day at a rate deter-
mined by the duration of infection of the infected partner. Stages of HIV infection and the
overall duration from infection to death are modelled as a fixed duration after initial infec-
tion occurs, with βp, βa, and βs being the daily transmission probabilities during the primary,
asymptomatic, and symptomatic stages lasting for δp, δa, and δs days respectively. The total
time from infection to death is given by ∆ days.
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At each time step, every partnership is dissolved with probability σ. HIV positive individuals
are removed from the population after having been infected for ∆ days by terminating all of
their active partnerships, removing them, and replacing them with an unpartnered susceptible
individual of the same gender. Thus the total size of the population of males and females
remains constant.
In light of these extensions to the model, the simulation algorithm for each time-step described
on page 181 of [259] can be updated as follows:
Model algorithm at each time-step
1. Form new partnerships according to the following algorithm:
a) Draw a Bernoulli trial with probability ρ. If a success form a new partnership by
following i–iii, if a failure skip to (b).
i. Select one male and one female at random from the population.
ii. Form a partnership between the pair with probability φ(i, j)
iii. If the partnership is formed, go to (b), otherwise return to (i) to sample a new
pair.
b) Repeat (a) n = (Nm +Nf )/2− P times.
2. For every discordant partnership, transmit infection with probability βd, where d is the
stage of infection of the infected partner.
3. Dissolve every partnership with probability σ.
4. Decease and replace any individual for which the duration of infection d = ∆ by:
a) Terminating all of the individual’s partnerships.
b) Removing the individual from the population.
c) Replace the individual with an unpartnered susceptible of the same gender.
2.3.2 Simulation design
To investigate how different stages of HIV infection modulates the influence of concurrency on
the epidemic, we consider two basic simulation scenarios: one in which the daily HIV transmis-
sion probability depends on the stage of infection, and the other in which a constant transmission
probability is used throughout the time from infection until death. Each of these scenarios is
simulated for eleven different levels of concurrency determined by values of ε given by the
function
ε = 1− 1.02 · [e3.9·(q−1) − .02], q = 0, 0.1, 0.2, . . . , 1.0. (2.2)
The sequence of values of ε yielded by this function result in roughly evenly spaced values of
concurrency measured by the κ3 or point-prevalence measures of concurrency (see Figure 2.1
and Table 2.2).
The transmission probabilities and duration of stages of infection parameters for the staged
transmission scenario are taken from Hollingsworth, Anderson, and Fraser’s re-analysis of Wawer
and colleagues’ retrospective discordant couple study in Rakai, Uganda [138, 260]. The annual
hazards reported by Hollingsworth and colleagues are converted to daily hazards, which are
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used to approximate daily transmission probabilities. The resulting daily probabilities used for
the staged transmission scenario are βp = 0.00732, βa = 0.00029, and βs = 0.00208 per day.
The duration of each of the stages are δp = 88 days, δa = 3054 days, and δs = 274 days, and
the total duration from infection to death is ∆ = 3723 days, including a period of 307 days of
no transmission before death, as estimated by Hollingsworth and colleagues. For the constant
transmission scenario, a weighted average of the staged daily transmission probabilities is given
by
βc =
βp · δp + βa · δa + βs · δs
∆
= 0.00056. (2.3)
Infected individuals are exposed to transmitting with this probability for the entire δc = ∆ days
until death.
Parameter values for the partnership formation and dissolution are the same as those used in
Morris and Kretzschmars simulations [230]. The value of ρ = 0.01 and σ = 0.005. Together, this
means that on average there are 2/3 of a partnership per person in the population, partnerships
last for an average of 200 days and a median of 138.6 days, and individuals have 1.22 new
partners per year in all simulation scenarios. The third column of Table 2.1 summarises the
parameter values used for the simulations.
HIV epidemics are simulated in populations of Nm = 10, 000 men and Nf = 10, 000 women for
250 years. Before seeding HIV into the population, the pair formation process is run for 5 years
without infection until a steady-state is reached. Then ηm = 100 (1%) males and ηf = 100 (1%)
females are randomly selected and seeded with HIV infection. The epidemic seed is relatively
large to avoid stochastic extinction of the epidemic in accordance with our goal of investigating
the effect of concurrency on long-term epidemic behaviour. The duration of infection assigned
to seed infections is drawn uniformly between 0 and ∆− 1 to avoid dependency in the epidemic
created by all of the seed infections progressing through the stages of infection and dying
simultaneously. Simulations are replicated 100 times for each combination of parameters.
For each level of concurrency, and for staged and constant transmission probabilities, the
average HIV prevalence over the 250 years of the epidemic is presented. Box plots show the
range of values of HIV prevalence after 250 years for the 100 simulations. For the staged HIV
transmission scenario, the proportion of transmissions that occur in each stage of HIV infection
when the epidemic has reach equilibrium is calculated for each level of concurrency.
2.3.3 Sensitivity analyses
We conducted sensitivity analyses for two alternative sets of parameters. For the first we change
the transmission probabilities in the staged HIV transmission scenario. In the simulations
described in section 2.3.2, we compared the effect of concurrency with staged and constant HIV
transmission by holding constant the average transmission probability over the entire duration
of infection. In the first sensitivity analysis, we increase the average transmission probability for
the staged transmission scenario so that the endemic HIV prevalence is the same for both the
constant and staged HIV transmission scenario when there is no concurrency. This is achieved by
multiplying the scaled transmission probabilities in each stage by a constant k = 1.435, yielding
transmission probabilities of 0.01050, 0.00042, and 0.00299 for the primary, asymptomatic, and
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symptomatic stages. The same eleven levels of concurrency are considered. Parameter values
for this scenario are shown in the fourth column of Table 2.1.
In the second sensitivity analysis, instead of using partner formation and dissolution rates
from Morris and Kretzschmar’s seminal paper, we replicated the simulations using parameters
calculated from baseline sexual behaviour data from the Manicaland HIV/STD Prevention
Project in eastern Zimbabwe. Data were collected from a general population of 4419 men and
5424 women aged 15–54 in twelve sites in Manicaland province, Zimbabwe between 1998 and
2000. Further information on the design of study are available from [65]. Data used to select
model parameters include reported average number of current partnerships (“How many sexual
relationships do you consider yourself to be involved in at the moment?”) and the number of
new sexual partners in the past year (“How many of your partners in the past 12 months were
you having sex with for the first time?”). Men aged 15–49 reported an average of 0.87 (standard
error 0.017) current partnerships while women aged 15–49 reported an average of 0.69 (SE 0.011)
current partnerships. For the number of new partnerships in the past year, men and women aged
15-49 reported means of 0.95 (SE 0.037) and 0.23 (SE 0.018), respectively. Taking the average of
the mean number of current partners and contact rate reported by men and women yields model
parameters such that individuals have an average of 0.59 new partners per year, partnerships
last for a mean of 1.31 years, and the average number of current partnerships is 0.78. To achieve
these statistics in the model, the partnership formation parameter is ρ = 0.00768 and the daily
probability of partnership dissolution is σ = 0.00196 per day. These parameters are summarised
in column five of Table 2.1. The same sequence of values ε are simulated as before, but the
resulting levels of concurrency are slightly different. Now, as ε increases from 0 to 1, the point
prevalence of concurrency ranges from no concurrency to 19%, or κ3 ranging between 0 and
0.80.
The model is implemented in C++ using a discrete time-to-event based simulation approach.
Pseudo-random number generation is done using the Mersenne Twister algorithm [287]. The C++
model code is interfaced with R [288]. C++ and R code for the model and reproducing the results
is available at http://link.springer.com/content/esm/art:10.1007/s10461-010-9787-8/
MediaObjects/10461_2010_9787_MOESM2_ESM.zip. All analyses were conducted using R ver-
sion 2.10.1.
2.4 Results
We first examine the relationship between the parameter ε, which controls the probability
that individuals who already have a partner form a new partnership, and characteristics of
the resulting sexual network. Figure 2.1 shows the following network statistics for values of ε
ranging from one to zero:
• the point prevalence of concurrency, defined as the number of individuals with more than
one partnership at a point in time (on the right axis).
• the κ3 measure of concurrency proposed by Kretzschmar and Morris [259].
• the proportion of isolates (the proportion of the population with no partnerships).
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Figure 2.1: Concurrency measures and other network measures plotted against parameter ε in
equation (2.1). Based on parameters ρ = 0.01 and φ = 0.005.
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Table 2.2: Simulated values of ε and corresponding network measuresa
ε Point κ3 Proportion Mean degree Variance of
Prevalence isolates of non-isolates partner distribution
1.000 0.0% 0.00 0.33 1.00 0.22
0.990 1.7% 0.05 0.35 1.03 0.26
0.975 3.3% 0.11 0.37 1.05 0.29
0.954 4.9% 0.16 0.39 1.08 0.33
0.922 6.5% 0.23 0.40 1.12 0.37
0.875 8.1% 0.30 0.42 1.16 0.42
0.806 9.6% 0.37 0.44 1.20 0.47
0.704 11.1% 0.44 0.46 1.24 0.52
0.553 12.3% 0.52 0.48 1.28 0.57
0.330 13.4% 0.59 0.50 1.33 0.62
0.000 14.4% 0.67 0.51 1.37 0.67
aNetwork measures associated with parameters ρ = 0.01 and σ = 0.005 after
Morris and Kretzschmar [230].
• the mean partner degree (the average number of partnerships per person in the popula-
tion).
• the variance of the partnership degree distribution.
The figure also plots the expression
log((1− ε)/1.02 + .02)
5.8
+
2
3
,
showing that this provides a relatively good model for the change in the point prevalence of
concurrency and the value of κ3 as ε changes.
Table 2.2 shows the value of the network statistics for the specific values of ε chosen according
to equation (2.2) for varying concurrency in epidemic simulations. In addition it reports the
mean degree of non-isolates, that is the average number of partners for individuals that have at
least one partnership. This table shows, firstly, that we have indeed selected values of epsilon
that give relatively evenly spaced levels of concurrency, as measured by the point prevalence and
κ3 indicators. Secondly, it points out that varying concurrency affects other properties of the
network, underlining the challenge of designing modelling strategies that isolate concurrency
without affecting other properties of sexual network structure that may affect epidemic growth.
2.4.1 Concurrency and constant versus staged HIV transmission
Figure 2.2 shows the trend in HIV prevalence over time for the staged and constant transmission
scenarios at different levels of concurrency and Figure 2.3 compares box plots of the final HIV
prevalence in the 100 simulations of staged and constant HIV transmission risk for each level
of concurrency. In each scenario, increasing concurrency increases both the growth rate of
the epidemic and the endemic prevalence of HIV. However, the influence of concurrency is
weaker when transmission probability is constant (Figure 2.2(a) and Figure 2.3, black boxes)
than with the staged transmission (Figure 2.2(b) and Figure 2.3, red boxes). Indeed, with
staged transmission, concurrency makes the difference as to whether an epidemic can spread
at all—for instance, with staged transmission and up to 8% of individuals having concurrent
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Figure 2.2: HIV prevalence over time for constant transmission scenario (a) and staged trans-
mission scenario (b). Darker colors indicate more concurrency. Lines indicate the
mean of 100 simulations.
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Figure 2.3: Box plots of HIV prevalence after 250 years at different levels of concurrency for
constant transmission (black) and staged transmission (red). Box plots indicate
quantiles based on 100 simulations of each scenario.
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Figure 2.4: Proportion of transmissions occurring during each stage of infection once the epi-
demic has reached steady state for staged transmission scenarios where the epidemic
spreads.
partnerships, HIV fails to spread, but with 14% of partnerships being concurrent, HIV becomes
hyper-endemic, with prevalence greater than 15%.
While the difference made by concurrency is greater in the staged transmission scenario, the
endemic level of HIV prevalence is greater with constant transmission. With the highest level
of point prevalence of concurrency at 14%, HIV prevalence is 21% with constant transmission,
but 16% with staged transmission.
2.4.2 Concurrency and the contribution of primary infection
For the levels of concurrency where the epidemic spreads, Figure 2.4 shows the proportion of
transmissions that occur during each HIV infection stage once the epidemic has reached a steady
state. The amount of concurrency has a strong influence on the proportion of HIV infections
attributed to primary infection. For the lowest level of concurrency where the epidemic spreads
(point prevalence 8%, κ3 = 0.3), the primary, asymptomatic and symptomatic stages account
for 16%, 53%, and 31% of transmissions, respectively. At the highest levels of concurrency
(point prevalence 14%, κ3 = 0.67), the three stages are responsible for 28%, 46% and 26% of
transmissions.
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Figure 2.5: Simulations results for scenario with staged transmission probabilities multiplied by
k = 1.435.
0 50 100 150 200 250
0.
0
0.
1
0.
2
0.
3
Constant Transmission Probability
Year
HI
V 
Pr
ev
ale
nc
e
κ3 = 0.67, Point Prev = 14%
κ3 = 0.30, Point Prev = 8%
κ3 = 0.00, Point Prev = 0%
0 50 100 150 200 250
0.
0
0.
1
0.
2
0.
3
Staged Transmission Probability
Year
HI
V 
Pr
ev
ale
nc
e
κ3 = 0.67, Point Prev = 14%
κ3 = 0.30, Point Prev = 8%
κ3 = 0.00, Point Prev = 0%
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2.4.3 Increased staged transmission rates
In the above comparison we preserved the same average transmission probability over the du-
ration of infection. In an alternative analysis, we preserved the endemic HIV prevalence for the
serial monogamy case across simulations with constant and staged transmission. The results of
this are shown in Figure 2.5. In both scenarios, endemic HIV prevalence was 16% when there
is no concurrency. When transmission is constant, the endemic prevalence ranges between 16%
and 21% as concurrency increases (the same as the black boxes in Figure 2.3). For staged
transmission, the endemic prevalence increases from 16% to 37% for the same range of values
for concurrency. This suggests that the effect of concurrency on the size of the epidemic was
not an artefact of the staged transmission scenarios being nearer the epidemic threshold in
the simulations where we retained average infectiousness. Increasing the staged transmission
probabilities does not substantially alter the proportion of transmissions that occur during each
stage of infection. It reduces the proportion of transmissions during primary infection by about
1.3 percentage points.
2.4.4 Parameterisation from the Manicaland HIV/STD Prevention Project
The results of these simulations using the partner formation and dissolution parameters ρ =
0.00768 and σ = 0.00196 are presented in Figure 2.6. These parameters create a lower rate of
new partner acquisition but a higher overall number of partnerships in the population at any
point in time, compared to the parameter values used by Morris and Kretzschmar. The larger
number of partnerships also results in a higher level of concurrency for the same value of ε.
When partnership formation is completely random (ε = 0), the point prevalence of concurrency
is 19% (κ3 = 0.80) using the Manicaland parameters compared to 14% (κ3 = 0.67) using Morris
and Kretzchmar’s parameters.
The qualitative results of these simulations are remarkably similar to the results using Morris
and Kretzschmars parameters considering how different are the partnership durations. The
range endemic HIV prevalences as concurrency increases is slightly wider for the Manicaland
parameterisation–15% to 26%–compared to the Morris and Kretzschmar parameterisation–16%
to 21%. When transmission probabilities are staged, the lowest point prevalence of concurrency
that produces an HIV epidemic is 9% (κ3 = 0.27), similar to the 8% (κ3 = 0.30) using the
previous parameters. The endemic HIV prevalence increases to 23% when the point prevalence
of concurrency is 19% (κ3 = 0.80). The proportion of transmissions attributable to primary
infection in the endemic state ranges between 15% when 9% of individuals have concurrent
partnerships to 29% when 19% of individuals have concurrent partnerships.
2.5 Discussion
This study systematically compares a constant transmissibilty model of HIV transmission to
one where the transmission probability depends on the time since infection to understand how
the presence of primary HIV infection affects the importance of concurrency and vice versa.
The model shows that primary infection substantially amplifies the importance of concurrent
sexual partnerships, and that the sensitivity of epidemic spread to the degree of concurrency
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Figure 2.6: Simulations results for scenario with partnering parameters adapted from Manica-
land HIV/STD Prevention Project.
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is much greater than suggested by earlier models without primary infection. The reason for
this powerful interaction is that the potential for transmission in primary infection is “wasted”
under serial monogamy, since the newly infected individual is held in a sero-concordant part-
nership [289]. With concurrency, the potential for transmission in the primary stage is better
realised, since the newly infected individual can also be in another partnership with an unin-
fected individual. With constant infectiousness, the overall spread of the virus is less dependent
on onward transmission within the first few months of infection, so the delay for a new partner
under serial monogamy has less effect. As illustrated through this model, exposing susceptible
individuals to transmission during primary HIV infection is likely to be an important factor in
creating large HIV epidemics such as those experienced in sub-Saharan Africa and elsewhere;
concurrency is one efficient means of generating such exposures.
An initially surprising finding is that, at all levels of concurrency, the endemic prevalence of
HIV was lower when the transmission probability varied over the course of infection compared
to when it was constant. This is because, when there is a variable number of contacts per
sexual partnership, adding variability in the transmission probability over the course of infection
reduces the average infection probability per discordant partnership (irrespective of patterns of
concurrency) [178]. The reduction in endemic prevalence associated with variable infectivity is
not manifested in models that do not model partnership durations because they assume that
sexual partnerships consist of a single instantaneous contact. This finding may have important
implications for making predictions based on models that assume fixed infection probability per
partnership.
The proportional contributions of each stage of infection in our model was calculated without a
statistical fit to empirical HIV prevalence and sexual behavior data, so should not be interpreted
as literal estimates of these quantities. These findings are also not directly comparable with other
model estimates that do not include concurrency but do include heterogeneities in risk behavior
and different patterns of partnership formation [285]. Rather, we illustrate the potential for this
interaction, and how concurrency can dramatically change the importance of primary infection
in a particular population where individuals have a relatively large number of short duration
partnerships over their lifetime. The model also does not include possible reductions is risk
behavior associated with ageing or illness, which would likely increase the relative importance
of primary infection. In our simulations, and those of the Morris and Kretzschmar [230], the
method of increasing concurrency also increases the variance in numbers of sexual partnerships,
which could to contribute to the observed impact of concurrency on epidemic spread [220].
Goodreau and colleagues conducted a similar analysis to ours using a much more sophisticated
model that statistically fits modelled sexual networks to higher order network statistics in data
collected amongst young adults in Zimbabwe [290]. They consider four different estimates
for stage-specific infectivity, including the estimates from Hollingsworth and colleagues that
we used. They reach very similar conclusions as did we—that “at current behaviour levels, the
epidemic cannot be sustained in this population without both concurrency and acute infection.”
One weakness of both our model and Goodreau and colleagues’ is that the epidemics grow
more slowly than have the actual HIV epidemics in southern Africa. Concurrency is sometimes
considered as an alternative mechanism to high partner change rates in high-risk sub-populations
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for generating a large generalized epidemics, but the slow growth of the epidemic in these
models suggests that, while concurrency with primary infection can create endemic levels of
HIV prevalence similar to what have been observed, long-term concurrency alone is not capable
to explain the explosion of HIV over only a few years in southern Africa. Other factors not
included here, such as small groups with greater number of sexual partners and co-factors that
increase HIV transmission, are also likely to be part of that story [270, 291].
Concurrency was so crucial to the spread of HIV in these models models to because it was
a mechanism that created exposure of susceptible individuals during the period of high infec-
tiousness in primary infection. Other factors that elevate infectiousness during later stages of
infection, such as sexually transmitted infections or anal intercourse, be another means of cre-
ating high-risk exposures [292]. Concurrency also increases the transmission of other sexually
transmitted infections [223, 224], and so could be playing a double role of not only creating more
rapid exposures of susceptible individuals to HIV, but also a conduit for sexually transmitted
infections that make HIV transmission more likely to occur.
Our model assumed that individuals in concurrent partnerships had the same risk of HIV
transmission as individuals in monogamous partnerships. This might not be the case if individ-
uals in concurrent partnerships have less frequent sexual intercourse as individuals in monoga-
mous partnerships [150, 214]. Sawers, Isaac, and Stillwaggon extended our model to incorporate
this ‘coital dilution’ in which individuals in ‘non-primary’ partnerships have reduced HIV trans-
missibility compared to those in primary partnerships [293]. They find that when coital dilution
is above 25%, the epidemic no longer spreads even at the highest level of concurrency that we
consider. These results are corroborated by the results of exploratory analyses that we con-
ducted with a more crude implementation of coital dilution [294]. Implementing coital dilution
in this way means that as concurrency increases, the total amount of coitus in the population
decreases. Considering this, it is not as surprising that coital dilution reverses the effect of
concurrency, and it could also be argued that this breaks with the paradigm set out by Morris
and Kretzschmar of preserving the rest of the system while manipulating concurrency. In a
model of gonorrhoea transmission with concurrency, Welch and colleagues implemented coital
dilution conserving the overall number of coital acts in the population as concurrency varied,
and found that coital dilution affected the endemic level of infection, but only slightly [279].
The rapidity with which our results were replicated and extended by Sawers and colleagues is
a good example of how publishing model simulation code accelerates scientific discussion and
progress.
Small changes in the proportion of individuals having concurrent partnerships effected large
differences in endemic HIV prevalence, suggesting that slight differences between sex partner
networks in different settings could underlie disparate HIV epidemic levels. For example in-
creasing from 10% to 11% of individuals having concurrent partnerships increased the mean
endemic HIV prevalence from 3% to 7%. Further increasing concurrency to 12% pushed HIV
prevalence to 11%. This presents challenges for empirical work seeking to link concurrency and
HIV transmission in surveillance data; random statistical variation or small temporal changes
in the amount of concurrency could mask associations [292]. On the other hand, this sensitivity
to the amount of concurrency could have positive implications for HIV prevention efforts.
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More recently, others have investigated the potential impact of prevention interventions that
reduce concurrent sexual partnerships. McCreesh and colleagues use an individual-based sim-
ulation model carefully calibrated to behavioural and epidemiological data from rural Uganda
to investigate the impact of a hypothetical intervention that reduces concurrency over 10 years
but does not affect the overall number of partnerships [202]. This is accomplished by redis-
tributing partnerships from those with concurrent partners to individuals who do not have any
partners, similar to the approach pioneered by Morris and Kretzschmar. The result of this was
that an intervention which reduced concurrency by 20% reduced HIV incidence by 4.1% in men
and 9.2% in women, in relative terms. An intervention reducing concurrency by 50% reduced
incidence by 6.0% in men and 16.2% in women. Based on this they do not support concurrency
as a priority target for behaviour change interventions. However, it important to note that,
while a useful device for isolating concurrency in theoretical mathematical models, it is unlikely
that in a successful intervention reductions in concurrency would be compensated by increases
in sexual partnerships by those who are not sexually active. As such, these results should not
be interpreted as an evaluation of existing behaviour change communication campaigns that
communicate the potential HIV risk associated with concurrency [295].
Enns and colleagues compared interventions that reduce concurrency by removing the same
number of partnerships from individuals with three or four concurrent partners at the same time
and individuals with only two concurrent partners [296]. This comparison pinpoints the key
tenet underlying public health interventions aimed at reducing concurrency: that it is important
to make people in aware of the HIV risk associated with having only two partners rather than
just the risk associated with “many” partners. They test the intervention in models calibrated
to represent HIV epidemics in four countries—Swaziland, Tanzania, Uganda, and Zambia—but
use the reported number of partnerships in the last year as the point distribution of concurrent
partnerships, and so likely overestimate the amount of concurrency in the populations compared
to what is reported. Their analysis finds that on average reducing concurrent partnerships by
10% averts 11.7% of new infections over 10 years when reducing concurrency amongst individuals
with many partnerships, but only an 8.7% reduction when reducing concurrency in individuals
with only two partners. They find that even interventions that only reduce concurrency by 10%
at an annual cost of US$1 per person would be cost-saving due to averted treatment costs, but
it is to be reminded that there is not empirical evidence to quantify the level of effectiveness
that such an intervention might achieve. The effectiveness of the intervention declined by
around 30% when the baseline amount of concurrency was reduced by 50%. The finding that
intervening amongst higher risk individuals has a greater benefit than amongst those with lower
risk behaviour is expected [270], but quantifying this is a useful reminder for designing targets of
intervention programmes and weighing the relative effort required to reach higher versus lower
risk individuals.
Finally, accurate modelling of concurrency and the role of primary infection is also likely
to be important for assessing the efficacy of interventions that target prevention of onward
transmission by HIV positive individuals, in particular universal HIV testing and immediate
treatment [185], and interventions that target those currently in primary infection [297]. These
results show that the roles of concurrent sexual partnerships and primary HIV infection can only
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be understood in combination, and that primary infection in the context of concurrent sexual
partnerships may be a factor that has enabled HIV to spread through general populations to
such high levels.
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3 An epidemiological definition and
indicator for concurrent sexual
partnerships
3.1 Background
As we found in chapter 2, mathematical models have demonstrated that concurrency can in-
crease the size and speed of HIV epidemics [222, 230, 231, 267, 290]. In relation to the hyperen-
demic spread of HIV in southern Africa, the concurrency hypothesis argues that, while persons
experiencing generalised HIV epidemics do not necessarily have more sexual partners over their
lifetime than those in other regions of the world, they are more likely to have those partners
concurrently, allowing HIV to spread quickly across connected sexual networks.
Evidence for the concurrency hypothesis is limited and hotly debated [209, 215, 225, 226, 232,
298–301]. Empirical studies in the United States have associated concurrency with increased
an risk of transmitting a sexually transmitted infection [223, 224], but analyses have failed
to find an association between concurrency and HIV spread in sub-Saharan Africa [212, 219].
Some quantitative and qualitative studies have suggested that concurrency is more common
and acceptable in sub-Saharan Africa than elsewhere [75, 302], but a comprehensive review of
sexual behaviour globally concluded that while generally fewer Africans reported multiple sexual
partnerships, sufficient comparable data were not available to assess patterns in concurrency
[62].
The single point of agreement in the otherwise vitriolic debate is that the lack of a consistent
definition and measure of concurrency in the literature has hampered research to establish the
importance of concurrency in the spread of HIV in sub-Saharan Africa. A common definition
and measure of concurrency would accelerate epidemiological research on concurrency through
enabling comparisons of concurrency over time, across different settings, and between studies.
This chapter reviews approaches to measuring concurrency in the literature, describes a rec-
ommended definition, indicator, and survey instrument for measuring concurrency arrived at
through a consensus building process, and evaluates the characteristics and performance of this
indicator using sexual behaviour data from a high HIV prevalence population in South Africa.
3.1.1 Contributions and dissemination
The meeting to agree on a consensus definition, indicator, and instrument to measure concurrent
sexual partnerships was convened through the UNAIDS Reference Group on Estimates, Mod-
elling, and Projections chaired by Professor Geoffrey Garnett at Imperial College London. This
meeting was organised in collaboration with Goeffrey Garnett and Kelsey Case from Imperial
63
College London, and Dr. Mary Mahy and Dr. Peter Ghys from the Epidemiology and Anal-
ysis Division of UNAIDS. Mary Mahy assisted with the procurement of some existing sexual
behaviour survey instruments that were reviewed and all members of this group reviewed and
revised draft meeting agendas and meeting participant invitations. Kelsey Case coordinated
logistical aspects of the meeting. The full list of meeting participants who contributed to the
consensus recommendations is available in appendix 3.A. The author of this thesis prepared
the first draft of the agenda and participant list for the consensus building meeting, reviewed
literature and drafted materials and presentations that framed the purpose and outcomes of
the meeting, contributed to presentations and discussions during the consensus building meet-
ing, and was responsible for drafting and revising materials describing and disseminating the
conclusions of the process.
The recommendations for a consensus definition and indicator for concurrency were summa-
rized in a comment in The Lancet [263]. All meeting participated revised and approved this
comment for publication. The recommendations are described in full along with a priority re-
search agenda in the meeting report, co-authored with Kelsey Case, available at http://www.
epidem.org/Publications/Concurrency%20meeting%20recommendations_Final.pdf.
The demonstration of the calculation of the indicator and evaluation of the assumptions was
done using data from the Africa Centre for Health and Population Studies directed by Professor
Marie-Louise Newell. This analysis was conceived of by the author of this thesis and conducted
in collaboration with Dr. Nuala McGrath from the London School of Hygiene and Tropical
Medicine and the Africa Centre for Health and Population Studies. This work was published
as a peer-reviewed research letter in AIDS [303].
3.2 Methods
The research presented in this chapter consists of two parts. The first describes the process and
results of an international consultation that was conducted to create a consensus recommenda-
tion for an epidemiological definition, primary indicator, and survey instrument for measuring
concurrent sexual partnerships in a population. The second part uses sexual behaviour surveil-
lance data collected in a general population cohort in rural South Africa to demonstrate the
calculation of the consensus indicator and to evaluate the influence of specific decisions regarding
how the indicator should be calculated.
3.2.1 Consultation process to recommend a consensus definition, indicator,
and instrument for measuring concurrency
In April 2009, the UNAIDS Reference Group on Estimates, Modelling, and Projections (http:
//www.epidem.org) convened a meeting to agree on and recommend a consensus definition,
indicator, and survey instrument for measuring concurrent sexual partnerships in a population
and to identify a priority research agenda for methodological and epidemiological research re-
lated to the measurement of concurrency in sub-Saharan Africa and its association with HIV
transmission. In advance of this meeting, academic literature was reviewed on existing ap-
proaches to measuring concurrency, on the theoretical importance of concurrency for the spread
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of HIV, and on methodological challenges and research on measuring sexual behaviour data.
Existing survey instruments that had been used for sexual behaviour surveillance were collected
and evaluated for the ways in which questions pertaining to concurrency are asked.
A list of meeting participants was assembled to represent three key constituencies: researchers
studying the role of concurrency in the spread of HIV in sub-Saharan Africa using mathematical
modelling and empirical research, representatives of sexual behaviour and HIV surveillance en-
terprises including nationally-representative household-based surveys, such as the Demographic
and Health Surveys (DHS) and Multiple Indicator Cluster Survey (MICS) and population-
based cohort studies comprising the ALPHA network, and international, national, and non-
governmental organisations who use surveillance data and epidemiological research to make
decisions about HIV prevention strategies, including around concurrent sexual partnerships.
The meeting agenda was constructed to cover the various topics that needed to be consid-
ered in selecting a recommended indicator. These included presentations on the theoretical
predictions of concurrency hypothesis, existing indicators, approaches, and instruments used to
measure concurrency, the experience of cross-sectional and longitudinal cohorts that measure
concurrency and general considerations for sexual behaviour surveillance including reporting
bias in sexual behaviour surveys and methods to reduce this. Meeting participants were divided
into three working groups, with each group including participants representing each of the con-
stituencies participating in the meeting. Each working group addressed the following questions
over two sessions:
1. What do we really want to know, and what can be realistically collected? How might this
be different in national population-based surveys versus research settings?
2. Which elements of existing tools are successful at capturing concurrency?
3. What additional variables need to be collected to understand the link with HIV?
4. What questions should be included in household survey questionnaires to capture concur-
rent sexual partnerships? (create a model questionnaire)
5. What research designs and instruments should be used for comparing the household survey
methods to alternative methods and tools? Can these comparisons be used to derive
“correction factors”?
6. What research designs should be used for linking concurrency to HIV transmission?
Guided by these questions, each working group independently reported their recommenda-
tions for definitions, indicators, survey instruments, and research designs. Following presen-
tation of recommendations from each working group, the full group of meeting participants
discussed proposals. Decisions for final recommendations were taken by consensus of all meet-
ing participants.
Results presented in this chapter pertain to the recommended definition, indicator, and
survey instrument for measuring concurrency. Full recommendations of the meeting partic-
ipants regarding other topics that should be included in sexual behaviour surveillance and
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priority methodological research topics and designs are available in the full report at http:
//www.epidem.org/publications.htm.
3.2.2 Calculation and evaluation of the recommended indicator
We use data from the from the Africa Centre Demographic Information System (ACDIS) col-
lated by the Africa Centre for Health and Population Studies to demonstrate the calculation
of the recommended concurrency indicator and to explore the influence of decisions that were
made. The population surveyed by the Africa Centre consists of all households residing in a
geographically defined area with high HIV prevalence in rural KwaZulu-Natal province, South
Africa. The Africa Centre began HIV and sexual behavioural surveillance in 2003, and have
conducted annual sexual behaviour surveys, including detailed sexual partner histories, and HIV
surveys of all adults residing in the surveillance area since 2005. The setting, study population,
and surveillance activities are described in greater detail in chapter 4 and in the cohort profile
[262]. Data used for this analysis are all sexual behaviour surveys conducted over the six years
from 2005 through 2010 amongst resident men aged 15–49 years at the time of the survey. There
is a total of 26,088 observations on 13,785 men. The analyses conducted presented in section
3.5.
3.3 Review of approaches to measuring concurrency and its
association with HIV transmission
The proliferation of different indicators for measuring concurrency reported in the literature has
prevented estimates of concurrency from being compared across studies. The use of different
indicators is understandable because it is not obvious what measures of concurrency, or other
network properties, correlate best with individual or population HIV risk [277]. Instead, indi-
cators are often chosen according to the purpose of the study and limitations imposed by the
survey instrument used to collect the available data. The most commonly reported indicator of
concurrency has been some measure of the prevalence of concurrency in a population, but dif-
ferent choices of both numerator and denominator make the concurrency prevalences reported
in different studies incomparable. Different choices of how to define individuals who have had
concurrent sexual partnerships to be included in the numerator are:
• individuals engaged in more than one sexual partnership at the time of interview. The
number of sexual partnerships in which the respondent is involved at the time of the
interview may be established either by asking a single direct question to this effect, such
as “How many sexual relationships are you currently involved in?” [90, 130, 304], or
by asking specific questions about each of some number (often three) of the most recent
sexual partners, and for each partner asking whether that sexual partnership is ongoing
[231, 305, 306].
• individuals who had any overlapping sexual partnerships within the past year [218, 307,
308]. Determining whether a respondent had any overlapping sexual partnerships within
the past year is done by asking the respondent the dates of first and most recent sexual
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intercourse with each of three or more sexual partners and comparing these dates to see
if the dates of intercourse of any two partners overlapped within the past year.
• individuals who ever had sex with anyone other than their main partner during their
current or most recent relationship [305, 309]. This is determined by asking details about
an individuals current or most recent regular sexual partner, and asking a specific question
as to whether the respondent had sex with any other person between the time first and
most recent times of sex with this partner.
• as a proxy for concurrency, individuals who have had multiple sexual partners in a recent
time period, such as the past 30 days [302] or three months [310]. Again, determination of
whether the respondent had multiple sexual partners within this period may be determined
either by a single question about the number of partners had during the period, or by
asking dates of most recent sex with each of a number of recent partners and determining
whether more than one falls within the retrospective window.
The denominators used in the calculation of concurrency prevalence have also varied. Possible
choice of denominators include for a prevalence measure of concurrency include:
• the entire adult population (or sampled population),
• the population who have ever had sex,
• the population that is currently sexually active, or that was sexually active in the past
year, or
• the population that has had multiple partnerships in the past year.
As noted, the indicator of concurrency based on the current number of partnerships, or the
proxy indicator based on the number of sexual partnerships during a recent time period can
be estimated either by asking a direct question about this behaviour, or by calculating the
behaviour from sexual partner histories including detailed information about the dates of first
and last sexual intercourse with many recent sexual partners. In theory, if sexual behaviour is
perfectly reported, estimates of the indicator from both approaches should be the same, but in
practice they have been observed to differ [311]. This difference is at least partially attributed
to sexual partner histories being potentially long and cognitively challenging to answer, which
may result in increased missing data and underreporting of sexual partnerships [311]. Measures
of concurrency that rely on dates of first and most recent sex with sexual partners may be
particularly sensitive bias due to poor recall of dates. Thus to compare prevalence measures of
concurrency between studies and over time, it will likely be important not only that the same
indicator of concurrency be used in the numerator, and the same population in the denominator,
but also that the instrument used to characterise the numerator be consistent.
Beyond the prevalence of concurrency in a population, other measures have been proposed
that seek to more sensitively capture the epidemiological risk associated with concurrency.
Measures that capture the duration of overlap of partnerships may provide a more precise
measure of the exposure to risk from concurrency, but rely on precise reporting of dates of first
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and last sexual intercourse with each partner. Lagarde colleagues and Foxman and colleagues
both calculate the number of days of overlap of pairs of sexual partnerships in the past year [212,
312] (for Foxman and colleagues periods of overlap are actually considered as negative duration
‘gaps’ between sequential partnerships). Another measure reported in empirical estimates of
concurrency is the κ = σ2/µ+µ− 1 proposed by Kretzschmar and Morris based on the mean µ
and variance σ2 of the partner degree distribution (the distribution of number of current partners
at the time of the survey). When calculating this statistic, Le Pont and colleagues excluded
individuals with no current partners [216], while Lagarde and colleagues included all respondents
in the mean and variance calculation [212] (consistent with the calculation of the statistic in
mathematical models). When the partner degree distribution follows a Poisson distribution,
the κ statistic approximates the proportion of partnerships which are concurrent [259], but if
the observed degree distribution is not Poisson, empirical estimated obtained by calculating κ
based on the mean and variance would differ from estimates calculated by summing the number
of pairs of concurrent partnerships and dividing by the total number of partnerships. Finally,
Lagarde and colleagues proposed an innovative indicator which they termed the individual
index of concurrency that represents the ratio of the actual duration of overlap between two
partnerships to the expected amount of overlap if partnerships of the same duration had formed
and dissolved at random time points [212]. This measure of the synchronicity of multiple sexual
partnerships seeks to distinguish the effect of concurrency from multiple sexual partnerships or
the overall total duration spent in a sexual partnership. The common disadvantages of all of
these indicators compared to concurrency prevalence indicators are that they are more difficult
to calculate from data, not as intuitively interpretable, and may be even more sensitive to date
misreporting in sexual partner histories than concurrency prevalence measures.
An ideal indicator for concurrency in a population would detect variation in concurrency
across populations and over time and would capture the exposure to concurrency sufficiently
to test the hypothesised association between concurrency and HIV spread, and in particular
be able to distinguish concurrency from the well established risk factor of having many sexual
partners, while being as easy to measure and calculate as possible.
3.4 Recommended definition, indicator, and survey instrument
for concurrent sexual partnerships
3.4.1 Definition
The participants of the UNAIDS Reference Group meeting recommended the following definition
for concurrent sexual partnerships:
Overlapping sexual partnerships where sexual intercourse with one partner occurs
between two acts of intercourse with another partner.
This definition embodies the generally understood, but often unstated, definition of concur-
rency in the literature, while emphasising that, for the purpose of defining concurrent sexual
partnerships in the context of HIV epidemiology, sexual partnerships matter in terms of acts of
sexual intercourse.
68
The Reference Group Meeting also discussed the terminology used to describe concurrency
in relation to HIV epidemiology. The acronym ‘MCP’ has at times been used in literature
and discussion about concurrency. In some cases, this is used as an acronym for ‘multiple and
concurrent partnerships’, a phrase for concomitantly describing the related but not synonymous
risk behaviours of having multiple sexual partners over some time period and having concurrent
sexual partners. In other instances MCP is used as an acronym for the phrase ‘multiple con-
current partnerships’, for which the definition is ambiguous, but is often used as a synonym for
‘concurrent sexual partnerships’. Due to the ambiguity around the meaning of ‘MCP’, it was
recommended that this acronym is not used to identify or describe concurrency, preferring the
phrases ‘concurrent sexual partnerships’, ‘concurrent partnerships’, or simply ‘concurrency’.
3.4.2 Indicators
The primary indicator of concurrency recommended is the point prevalence of concurrency in a
population, defined as the percentage of the adult population that has more than one ongoing
partnership at a point in time, where, as emphasised in the definition of concurrency, partner-
ships are ‘ongoing’ if sexual intercourse occurs with that partner before and after that point
in time. By considering only the ongoing partnerships that overlap at a single point in time,
this indicator emphasises the occurrence of sustained overlapping partnerships versus having a
single long-term partnership with occasional once-off sexual encounters, thereby differentiating
the exposure to concurrency in the population. The numerator for the indicator is the number
of respondents with more than one ongoing partnership at the point in time six months before
the day of the interview, rather than the number of partnerships ongoing at the day of the inter-
view. This choice of a six month retrospective is made because, firstly, the point prevalence of
concurrency can be calculated from the data currently collected by the standard questionnaire
used by the Demographic and Health Survey and other large national surveys [313], which cur-
rently do not include a question about whether partnerships are ongoing, and, secondly, because
calculating the point prevalence six months in the past relies on actual dates of first and most
recent sexual intercourse with each partner rather than speculation by the respondent as to
whether or not each of his or her partnerships are ongoing. The denominator for the indicator
is the total number of respondents aged 15 to 49 years. Using the whole population as the
denominator, instead of choices such as the sexually active population or the population with
partnerships at the time of the point prevalence measurement, ensures that the measurement
of concurrency will not be affected by changes in other sexual behaviours that could change the
denominator. For example, if the sexually active population were the denominator, an increases
in the age at first sex would create an increase in the indicator of concurrency even if there was
no change in the amount of concurrency occurring. This choice of using the total population as
the denominator was also consistent with the already established United Nations indicator of
multiple sexual partnerships (described as higher-risk sex) [314].
In addition to the main point prevalence indicator, the Reference Group acknowledged two
other indicators that also provide useful summaries of concurrency in a population. The first
is the cumulative prevalence of concurrent partnerships, defined as the proportion of the adult
population who have had any overlapping relationships in the past year. This is measured by
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Figure 3.1: Example of calculation of concurrency indicators based on hypothetical sexual part-
ner histories. Dates of first and last sex with up to three partners in past year in
survey of six respondents. Point prevalence of concurrency 6 months before inter-
view date is 33.3% (respondents 1 and 6 had concurrent partners 6 months before
interview). Cumulative prevalence of concurrency is 50% (1, 3, and 6 had concurrent
partnerships in past year). Proportion of individuals with multiple partnerships in
past year who had concurrent partnerships in past year is 60% (1, 3, and 6 had con-
current partnerships in past year, while 2 and 5 had multiple partnerships that were
not concurrent). Respondent 5 reported both one partnership ending and another
beginning 6 months before interview date. Consensus of meeting participants was
that this should not be included in numerator for calculation of these indicators, as
it is not possible to tell whether these partnerships are serial or concurrent.
identifying the individuals for whom any of the sexual partnerships reported in the past year
have been overlapping based on sexual partner histories. This measure may give a more complete
picture of the total population engaging in any form of concurrent partnership, including short
and once-off partnerships that may be missed in the point prevalence, but does not distinguish
as clearly as does the point prevalence between the populations having sustained overlapping
partnerships, compared to having many partners.
The second additional indicator is the proportion of multiple partnerships that are concurrent,
calculated by dividing the number of adults with concurrent partnerships in the past year by
the number of adults with multiple partnerships in the past year. This indicator seeks to
isolate the effect of having concurrent partnerships from the already established risk factor of
multiple partnerships—an important measure for research into the role of concurrency in HIV
transmission. The interpretation of this indicator is subtle and the programmatic implications
of changes in this indicator over time can only be made carefully in conjunction with other
indicators. Figure 3.1 demonstrates the calculation of each of the measures from sexual partner
histories (see section 3.4.3) from a hypothetical survey of six respondents.
Meeting participants recommended against measures of concurrency based on the proportion
of individuals who have ever had sexual intercourse with another person during their current or
most recent partnership. This indicator is problematic because it does not restrict the period
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within which concurrent partners occur, so individuals in longer partnerships have more oppor-
tunity to have had concurrent partnerships even though it may not convey more risk. It also
does not capture the intensity or exposure to concurrent partnerships as concurrency involving
a single sex act with one partner is captured equally with long-term concurrency over many
months. It was also recommended against reporting the percentage of individuals who have
had more than one sexual partner in the past month as a ‘proxy’ measure of concurrency. This
measure does not actually measure overlapping partnerships, but is rather a measure of having
had recent multiple partnerships, which may have been serially monogamous or concurrent.
Such measures are not likely to be able to disentangle the risks of concurrency and multiple
sexual partners.
3.4.3 Survey instrument
Calculation of each of the recommended indicators requires ‘sexual partner history’ modules to
collect information about the timing of sexual activity with recent sexual partners. For compa-
rability of measurements, the Reference Group meeting participants emphasised the importance
of questions being asked and answered in a consistent way, as subtle differences in wording or
response categories may affect the results of the survey [315]. The three questions to be asked
about each of the last three sexual partners in the past twelve months that are minimally re-
quired to calculate indicators of concurrency, and which should be included in every survey,
are:
Q1: When was the last time you had sexual intercourse with this partner? (Answer in
days/weeks/months ago)
Q2: When was the first time you had sexual intercourse with this person? (Answer in days/
weeks/months ago)
Q3: Are you still having sex with this person?
The consensus was that questions about dates (e.g. first and last sex) should be asked in terms
of how long ago (days ago, weeks ago, months ago, years ago) events occurred rather than the
calendar date on which events occurred. Especially in areas in which literacy is relatively lower,
this was perceived to likely be easier for respondents to recall. Questions about partners should
be framed specifically around sexual partners and questions about dates should specifically refer
to acts of sex to distinguish between disease risk behaviour and culturally defined notions of
relationships. For example, prompting questions should be similar to “Tell me about your most
recent sexual partner,” rather than “Tell me about your most recent partner” or “Tell me about
your most recent relationship,” and questions about dates of first and last sex should be “When
was the first time you had sexual intercourse with this person?” rather than “When did this
relationship begin?” Extra care should be given to ensure that these distinctions are maintained
in translation of questions.
It was recommended that this information be collected about the three most recent sexual
partners in the past 12 months. Theoretically, any number of partners greater than one could
be used, and ideally all from the past year would be included. However, three partners is an
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accepted norm because it is not too onerous and potentially contains information about at least
one non-marital partner for polygynously married men.
3.5 Evaluation of the recommended indicator using
demographic surveillance data from a high-prevalence
population in rural South Africa
The most contentious choice made in reaching consensus about an indicator to measure con-
current sexual partnerships was the decision that the measurement of concurrency be based
on reporting overlapping partnerships six months before the interview, rather than based on
the reported number of current sexual partnerships at the time of the interview. The ratio-
nale for measuring concurrency at a retrospective time point before the interview instead of
concurrency at the time of the interview was so that the indicator would be based on actual
observed episodes of concurrency, rather than speculation about the prospects of future sexual
acts with recent partners. A disadvantage of the retrospective indicator is that it is reflective of
sexual behaviour six months before the survey completion, and so is a more outdated measure
of current trends. The retrospective indicator requires the collection of detailed information
about each partner in sexual partner histories which could be challenging to recall accurately,
while the ‘current’ concurrency indicator could be measured using a single question of the form
“How many sexual partners are you currently having sex with?”
Having decided to estimate concurrency at a time before the survey, the next decision was
what this retrospective time point should be. Using dates of first and last sex with the three
most recent partners could result in systematic biases in the indicator. If the retrospective
time point is too recent, this could exclude concurrent partnerships where the respondent had
not had sex with the partner during the intervening period, but will have sex with the partner
again in the future. Thus too recent a retrospective time point would theoretically result in a
downward bias in the estimate of concurrency. On the other hand, if the retrospective period is
too long in the past, the truncation of data collection to be about the three most recent partners
means that individuals who had two or more new sexual partners since the retrospective time
point would not have the opportunity to report on whether concurrency occurred at the chosen
time point, also downward biasing the estimate of the indicator. The optimal choice for a
retrospective period at which to measure concurrency would be that which minimises these two
downward biases, but unfortunately the UNAIDS Reference Group recommendation to use a
six month retrospective period was made without the benefit of empirical data. Evaluating the
importance of this decision was identified as a priority area for research following the UNAIDS
Reference Group meeting.
3.5.1 Data
We use the sexual partner history data from the Africa Centre Demographic Information System
to compare estimates of the point prevalence of concurrency based on reporting of current
concurrency and concurrency at different retrospective time points before the interview. The
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sexual behaviour survey includes questions about up to the three most recent sexual partners in
the past year required to calculate the recommended point prevalence of concurrency indicator:
• Are you still in a sexual relationship with (partner)?
• How long were you/have you been sexually involved with this partner?
• When was the last time you had sex with (partner)?
The latter two questions are answer as the duration before the interview in days, weeks, months,
or years at the discretion of the respondent. Asking how long the respondent has been sexually
involved with the partner was not the recommended way to ask about the time of first sex in
the model survey instrument in section 3.4.3 because it could leave ambiguity as to whether
the reference point is the current time or the time of last sex. To calculate the time of first
sex, which is used to assess the point prevalence of concurrency, we subtracted this duration
from the time of the interview if the respondent reported the partnership is still ongoing, and
subtracted it from the time most recent sex if the respondent reported the partnership was no
longer ongoing. We compare estimates of concurrency between current and various retrospective
time points only for men’s sexual behaviour surveys because in every round less than 0.4% of
resident women respondents reported any form of concurrency.
3.5.2 Analyses
We calculated the ‘current’ point prevalence of concurrency based on the reported number of
ongoing sexual partners at the time of the survey, based on answering ‘yes’ to the question “Are
you still in a sexual relationship with (partner)” for more than one partner. We calculated the
value of the ‘retrospective’ point prevalence of concurrency for each month ranging from 1 to
11 months before the interview based on the reported time of first and last sex with each of
the sexual partners. If the respondent reported that he was still in a sexual relationship with
a partner, the date of first sex was determined by subtracting the reported duration sexually
involved with the partner from the date of the interview. If the respondent reported no longer
being sexually involved with the partner, the date of first sex was determined by subtracting
the duration sexually involved from the reported date of last sex. The estimates use pooled
data over the six years of surveys included in the analysis. Confidence intervals represent exact
binomial 95% confidence intervals.
Next we calculated the percentage of respondents who had missing data about the dates of
first or last sexual intercourse with any of reported sexual partners in the last year stratified by
the number of partnerships in the past year. To explore the extent to which any discrepancy
between the current and retrospective concurrency estimates might be explained by increased
missing data for those with more sexual partners, we calculated adjusted concurrency estimates
weighted by the inverse probability of having complete data about the dates of first and last
sex for all sexual partnerships, using the weights:
wi,j =
Total number of respondents in age group i with j partners in the past year
Number of respondents with complete data in group i with j partners in the past year
.
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Figure 3.2: Point prevalence of concurrency calculated using the number of current partners at
the time of the survey (left most square) and for retrospective ranging from 1 month
to 11 months before the interview. Based on resident male respondents age 15–49
years, pooled over years 2005 to 2010.
Weight-adjusted estimates of the six month retrospective indicator by five-year age groups are
compared with the current point prevalence of concurrency and the unadjusted retrospective
point prevalence.
The analysis here does not consider factors such as the design of the survey or non-response,
so results should not be considered as estimates of the level or trend in concurrency in this
population over time. This is the focus of chapter 4. The purpose is only to calculate the point
prevalence of concurrency indicator in different ways using the same respondents to understand
how the choices made in the UNAIDS Reference Group recommendations affect the behaviour
of the indicator.
3.5.3 Results
Figure 3.2 shows the estimates of concurrency at each retrospective month. At about four
to six months before the interview, the estimate stabilises, which suggests that six months is
within the optimal measurement period. As hypothesised, closer to the interview the estimate of
concurrency is lower. This could be because respondents have not recently had sex with a long-
term partner or because of a reluctance to report recently initiated or dissolved partnerships.
The estimates of concurrency relating to the time points seven to eleven months before the
interview were also lower, which could possibly be due to the truncation of the survey instrument
to only three partners in the past year. However, we do not think that this is likely to have
exerted substantial bias because only 0.2% of men who were not already classified as having
concurrent partners reported having more than three partners in the past year. We believe
that this bias at longer retrospective periods is more likely due to poor recall leading to under-
reporting or misreporting details of sexual behaviour so long before the interview.
There was a substantial discrepancy between the point prevalence of concurrency of 6.7%
based on the reported number of current partners at the time of the interview and the 4.8% es-
timated using the 6-month retrospective period recommended by the UNAIDS Reference Group
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Figure 3.3: The percentage of respondents with missing date of first sex or date of most recent
sex for at least one partner by number of reported partners in past year.
(p < 0.001). It is not immediately obvious which represents a more accurate estimate of the
true point prevalence of concurrency. The ‘current’ concurrency indicator might overestimate
true concurrency if respondents are overly optimistic about their future prospects with sexual
partners and report that they are still in a sexual partnership with a partner when in fact
future sexual relations (and hence the overlapping concurrent partnerships) are not realised.
Alternately, the six month retrospective indicator could underestimate true concurrency if re-
spondents under-report partnerships which have dissolved by the time of the survey or misreport
the dates of these partnerships.
Another mechanism that could explain a lower point prevalence estimate for retrospective
concurrency compared to current concurrency is if individuals with more partners in the past
year are more likely to have missing data about the dates of first and most recent sex for any
of their partners, which would affect the estimate of retrospective concurrency, but not current
concurrency [311]. Figure 3.3 shows that this is indeed the case. For those with only one partner
in the past year, 5.9% are missing data about the date of first or most recent sex with that
partner. For those with two partners, this increases to 16.1% of men missing data about the
first or last sex for at least one of the partners, 20.2% of those with three partners are missing
data, and 25.9% of those with four or more partners are missing data.
Weighting the six month retrospective indicator by the inverse of the probability of having
complete sexual partner history data conditional on the number of partners in the past year
increased the estimate of the six-month retrospective point prevalence of concurrency to 5.7%.
This partially, but not completely, closes the discrepancy between the 4.8% na¨ıve estimate the
six month retrospective point prevalence and the 6.7% estimate of current point prevalence of
concurrency. Figure 3.4 compares these three estimates—the current point prevalence estimate,
the six month retrospective estimate, and the six month retrospective estimate adjusted for
missing data—within five year age groups. There was a discrepancy between the current and
retrospective indicators in all but one age group, but the difference was largest in the younger
age groups. In the older age groups adjusting for disproportionate missing data in those with
more partners explained the discrepancy. That the remaining discrepancy between current and
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Figure 3.4: Current versus retrospective point prevalence of concurrency by five year age groups.
Squares represent point prevalence of concurrency based on current number of sex-
ual partners at the time of the survey, black circles represent the point prevalence
of concurrency six months before the survey, and grey circles represent the point
prevalence of concurrency six months before the interview adjusted for increased
missing data among those reporting more partnerships.
retrospective concurrency is in young men could suggest that overoptimistic intentions about
future sexual relations could be inflating the current concurrency estimate. Another possibility
is simply that young men, as they age, could be having more concurrency at the time of the
survey than they were six months before. However, if this were a predominate trend in explaining
the discrepancy, then we would have expected to have seen a gradual reduction each successive
month in Figure 3.2 instead of the trend which we observed.
3.6 Discussion
The success of the proposed consensus indicator should be judged by two criteria: the ability of
the indicator to robustly identify trends in concurrency across time and space and adjudicate
the hypothesised epidemiological association between concurrency and HIV spread, and, second,
the extent to which the indicator is disseminated and adopted.
On the second criterion, the indicator proposed by the UNAIDS Epidemiology Reference
Group has been an unqualified success. A report describing the proposed indicator, including
detailed instructions for its calculation, was produced and disseminated rapidly following the
meeting. The recommendations were summarised in a Comment in The Lancet published online
on the following World AIDS Day (1 December 2009).
Nearly all of the papers published subsequent to the meeting have incorporated the consensus
point prevalence indicator, often reporting the estimate of the proposed indicator alongside other
measures of concurrency [202, 316–320]. Not all have necessarily reported the indicator, usually
because of limitations in previously collected data [321]. However, in these cases, the existence
of the consensus indicator allows it to be clearly stated that the measure being reported does
not conform to the recommended indicator and so may not necessarily be comparable to other
estimates.
Specific recommendations for the standard Demographic and Health Survey questionnaire
76
were prepared and submitted to Measure DHS, the organization responsible for designing and
implementing the Demographic and Health Surveys. A number of these recommendations
were adopted and a revised questionnaire has been used for DHS surveys in five countries:
Congo Brazzaville, Lesotho, Malawi, Mozambique, and Tanzania. Measure DHS has produced
a Methodological Report describing in detail how to calculate the recommended concurrency
indicators from DHS survey data and presenting the data on concurrency from these five surveys
[322]. Population Services International have issued a Research & Metrics Toolkit describing the
indicators and their calculation [323]. The indicators were submitted for review to be considered
for inclusion in the next revision of the set of HIV prevention indicators required by the UN
General Assembly Special Session on HIV/AIDS. The ALPHA network of general population-
based cohorts in southern and eastern Africa convened a meeting in December 2009 to define
a coordinated research agenda around concurrency and measuring sexual behaviour over the
period 2010 to 2015.
Whether the indicator fulfills the first criterion remains equivocal. Our analysis, using six
years of surveillance data from rural KwaZulu Natal, South Africa, concluded that six months
before the survey appeared to be a good choice for measuring retrospective concurrency in
terms of minimising the downward biases that could occur if the retrospective time point was
too recent or too far in the past. In data about sexual partnerships amongst young adults in
peri-urban growth points in Zimbabwe, Goodreau and colleagues found that the estimate of the
point prevalence of concurrency was highest two months before the survey [290], compared to
the four months in the data we analysed (Figure 3.2), but they did not publish the estimates
for all months so it was not possible to see if the estimate was relatively stable over a period of
a number of months, as we found.
We identified a substantial difference between concurrency estimated based on the reported
number of current partners at the time of the interview and the recommended method of
calculating partnership overlaps at a retrospective point before the survey. Missing data on
the dates of sexual relationships exert a downward bias on the retrospective point prevalence
indicator, highlighting the importance of considering missing data when estimating population-
level concurrency indicators using sexual partnership histories, taken up in the next chapter.
Missing data did not fully explain the discrepancy though, and further research is needed to
determine whether the residual discrepancy is attributable to overestimation of future relations
or underreporting of retrospective partners.
Morris, Epstein, and Wawer also comment on the discrepancy between current concurrency
and six month retrospective concurrency [264]. While acknowledging the potential unreliability
of questions about future intentions, they postulate that the potential for error in this is much
less than likely error resulting from date misreporting, poor recall, and truncation, and so
current concurrency indicator is preferred. However, the evidence given to support this, that in
a study of sexual behaviour in the US the discrepancy between men’s and women’s disappeared
when considering the current number of sexual partners, references a paper which does not
report current number of partners, only lifetime partners and partners in the last year. Morris,
Epstein, and Wawer compare the cumulative prevalence of concurrency and the point prevalence
of concurrency indicators in three sexual partner history data sets collected between 1992 and
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1994 in Uganda, Thailand, and the United States. They find that men in Thailand and Uganda
have similar levels of concurrency when measured by the cumulative prevalence indicator, but
that men in Uganda have much higher levels of concurrency indicated by the point prevalence
indicator, concluding that the point prevalence indicator, but not the cumulative prevalence
measure, distinguish the different levels of HIV in these three populations. Pre-publication
presentation of this example informed the discussions that led to the UNAIDS Reference Group’s
recommendations, and so this finding should not be considered as independent confirmation of
the recommendation but rather as part of the process by which it was reached.
Using an extensive sexual partner history survey conducted in a rural population in northern
Malawi, where polygyny remains common, Glynn and colleagues evaluated the influence of
the recommendation that partnerships starting and ending on the same date be excluded as
concurrent partnerships and the truncation to only three partners [320]. They found that
neither of these assumptions substantially affected estimates of the concurrency. In contrast
to our findings based on data collected in rural KwaZulu Natal, Glynn and colleagues did not
find a substantial difference between six month retrospective concurrency (12.0% of men age
15–59 years) and current concurrency (11.5% of men age 15–59 years). The majority of men’s
concurrency in northern Malawi is the result of formal polygyny, whereas in KwaZulu-Natal
even being married was uncommon for men. This difference could influence the reporting,
acceptability, and stability of concurrent partnerships between these two settings. Similar to
our findings, though, is that discrepancies between indicators were larger for younger men than
for older men.
Glynn and colleagues also investigated different ways of assessing the cumulative prevalence
of concurrency, and found that the cumulative prevalence of concurrency estimated based on
overlapping dates of first and last sex was much lower than when concurrency in the last year was
assessed using a direct question “Over the last year, during your relationship with him/her, did
you have other sexual partners?” Maughan-Brown and Venkataramani raise a similar concern
based on two rounds of data collected amongst young adults in Cape Town, South Africa [324].
In 2005, 17% of men and 10% of women who only reported having one sexual partner in the
past year in the sexual partner history module answered ‘yes’ to the question that they were
having sex with someone else while with this partner. This is not definitive evidence of under-
reporting because the timing of the other partner is not specified to be in the past year, but
nonetheless it is suggestive. In 2009, after extensive efforts to improve the completeness and
accuracy of sexual partner reporting, they found similar levels, and additionally found that 8%
of respondents who only reported one partner in the sexual partner history answered that they
had more than one sexual partner in the last twelve months in response to a direct question to
this effect. In addition to our finding that missing data increases with more partners in sexual
partner histories, this suggests that some partners who are acknowledged in other parts of the
survey are completely unreported in sexual partner histories, which would downward bias the
recommended indicator.
A common concern of all of these investigations into the indicators has been the extent and
impact of under-reporting of sexual partnerships in sexual partner histories. This is a broad
concern for sexual behaviour surveillance, but the concurrency indicators are particularly sen-
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sitive to it. The best suited study to assess this is the Likoma Network Study in which a sexual
network survey was conducted amongst all adults in seven villages on Likoma Island in Lake
Malawi [325, 326]. Respondents were asked to privately give the names of their sexual part-
ners in audio computer-assisted self-interviews, and later names were matched with household
census records, allowing comparison of the reporting of sexual partnerships by both partners.
Helleringer and colleagues found that for recent partnerships (those starting less than one year
prior to the survey) men reported only 72% of the partnerships in which they were involved
while women reported only 50% of the short-term partnerships in which they were involved. For
long duration partnerships, reporting was higher—84% for men and 71% for women. Dissolved
partnerships were much less likely to be reciprocally reported than were ongoing partnerships,
leading Helleringer and colleagues to conclude that the point prevalence of concurrency should
be measured at the time of the interview, when reciprocal reporting of partnerships is higher,
rather than at six months before the survey. However, even when measuring current concur-
rency, including only self-reported partnerships had considerable implications for estimates of
concurrency. Amongst respondents who reported only partnerships with others in the sample,
estimates of the point prevalence of concurrency at the time of the interview based on self-
reported data only (as would be available in a typical egocentric network survey) were 1% for
women and 8.5% of men. This increased to around 9% for women and 16.5% for men when
reports of partnerships from either partner were included. Helleringer’s study, which required re-
spondents to give their partners’ names as a part of the audio computer-assisted self-interview,
could exacerbate the under-reporting of sexual of sexual partnerships in a survey, compared
to typical sexual partner history surveys in which partners are reported about without being
named. Nonetheless, if it is the case that considering partnerships reported by either partner
is a more accurate representation of the true sexual network, this study creates considerable
doubts about the ability of ego-centric sexual behaviour surveillance to accurately estimate the
levels levels of concurrency.
Helleringer and colleagues make a compelling case for preferring measurement of current
concurrency rather than six month retrospective concurrency as has been recommended by the
UNAIDS Reference Group. Thus far, most of these studies investigating current concurrency
have still relied on data collected through detailed sexual partner histories. An avenue which
has not been thoroughly explored is reporting of current concurrency using a direct questions
such as “How many sexual partnerships are you currently involved in?” Such an approach
would mitigate concerns about missing data and survey fatigue leading to underreporting of
partnerships, but might also be more susceptible to inflation if respondents do not have to
explicitly count their partnerships.
The flurry of new research focused on aspects of the measurement of concurrency has been
a direct response to the dissemination of the recommended consensus indicator, highlighting
the power of the process that was undertaken to provide focus and motivation to an important
topic area that had been fragmented. One explicit aim of the process was to create a priority
research agenda around measuring concurrency. But, in order to conclude the consensus build-
ing process with a firm proposal, a number of key decisions were made about the calculation of
the indicator without the benefit of empirical investigation. One reason for this is that it was
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perceived that many of the data most ideally suited to answer the questions did not yet exist,
which has led to a coordinated process to revise some sexual behaviour survey instruments to
be collect these data. However, given the concerns and critiques of the recommended indicator
that have been raised using existing data, in retrospect it is unfortunate that this evidence was
not brought to bear during the process and used to inform the selection of the indicator. It is
unknown whether additional empirical evidence would have affected the choice of indicator—
other reasons for selecting the recommended indicator included conformity with existing survey
data and the improbability of revising some commonly used survey instruments—but it would
have been informative to have been able to incorporate empirical data about the specific pro-
posed indicators into the process. This would have, however, required a reformulation of the
process as detailed specification of proposed indicators only emerged through the meeting at
which the final recommendations were discussed and proposed.
Since the dissemination of these recommendations, one well designed epidemiological study
has investigated the association between concurrency and HIV incidence at the community
level. Using an earlier round of sexual behaviour data collected in the same population in rural
KwaZulu-Natal as we analysed in section 3.5, Tanser and colleagues assessed the association
between the point prevalence of concurrency and number of lifetime partners amongst men in
2004 with HIV incidence amongst women over 2004 to 2009 [304]. In this round of the survey,
the point prevalence of concurrency was based on the question “How many sexual relationships
do you consider yourself to be involved in at the moment?” rather than sexual partner histories.
Tanser and colleagues found no evidence of an association between between concurrency and
HIV transmission at the community level, but did find that the average number of lifetime sexual
partners was associated with HIV transmission. While this study is the most methodologically
robust empirical test of the concurrency hypothesis to date, it is not without its limitations
which have led some to reject it as an adequate assessment of the hypothesis—the measure of
exposure to concurrency was very crude and assumed that similar levels of concurrency persisted
over the six subsequent years of incidence measurement [327], it assumes that patterns of sexual
networks are geographically local [328, 329], and that measurement error in concurrency could
attenuate their estimated effect [330]—and so it has not ended the debate about the importance
of concurrency as a driver of generalised HIV epidemics. It has, however, refocused public health
attention on the risks associated with having multiple sexual partners, including concurrency,
a long-known risk for HIV acquisition and transmission [114, 331].
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4 A novel approach to adjusting for missing
data in population-based surveillance to
estimate trends in sexual behaviour in a
high HIV prevalence region in South
Africa
4.1 Background
Protective changes in sexual behaviours, at the population level, have been recorded in all
countries to date that have experienced substantial reductions in the burden of HIV, including
in sub-Saharan Africa [89, 90, 332, 333]. Monitoring trends in sexual risk behaviours is an
essential component of comprehensive HIV surveillance to predict future changes in the epidemic
and evaluate the effectiveness of components of HIV prevention programmes [148, 334]. Today,
in the era of widespread access to antiretroviral therapy (ART) in generalised HIV epidemics,
monitoring population-level sexual behaviours remains as important as ever. While ART is
potentially a potent tool for preventing HIV infections [105], in HIV epidemics concentrated
amongst men who have sex with men in high-income countries, where effective antiretrovirals
have been available for 15 years, increases in sexual risk behaviour have largely offset any
prevention benefits of treatment [335–337]. Sufficient data are not available yet to determine
whether similar patterns will occur in generalised HIV epidemics [338], or if the availability of
ART be synergistic with HIV testing and enable informed decisions about strategies to avoid
HIV [161, 339], but what can be presumed is that robustly measuring sexual risk behaviour will
be crucial to understanding the future trends in HIV infections in southern Africa.
The first coordinated effort to collect population-level data about sexual behaviours in low-
and middle-income countries in response to the HIV pandemic was undertaken in by 1988 by
the World Health Organization’s Global Programme on AIDS [129]. Today, rigorous, rapid, and
regular nationally-representative surveys of sexual behaviour are available for many of the most-
affected countries through the Demographic and Health Surveys commissioned by USAID [149],
and other similar national household surveys, such as the National HIV Prevalence, Incidence,
Behaviour and Communications survey conducted every three years in South Africa [340–342].
Other studies more intensively monitor sexual behaviour in smaller well-characterised popula-
tions, such as the population-based cohort studies in the ALPHA network [343, 344]. Sexual
behaviour surveys are also a standard component of observational studies and clinical trials
relating to HIV, even those with biological or biomedical focus and conducted in both general
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population or select sub-populations, and are a valuable source of information for enhancing
the interpretation of the main study outcomes by adjusting for exposure to sexual risk factors,
as well as being a resource for additional scientific and public health enquiry.
A common challenge for all of these surveillance efforts is survey non-participation and in-
completion. For example, in Demographic and Health Surveys with HIV testing conducted
between 2003 and 2006, between 2.5% and 14% of sampled participants did not participate
in the individual interview either due being absent at the time of the survey or refusing to
participate, and between 3.5% and 30% did not participate in HIV testing [150, 345]. Missing
data can result in statistical inferences that are not representative of the entire population of
interest if members of the population with certain characteristics are less likely to respond [346].
In investigating trends in behaviours over time, it is important to consider “missing data” in
order to exclude the possibility that apparent changes in behaviour over time are the result of
a changing composition in the population who choose to participate in the survey.
A number of approaches exist to statistically adjust for missing data and have been widely
adopted in the epidemiological literature [347]. In the context of HIV prevalence, several stud-
ies have investigated the influence of missing data on HIV prevalence estimates form household
surveys because of the precedence given to these estimates [261, 348]. Mishra and colleagues use
multiple imputation to adjust for missing HIV statuses on the basis of other observed covari-
ates, concluding that HIV prevalence non-tested men and women had higher HIV prevalence
than the tested population in about half of countries, but that the impact of the adjustment on
the overall population HIV prevalence was insignificant [345]. Marston, Harriss, and Slaymaker
also used multiple imputation to adjust for missing HIV statuses in DHS surveys. Focusing
specifically on HIV statuses of individuals who did not participate in the survey because they
were absent at each of the survey visits [349], they estimated that HIV prevalence was likely to
be higher amongst this mobile group, but at the population level, adjusted prevalences were less
than one percentage point higher, a similar result as was found by Mishra and colleagues. Using
longitudinal data from population-based cohorts, others have found that respondents who know
that they are HIV positive from prior HIV testing are more likely to refuse subsequent HIV-
testing, inducing a downward bias in HIV prevalence estimates that will increase as population
levels of HIV testing increase [150, 151]. Current research is focusing on using ‘selection models’
from econometrics that use instrumental variables which affect the probability of survey partic-
ipation, but do not affect HIV status, to adjust for this bias. Ba¨rnighausen and colleagues used
a Heckman sample selection model to estimate that adjusting for unobserved selection bias in
HIV prevalence increased the HIV prevalence estimate amongst adult men in the 2007 Zambia
Demographic and Health Survey from 12% to 21% [152].
While research continues to determine whether HIV prevalence estimates should be system-
atically adjusted for missing HIV status outcomes, the influence of missing data on estimates of
and trends in population-level sexual behaviour has not been investigated. The intrinsic struc-
tural correlations between different sexual behaviour indicator outcomes presents challenges for
straightforward application of standard approaches that use probabilistic models to estimate
or impute missing outcomes. Sexual behaviour survey instruments involve skip patterns and
filter questions such that the response to one item affects subsequent questions. For example,
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one cannot have concurrent partnerships if one has not been sexually active in the past year,
or a condom cannot be used with a casual sexual partner if one has not had such a partner.
Standard methods and existing software for analysing missing data are not naturally suited to
enforce these structural considerations in the data, which could result in the generation of incon-
sistent augmented data. These structural patterns in the survey instrument can also be related
to missingness. For example, in chapter 1 we found that having complete information about
all sexual partners in the past year to calculate the concurrency indicator decreased for those
who had more sexual partners, resulting in a downward bias in the estimate of the concurrency
indicator.
In this chapter, we propose an approach to adjusting for missing data in sexual behaviour
surveys that maintains the internal consistency imposed by the survey instrument. The method
considers missing data on individual variables caused by respondents who participate in and
complete part of the survey but fail to answer certain questions (item nonresponse), and missing
data resulting from being absent or refusing to participate in the survey altogether (survey
nonresponse). The model for adjusting for item non-response extends the standard multiple
imputation algorithm to allow missing sexual behaviour data to be consistently imputed across
a range of outcomes. We also derive a new statistical model for estimating the number of sexual
partners in the past year that accounts for the tendency for many more respondents to report
exactly one sexual partner than would be estimated by typical probability distributions used to
model count data (e.g. Poisson, negative binomial). To adjust for survey nonresponse, we use
nonresponse weights based on the inverse probability of survey participation within a number
of strata. Combining these approaches to adjusting for item and survey nonresponse allows
us to estimate sexual behaviour indicators and trends over time in surveillance data with a
large amount of missing data. We apply this method to annual sexual behaviour survey data
collected between 2005 and 2011 in a rural population with extremely high HIV prevalence in
eastern South Africa to estimate general-population trends in sexual behaviour during period
of ART scale-up. This chapter focuses on the population-level trends in sexual behaviours,
HIV status, and knowledge of HIV status, and the influence of adjusting for missing data and
non-participation on the estimates and trends.
4.1.1 Contributions and dissemination
This work has been conducted in collaboration with Dr. Nuala McGrath from the London
School of Hygiene and Tropical Medicine and the Africa Centre for Health and Population
Studies, who has coordinated use of sexual behaviour and demographic data from the Africa
Centre Demographic Information System, discussed analytical approaches, and assisted with
the interpretation of results. We thank Professor Till Ba¨rnighausen of the Harvard School of
Public Health and Africa Centre for Health and Population Studies and from Professor Marie-
Louise Newell, director of the Africa Centre for Health and Population Studies and professor
at the University College London Institute for Child Health for valuable input on the data,
analysis, and results. Colin Newell at the Africa Centre for Health and Population Studies has
assisted with the revision of demographic and sexual behaviour datasets to enable this study.
Travel to initiate this collaboration was supported by the Imperial College Institute for Global
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Health and a Wellcome Trust fellowship to Dr. Nuala McGrath (#WT083495MA).
This work has been presented as an oral poster by Dr. Nuala McGrath at the XIX Interna-
tional AIDS Conference in Washington DC, 22–27 July 2012.
4.2 Methods
4.2.1 Data: The Africa Centre Demographic Information System
Longitudinal Data for this investigation come from the Africa Centre Demographic Information
System (ACDIS). ACDIS is a population demographic surveillance system maintained by the
Africa Centre for Health and Population Studies in Somkhele, South Africa. ACDIS registers
demographic events and socioeconomic and health information in the entire population residing
in a geographically defined surveillance area within the Umkhanyakude district of KwaZulu-
Natal province, South Africa. Figure 4.1 shows the location of the study area within South
Africa. This section briefly describes the setting, population, and surveillance activities of
ACDIS. A fuller description can be found in the cohort profile [262] and at the Africa Centre
website (http://www.africacentre.ac.za/).
Figure 4.1: Location of study area in South Africa. Note: Figure obtained courtesy of Nuala
McGrath. Figure appears in [262].
Population and setting
The population monitored by ACDIS consists of all households living within an area of ap-
proximately 438 km2 (169 mi2). In 2008, the size of the population was approximately 85,000
people living in approximately 11,000 households [262]. The average household size is 7.9 (sd
4.8) members. The population is characteristically rural in terms of infrastructure, but with
high variation in population density across the site, including an urban township and peri-urban
informal settlements. A legacy of apartheid, like other rural populations in South Africa, the
population in the Africa Centre surveillance area is characterised by a high rate of circular
labour migration in which some household members physically reside outside of the household
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most of the year, but maintain close relationships with, routinely visit, and financially support
the household. Often remittances from non-resident household members are the main source
of income for rural households. ACDIS registers these individuals as “non-resident” household
members and records information about their return patterns and remittances to the household,
in addition to the standard demographic and employment information collected of all household
members. The burden of HIV is extremely high in the population. Baseline HIV surveillance
conducted in 2003-2004 estimated that HIV prevalence was 13.5% in adult (age 15–49 years)
resident men and 26.8% in adult resident women and 33.9% and 41.2% in non-resident adult
men and women, respectively [350].
Routine demographic and HIV surveillance
Routine demographic surveillance in the Africa Centre surveillance area began in January 2000.
Fieldworkers from the Africa Centre visit each household twice per year and collect informa-
tion from a key informant residing in the household about the household membership and all
demographic events (pregnancies, births, deaths, in- and out-migrations, marriages, divorces)
experienced by household members. Once per year, the fieldworker collects information about
the education level and employment status of all resident and non-resident household members,
and about household assets and facilities.
The first round of HIV surveillance in the Africa Centre surveillance area occurred between
2003 and 2004 in conjunction with measurement of other bio-markers including height, weight,
and blood pressure. All resident men aged 15–54 years and women aged 15–49 years were eligible
to participate in HIV sero-surveillance, and a 12.5% sample of non-resident household members
were randomly selected to participate in sero-surveillance. Since 2005, HIV surveillance has
occurred annually in conjunction with general health and sexual behaviour surveillance (see
next section). In 2005 and 2006, all resident men aged 15–54 and women aged 15–49 were
eligible to participate in sero-surveillance, and a 10% sample of non-residents were randomly
selected according to five strata defined by ‘return patterns’—the frequency of returning home to
the household in the surveillance area. From 2007, for residents, eligibility for HIV surviellance
expanded to include adults aged 15 years and older. The age range for the non-resident sample
remained 15–54 for men and 15–49 for women.
Dried blood spots are collected from consenting participants via finger prick. Fieldworkers
return to the household up to four times to find eligible subjects who are absent at the initial
household visit. Dried blood spots are transported to a laboratory to be tested for HIV anti-
bodies. Later, participants wishing to learn their HIV status can confidentially obtain HIV test
results in counselling centres set up for that purpose in the surveillance area. Antiretroviral
therapy has been available to residents of the surveillance area through the public-sector ART
programme since 2004 [351, 352].
Sexual behaviour survey
A preliminary round of general health and sexual behaviour surveillance occurred from 2003 to
2004 in separate household visits from the baseline HIV surveillance described above. Annual
general health and sexual behaviour surveillance with a revised survey instrument commenced
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in 2005. These survey visits occurred at the same time and by the same fieldwork team as the
HIV sero-surveillance household visits. The analysis in this chapter utilises data collected in
annual survey rounds from 2005 to 2011.
From 2005 through 2008, all resident men aged 15–54 years and resident women aged 15–
49 years were eligible to participate in the general health survey. From 2009, eligibility to
participate in the general health survey was also expanded to include all residents older than 15
years. Eligibility to participate in the survey is determined based on being in the specified age
range on a fixed day in the December or January before the survey round (the exact dates on
which eligibility lists were drawn were 10 January 2005, 10 January 2006, 11 January 2007, 11
January 2008, 22 December 2008, 10 December 2009, and 22 December 2010). Inclusion on the
eligibility list is based on appearing as a resident household member on the household roster at
the most recent round of demographic surveillance prior to the creation of the eligibility list.
Individuals found living in a household at the time that the fieldworker visits for the HIV sero-
survey and general health survey, but who are not included on the eligibility list, are not eligible
to participate in the survey (if they had moved from another household in the surveillance area,
they would appear on the list and hence be eligible to participate). An implication of the creation
of eligibility lists in December/January prior to the survey is that, on average, respondents are
approximately one half year older at the time the survey is completed than when eligibility is
determined, and adolescents between 15 and 15.5 years are underrepresented in the survey. In
the years 2008 and 2011, 15 year-old residents were not included in the eligibility lists, and
those aged 16 to 16.5 years are underrepresented in the survey.
A 10% stratified random sample of non-resident household members between ages 15–54 years
(men) or 15–49 years (women) are selected for participation in the general health and sexual
behaviour survey. Ten strata are defined by sex and self-stated frequency of return visits to
the surveillance area (‘annual’, ‘occasional’, ‘month ends’, ‘every week/weekend’, and ‘other’).
Additionally, any non-residents who participated in the previous two years of round of non-
resident HIV surveillance and had a negative HIV test, but were not selected in the random
sample in a subsequent survey round, are included in the non-resident sample in order to
increase power for the non-resident HIV incidence cohort. Sampled non-residents are contacted
and interviewed when they are on a return visit at their home in the surveillance area, or are
contacted, met, and interviewed by a special tracking fieldwork team in their place of residence
outside the surveillance area, as far away as Johannesburg or Durban.
General health and sexual behaviour surveys are administered via face-to-face interview by
gender-matched interviewers after obtaining written informed consent. At the start of the visit,
participants separately consent to participate in the HIV sero-survey, general health, and sexual
behaviour portions of the study, and may choose to participate in all or only a subset of these
components. The general health portion of the survey asks questions about self-assessed general
health and physical fitness, confirmation of marital status, pregnancy or paternity history, and,
for women, current contracepting behaviour.
The sexual relationships portion of the survey asks the age at the respondent first had sex,
including a response option for ‘not yet had sex’, and then a series of questions about each of
up to the respondent’s last three sexual partners in the past year. These questions include:
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• the type of relationship with the sexual partner (husband/wife, regular partner, occasional
or casual friend, or visitor),
• whether the partner was older, younger, or the same age, and the number of years age
difference with this partner,
• whether the partner is a member of the same household,
• the proximity of the partner’s normal residence,
• whether and how often the respondent used a condom with the partner (‘never’, ‘some-
times/inconsistent’, or ‘always’),
• whether a condom was used at the last sexual intercourse with the partner,
• how long the respondent was sexually involved with the partner, with response in ‘days’,
‘weeks’, ‘months’, or ‘years’, and
• how long ago the respondent last had sex with the partner, with response in ‘days’, ‘weeks’,
‘months’, or ‘years’.
If the respondent had debuted sexual behaviour, but did not have any partners in the past
year, these questions are asked about the one most recent partner (more than one year ago).
Finally, the respondent is asked the total number of sexual partners he or she had in the past
12 months.
4.2.2 Adjusting for nonresponse in sexual behaviour surveys
We develop a two-part approach to adjusting for missing data in the ACDIS sexual behaviour
survey which separately addresses missingness due to individuals who participate in the survey
but do not answer some questions or do not completing the full survey (item nonresponse)
and missingness due to survey non-participation (survey non-response). First, for adjusting
for item nonresponse, we create a data set of all individuals who consented to participate in
any portion of the individual surveillance—the general health survey, HIV sero-survey, or the
sexual behaviour survey. We use multiple imputation incorporating the available data from
the individual surveillance and other information from the routine demographic surveillance to
adjust for missing responses amongst this subset who participated in the survey. Second, to
adjust for survey non-participation by eligible respondents, either due to non-contact or refusal,
we calculate response weights according to a number of strata using information available from
the demographic surveillance. These two adjustments are combined to create overall adjusted
estimates of sexual behaviour indicators and other statistics of interest.
Multiple imputation algorithm for adjusting for item non-response in sexual
behaviour survey
For individuals who participate in any portion of the general health, HIV, or sexual behaviour
surveillance, we use multiple imputation to adjust for missing responses. Briefly, multiple
imputation involves using a model to simulate, or impute, values for missing observations a
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number of times. Statistics of interest are then estimated on each of the imputed data sets,
and finally an overall pooled estimate of the statistic and its standard error is obtained using a
formula that incorporates the sampling variation estimated from each imputed data set and the
variation between the estimates from each of imputed data sets, the portion of the uncertainty
attributable to the missing data [353].
A number of approaches have been considered for simulating imputed data sets [354–357].
An approach which has become particularly popular is multiple imputation by chained equa-
tions (MICE). In the MICE algorithm, the user specifies a generalised linear model for each
of variables for which there are missing outcomes as a function of the other variables in the
data. The algorithm is initiated by generating initial values for each of the missing outcomes;
in theory it should not matter how initial values are chosen, but choosing sensible values, for
example randomly resampling observed values, will accelerate the convergence of the algorithm.
Then for the first variable with missing data, the linear model is estimated using the full data
set (including observed and imputed values for the missing data). The estimated model is then
used to simulate new values for the missing outcomes. This proceeds in sequence for each of
the variables with missing outcomes. Once all variables have been imputed, the first step of
the chain is complete, and the algorithm returns to the first variable again and iterates through
the variables again.Variables are cycled through iteratively until the chain reaches convergence
[358]. Accessible software implementations of multiple imputation by chained equations are
available in statistical packages commonly used for epidemiological analyses, including Stata
[359], R [360, 361], and SAS [362, 363]. These software implementations include facility for
flexible specification of regression models, including interactions, for a number of different types
of variables, including continues, count, binary, categorical, and ordered-categorical.
The standard MICE algorithm described above is not suited to account for the structure of
sexual behaviour surveys. We extend the conventional MICE routine to impute internally con-
sistent values missing responses by conditioning on the values of other items for that individual
(either answered or imputed) in a way that mimics the skip patterns of the survey. Sexual
behaviour outcomes are imputed in the following way:
1. Whether or not an individual has ever had sex is imputed as a binary outcome using a
logistic regression model conditioning on the other variables included in the imputation
(excluding subsequent sexual behaviour outcomes).
2. For those individuals who have had sex (observed or imputed), the number of sexual
partners in the last year is imputed using a one-inflated negative binomial regression model
(see next section). This is accomplished by first estimating the regression parameters on
the subset of data consisting of those who had a ‘true’ value for the ever had sex value at
the previous iteration of the imputation chain. Then, these regression parameters are used
to simulate the number of partners in the last year for those with missing data for this
outcome and have a ‘true’ outcome (observed or imputed) for ever had sex in the current
iteration. Using the value of ever had sex at the previous iteration to condition those
included in the regression model is essential because these correspond to the outcome
variable from the previous iteration which are used to estimate the model.
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3. For those with two or more sexual partners in the last year (observed or imputed), having
concurrent partners six months before the interview is imputed as a binary outcome using
a logistic regression model. Again, the number of partners in the last year from the
previous iteration is used to select those included in the imputation model, while the
number of partners in the current iteration is used to simulate values for missing data. In
addition to the general covariates included (Table 4.1), number of sexual partners in the
past year is included as a categorical variable using the levels 2 partners, 3 partners, or
4+ partners.
4. For those with one or more sexual partner in the last year, whether or not the individual
had a casual sexual partner in the last year is imputed as a binary outcome using a logistic
regression model. The number of partners in the last year (as a categorical variable) and
the concurrency status are included as covariates in the imputation model.
5. For those who had two or more sexual partners in the past year and at least one of these
was a casual partner, whether or not the individual had a regular partner in the last year
is imputed as a binary outcome. Number of partners in the last year (as a categorical
variable) and concurrency are included in the imputation model. If individuals had at
least one sexual partner in the last year, but not a casual partner, then this partner must
have been a regular partner.
6. For individuals who had a casual partner in the last year, whether a condom was used at
last sexual intercourse with a casual partner is imputed as a binary outcome. Number of
partners in the last year and concurrency are included in the imputation model.
7. For individuals who had a regular partner in the last year, whether a condom was used at
last sexual intercourse with a regular partner is imputed as a binary outcome. Number of
partners in the last year and concurrency are included in the imputation model.
8. For individuals who had a regular partner in the last year, the age difference with the
most recent regular partner is imputed as a continuous outcome. Number of partners in
the last year and concurrency are included in the imputation model.
Multiple imputations are conducted separately for men and women and for residents and
non-residents. Additional variables included in the imputation models for all outcomes are
grouped broadly into three groups: demographic characteristics, socioeconomic variables, and
health and HIV variables. These variables and the type of regression model used to impute
each are described in Table 4.1.
One-inflated negative binomial model for number of sexual partnerships in the
past year
Due to social norms around monogamy in sexual relationships, typical probability distributions
for modelling count data, such as over-dispersed Poisson or negative binomial, do not adequately
reproduce observed distributions of reported numbers of sexual partners in the past year. These
distributions tend to underestimate the proportion of respondents who report exactly one sexual
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Table 4.1: Variables included in multiple imputation models
Variable Levels Variable type
Demographic
variables
Age group 17–19, 20–24, 25–29,. . . , 45–49,
50–54 (men)
Categorical
Residence location Urban, Peri-urban, Rural Categorical
Partnership None, Casual, Regular, Married,
Previously married, Polygynous
Categorical
Nights spent in HH in past
four months
0, 10, 40, 80, 110, 120 Categorical
Present previous night Yes, No Binary
Education None, Some primary, Primary,
Compulsory, Matric, Higher
Ordered-
categorical
Socioeconomic
variables
Attending school No, Part-time, Full-time Categorical
Employmenta Full-time, Part-time, None, Under 18 Categorical
Household water sourceb Internal, Local tap, Other Categorical
Household toilet typeb Flush, VIP, Pit, Other, None Categorical
Household electrifiedb Yes, No Binary
Household cooking fuelb Wood, Modern Binary
House owned by memberb Yes, No Binary
Household asset sum scoreb,c Continuous
Perceived financial statusb Extremely poor, Poor, Just getting
by, Comfortable, Very comfortable
Ordered-
categorical
Household missed mealb Yes, No Binary
Health &
HIV variables
General healthd ‘poor’, ‘fair’, ‘good’, ‘very good’,
‘excellent’
Ordered-
categorical
Can carry heavy objecte Yes, No Binary
Can walk five kme Yes, No Binary
Can do heavy worke Yes, No Binary
Ever been pregnant/
Fathered children
Yes, No Binary
HIV status Negative, Positive Binary
Ever had an HIV teste,f Yes, No Binary
Tested in health systeme,f Yes, No Binary
Knows HIV statusf Yes, No Binary
Heard about ARTf Yes, No Binary
Knows where to obtain
ARTf
Yes, No Binary
Knows somebody on ARTe,f Yes, No Binary
aEmployment question is only asked about household members 18 years and older.
bHousehold level variable answered by household key-informant.
cSum of binary indicator variables of household ownership of following assets: bed net, bed, bicycle, block maker,
car, car battery, cattle, electric cooker with oven, electric hotplate, electric kettle, refrigerator, gas cooker, hoe
or spade or fork, kombi or lorry or tractor, kitchen sink, motorcycle, other livestock, primus cooker, radio, sofa,
sewing machine, table and chairs, telephone, cellphone, television, video cassette recorder, and wheelbarrow.
dIn 2009, 2010, and 2011 surveys, response categories for the ‘General health’ question were collapsed to be
‘poor’, ‘fair’, or ‘excellent or very good’.
eVariables ‘Can carry heavy objects’, ‘Can walk five km’, ‘Can do heavy work’, ‘Ever had an HIV test’, ‘Tested
in health system’, and ‘Knows somebody on ART’ are not available in 2009, 2010, and 2011 surveys.
fVariables about HIV testing and antiretroviral therapy were not included in 2005 survey.
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partner in the past year. While using regression models based on these distributions to simulate
imputed datasets will correctly reproduce the mean and variance of the distribution of partners
in the past year, it will lead to biased estimates of other quantities of specific interest for sexual
behaviour indicators, such as the proportion having multiple sexual partnerships (and hence
concurrency) or the proportion practising secondary abstinence.
To overcome this, for respondents who report ever having had sex, we derive a one-inflated
negative binomial regression model simulate the number of sexual partners in the past year.
Two regression models are simultaneously estimated: first, for each individual, a probability is
estimated that the individual has exactly one sexual partner in the past year or that the number
of sexual partners is drawn from a negative binomial distribution, and the second regression
estimates the mean and size parameters of the negative binomial distribution.
Formally, we define the model as follows: for individual i, let Yi denote the number of sexual
partners in the past year (a non-negative count variable). Then Yi = 1 with probability φi ∈
(0, 1) and Yi is drawn from a negative binomial distribution with probability (1− φi), that is
Yi =
{
1 with probability φi
NegBin(µi, θ) with probability 1− φi
, (4.1)
where the negative binomial distribution is parameterised in terms of its mean µ and size
parameter θ such that the variance is µ+ µ2/θ, yielding the probability mass function
fNB(y|µ, θ) = Γ(y + θ)
Γ(y + 1)Γ(θ)
(
θ
θ + µ
)θ ( µ
θ + µ
)y
(4.2)
Both the mixture probability φi and the mean parameter of the negative binomial distribution
µi are specified as linear combinations of a set of regressors wi (xi) and parameters α (β) using
the link functions
logit(φi) = wiα (4.3)
log(µi) = xiβ. (4.4)
Taken together, the likelihood function for this model can be expressed as
L(α,β, θ) =
∏
i
{
(1− φi)fNB(yi|µi, θ) + φi if yi = 1
(1− φi)fNB(yi|µi, θ) if yi 6= 1
. (4.5)
For the log-likelihood l = logL, the gradient is
∂l
∂α
=
∑
i
{
1−fNB(yi|µi,θ)
(1−φi)fNB(yi|µi,θ)+φi if yi = 1
−1
1−φi if yi 6= 1
}
dφi
dα
(4.6)
∂l
∂β
=
∑
i
{
(1−φi)fNB(yi|µi,θ)
(1−φi)fNB(yi|µi,θ)+φi if yi = 1
1 if yi 6= 1
}
∂
∂µi
log fNB(yi|µi, θ)dµi
dβ
(4.7)
∂l
∂θ
=
∑
i
{
(1−φi)fNB(yi|µi,θ)
(1−φi)fNB(yi|µi,θ)+φi if yi = 1
1 if yi 6= 1
}
∂
∂θ
log fNB(yi|µi, θ) (4.8)
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(Note: The key to obtaining the convenient form above for the derivative of the log-likelihood
with respect to the parameters of the negative-binomial model is observing that, for a parameter
θ,
d
dθ
logL(θ) =
1
L(θ)
d
dθ
L(θ).)
Population-based re-weighting to adjust for survey non-participation
After using multiple imputation to augment missing data due to item non-response by those who
participated in the study, we adjust for survey non-response, either due to inability to contact
eligible individuals or refusal to participate, by calculating response weights as the inverse of
the probability of study participation. The probability of study participation is determined
according to a number of strata using routinely collected information about all population
members in the ACDIS database. Statistical analyses then incorporate response weights using
weighted estimating equations [364, 365].
For residents, response weights are determined according to strata defined by sex, age group
(17–19, 20–24, 25–29, . . . , 45–49, 50–54), residence location (rural, peri-urban, urban), and
education level (none, some primary, completed primary, completed compulsory, completed
matric, some higher education). The numerator for the response weight is the total number
in each of these strata in the eligibility list drawn up prior to the surveillance round (see
section 4.2.1). The denominator is the number in each strata who participated in any portion
of the individual surveillance.
For non-residents, two sets of weights are calculated to account for the stratified sampling pro-
cess and non-response weighting. Sample weights are calculated according to strata determined
by sex and the five categories of self-stated frequency of returning home (see section 4.2.1),
with the numerator being the number of eligible non-residents in each of these strata, and the
denominator being the number randomly selected to be included in the survey. Non-residents
who were not selected as part of the random sample, but included in the sample because of pre-
vious survey participation are assigned a sample weight of 1. Response weights are calculated
as the inverse of the probability of survey participation within each of the strata defined by sex,
frequency of return, whether randomly sampled or forced inclusion, and the age groups 17–24
years, 25–34 years, and 35–54/49 years. The total weights used for analysis are the product of
the sample weights and the response weights.
Combining item- and survey non-response adjustments for population estimates
of sexual behaviour indicators
Adjusted population-level estimates are calculated accounting for both the multiple imputation
to adjust for item non-response and weighting to adjusted for survey non-response. For a
statistic θ of interest, estimates θˆ and the associated standard error SE(θˆ) are calculated as
follows. First, for each of the M imputed data sets, we calculate a weighted estimate θˆm and
associated standard error SE(θˆm) using weighted estimating equations.
Then, following the rule for pooling imputation described by Rubin [353], the pooled estimate
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of the statistic θ is simply the mean of the estimates from each of the imputed data sets
θˆ =
1
M
M∑
m=1
θˆm. (4.9)
Defining Vm as the standard error estimate of θˆm, Vm = SE(θˆm), the pooled estimate of the
standard error of θˆ is
SE(θˆ) =
(
1
M
M∑
m=1
V 2m +
(
1 +
1
M
)
B
) 1
2
, (4.10)
where
B =
M∑
m=1
(θˆm − θˆ)2
M − 1 . (4.11)
This formula for the variance of θˆ can be deconstructed as a weighted average of the average
variance, 1M
∑
V 2m, and the between-imputation variance, B. As the number of imputations
M →∞, the precision of the estimate of the between-imputation improves, and overall standard
error estimate decreases accordingly (the 1/M term in equation 4.10) [353].
Unadjusted estimates are also presented based on excluding respondents with incomplete
data for the outcome of interest or covariates (‘available case analysis’). For non-residents,
unadjusted estimates incorporate sampling weights, but not response weights.
4.2.3 Statistical analyses
We produce annual estimates of sexual behaviour indicators, HIV prevalence, and the percentage
of the population who have been tested for HIV and received the result for the seven years from
2005 to 2011 (termed ‘knows HIV status’ in the results). We first report patterns of survey
participation and completion over the seven survey rounds and by age group (17–24, 25–34,
35–54 for men/35–49 for women).
The population-level indicators of sexual behaviour which are considered are:
• the percentage of the population reporting ever having had sex,
• the average number of sexual partners in the last year,
• the percentage of the population with more than one sexual partnership in the last year
(multiple partnerships),
• the percentage of the population with concurrent sexual partnerships six months before
the survey (point prevalence of concurrency),
• the percentage of the population reporting a casual sexual partnership in the last year,
• the percentage reporting using a condom at last sex with a casual partner amongst those
reporting having a casual partner in the last year,
• the percentage reporting using a condom at last sex with a regular partner amongst those
reporting having a regular partner in the last year, and
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• the average age difference in years between the respondent and his or her most recent
regular partner.
Additionally, we estimate the population HIV prevalence and the percentage of the population
who report knowing their HIV status.
Estimates and trends are reported separately for men (age 17–54 years at the time of each
survey) and women (age 17–49 years) and are reported for the total population of residents and
non-residents, and each of these groups separately. Eligible individuals age 15–16 years old are
not included in analyses due to the varying inclusion of this age group in eligibility lists over
the survey years (see section 4.2.1). Both unadjusted and adjusted estimates are presented.
Multiple imputations are conducted independently for each year, and separately for men and
women and for residents and non-residents. Adjusted estimates represent pooled estimates of
M = 100 imputed data sets.
To test for evidence of changes over time in sexual behaviour indicators, we estimate the
slope of linear trend over time using weighted generalized estimating equations (GEE) with
robust standard errors [364–366]. An exchangeable covariance structure is assumed to allow for
correlation in individuals appearing in multiple survey rounds.
Comparing the slope estimates between unadjusted and adjusted estimates gives an indication
of the extent to which apparent trends in the unadjusted (complete case) estimates reflect actual
trends in population level sexual behaviour or are the result of changes in the composition of
survey respondents over time.
Creation of imputed datasets was done using R version 2.13.1, and all analyses was con-
ducted using R version 2.15.0 [288]. The multiple imputation algorithm was implemented by
creating customised imputation models for multiple imputation framework in the R package
mi [361]. The one-inflated negative-binomial regression model is implemented based on code
for the zeroinfl() function in the R package pscl [367]. Weighted population estimates and
standard errors are calculated using the R package survey [368]. Weighted GEE models with
correlated error structure were estimated using the R library geepack [369].
4.3 Results
4.3.1 Survey participation and response over time
Tables 4.2 and 4.3 present the number eligible, number participating, and number with complete
sexual behaviour data in each survey round for men (Table 4.2) and women (Table 4.3). For
non-residents, the number sampled in each year is given and the percentage of total eligible
population classified as non-residents is presented.
The number of eligible participants increased in most years but not substantially. Overall for
men aged 17–54 years the number of eligible participants increased from 20,208 in 2005 to 21,737
in 2011, and for women aged 17–49 years the number increased from 21,099 to 22,241. The
percentage of the eligible population classified as non-residents was remarkably stable over time,
ranging between 47% and 48% for men and 35% to 38% for women. The proportion of eligible
non-residents included in the non-resident sample varied slightly over the rounds, between 12%
and 17% for non-resident men and between 15% and 20% for non-resident women.
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Table 4.2: Survey participation and completion amongst men, age 17–54 years
2005 2006 2007 2008 2009 2010 2011
Residents Eligible 10811 10763 11101 11241 11065 11727 11253
Participated 4793 4586 3261 3118 2934 3152 3493
44% 43% 29% 28% 27% 27% 31%
Complete SB 4018 3790 2588 2096 1542 1881 2001
84% 83% 79% 67% 53% 60% 57%
Non-residents Eligible 9397 9789 10170 10406 10288 10277 10484
Sampled 1353 1242 1232 1747 1379 1521 1566
Participated 355 284 325 322 406 405 438
26% 23% 26% 18% 29% 27% 28%
Complete SB 293 250 276 276 293 304 335
83% 88% 85% 86% 72% 75% 76%
All Eligible 20208 20552 21271 21647 21353 22004 21737
% Non-resident 47% 48% 48% 48% 48% 47% 48%
Sampled 12164 12005 12333 12988 12444 13248 12819
Participated 5148 4870 3586 3440 3340 3557 3931
42% 41% 29% 26% 27% 27% 31%
Complete SB 4311 4040 2864 2372 1835 2185 2336
84% 83% 80% 69% 55% 61% 59%
Complete SB – number with no missing data for sexual behaviour outcomes (% out of those who participated).
Table 4.3: Survey participation and completion amongst women, age 17–49 years
2005 2006 2007 2008 2009 2010 2011
Residents Eligible 13641 13574 14118 14234 13964 14852 13843
Participated 7711 7450 6181 5539 5807 5769 5897
57% 55% 44% 39% 42% 39% 43%
Complete SB 6561 6337 5016 3998 3413 3365 3215
85% 85% 81% 72% 59% 58% 55%
Non-residents Eligible 7458 7627 7873 8041 7882 7871 8398
Sampled 1315 1194 1107 1613 1376 1463 1525
Participated 422 324 330 424 476 412 461
32% 27% 30% 26% 35% 28% 30%
Complete SB 355 289 287 373 373 305 358
84% 89% 87% 88% 78% 74% 78%
All Eligible 21099 21201 21991 22275 21846 22723 22241
% Non-resident 35% 36% 36% 36% 36% 35% 38%
Sampled 14956 14768 15225 15847 15340 16315 15368
Participated 8133 7774 6511 5963 6283 6181 6358
54% 53% 43% 38% 41% 38% 41%
Complete SB 6916 6626 5303 4371 3786 3670 3573
85% 85% 81% 73% 60% 59% 56%
Complete SB – number with no missing data for sexual behaviour outcomes (% out of those who participated).
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Figure 4.2: Survey participation over time for age groups 17–24 years, 25–34 years, and 35–54
years. Solid lines show the proportion of eligible participants who participate in any
portion of the surveillance (HIV, general health, or sexual behaviour), and dashed
lines indicate the proportion of all eligible respondents who have complete data in
the sexual behaviour survey.
Survey participation was highest in 2005, the first year at 42% for men (44% for residents
and 26% of sampled non-residents) and 54% for women (57% of residents and 32% of sampled
non-residents). Participation amongst residents declines sharply after this year, reaching 27%
of resident men and 39% of resident women by 2010. For non-residents participation varied
over survey rounds, but not following a consistent trend. Participation increased modestly in
the 2011 survey.
Not only did survey participation decrease over time, but so did the proportion of participants
who have complete data for all sexual behaviour outcomes. For men this percentage decreases
from 84% in 2005 to 59% in 2011 and for women from 85% to 56%. This decline is principally
driven by an increasing proportion of respondents who consent to participate in the general
health or HIV sero-surveillance portions of the study, but not the sexual behaviour component.
Although there was no difference in the first year, in subsequent years non-residents were gen-
erally more likely than residents to have complete sexual behaviour data if they participated in
the study.
Figure 4.2 compares survey participation and completion by age groups. For men, partici-
pation was about 10% to 15% higher amongst 17–24 year-olds than 25–34 or 35–54 year-olds.
There was no difference in survey participation amongst the older two age groups, but 35–54
year-olds were less likely to have complete sexual behaviour data than were men 25–34 years.
The differential in participation between age groups was smaller for women than for men, al-
though the gradient in the proportion with complete sexual behaviour data was similar. For
women, the oldest age group had higher participation than the middle age group, similar levels
to the youngest age group. However, women were still the least likely to have complete sexual
behaviour data. These differential changes over time in survey participation and completion
for different age groups alone highlights the importance of adjusting for missing data when
investigating trends in sexual behaviours over time.
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4.3.2 Population trends in sexual behaviour indicators
Figure 4.3 shows annual estimates for each of the sexual behaviour indicators for all men and
women (both residents and non-residents). Both adjusted (solid lines) and unadjusted (dashed
lines) are presented. In the adjusted analysis, more women than men reported ever having had
sex in all but the most recent year. However, men report more partners in the last year, and
much higher levels of multiple partnerships, concurrency, and casual partnerships. On average,
men reported 0.23 more partners per year than did women. Reporting of multiple partnerships
and concurrency were both less than 1% for women in every year since 2008. For men, point
estimates for the percentage having multiple partnerships ranged between 11% and 20% and
ranged between 7% and 12% for the point prevalence of concurrency. Women tended to report
slightly larger age differentials with their last regular partner than did men, although both
appear to suggest that the average age differential has narrowed slightly over time.
The most dramatic change over the period is in reported condom usage at last sex with a
regular partner. Men and women report fairly similar levels of condom use with regular partners
at least through 2009, and condom usage with regular partners increases rapidly for both sexes
from around 26% in 2005 to 53% for women in 2011 and 45% for men in 2011. Estimates of
condom usage at last sex with a casual partner are noisy and have large standard errors, but
are at higher levels throughout the period than is condom usage with regular partners.
Figure 4.4 shows the average annual change in each of the sexual behaviour indicators over
the period 2005 to 2011 estimated as the slope in a weighted estimating equation, accounting for
participation of some respondents in multiple surveys. The blue points at the bottom of each
panel represent estimated trends for the total population of men and women, corresponding to
the annual estimates in Figure 4.3.
In adjusted estimates, the percentage of 17–54 year old men who had ever had sex increased
by around 0.7% per year. The percentage of women who had ever had sex did not increase
significantly in adjusted estimates. The average number of partners in the last year did not
change over time, but the percentage of men with multiple partners in the last year declined by
about 1.2% per year (95% CI 0.5%, 1.9%), and the point prevalence of concurrency declined by
about 0.6% per year (0%, 1.2%). For women, the percentage reporting multiple partnerships
declined by an average 0.4% per year (0.2%, 0.6%), but there was not a significant trend in
concurrency. There was no significant trend in reporting a casual partner for either men or
women.
The clear increasing trend in reported condom usage at last sex with a regular partner is
confirmed; amongst men condom usage with regular partners increased by an average of 2.6%
per year (1.5%, 3.7%) and amongst women it increased by an average of 4.2% per year (3.0%,
5.3%). The trend in condom usage with casual partners was less clear. There was some evidence
that it may have increased amongst men (estimate 1.95%; 95% CI -0.6%, 4.5%), but no change
amongst women (-0.8%; -4.6%, 3.1%). Recall, however, that condom usage with casual partners
was already much higher than with regular partners in 2005, and still remains higher in 2011.
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Figure 4.3: Unadjusted and adjusted estimates of sexual behaviour indicators by sex over 2005–
2011.
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Figure 4.4: Average annual change in sexual behaviour indicators for residents, non-residents, and the
whole population (colours), for men (left) and women (right). The scale represents the
average percentage point change each year over the period 2005–2011 for outcomes expressed
as %. For average annual partners the scale represents the average change each year in the
mean number of partners in the past year. For age difference with regular partner the scale
represents the average annual change in the mean age difference. Horizontal lines indicate
95% confidence intervals. Dotted lines indicate trends based on unadjusted annual estimates
and solid lines indicate trends based on estimates adjusted for non-response. Numerical slope
estimates and standard errors are indicated on the outside of each interval.
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Figure 4.5: Unadjusted and adjusted estimates of HIV prevalence by sex over 2005–2011 and
the percentage of the population who have had an HIV test and learned the result
over 2006–2011. Vertical lines indicate 95% confidence intervals.
4.3.3 Population trends in HIV status and knowledge of HIV status
Total population estimates of HIV prevalence and the percentage of the population who report
knowing their HIV status are shown in Figure 4.5, and Figure 4.6 shows the estimated average
annual change in HIV prevalence and knowledge of HIV status. HIV prevalence in females was
estimated to be 29% (95% CI 25%, 34%) and increased to an estimated 36% (31%, 42%) in
2011. The estimated average annual increase was HIV prevalence was lower in men; in 2005,
prevalence was an estimated 21% (13%, 28%). There was less evidence of a trend in male HIV
prevalence, with the estimated average annual change being 0.7% per year, 95% CI -0.5%, 2.0%.
Knowledge of HIV status increased dramatically for both sexes. In 2006, the first year in
which questions about previous HIV testing were included in the survey, 33% (95% CI 29%,
38%) of men and 48% (45%, 52%) of women had ever had an HIV test and learned the result.
By 2011 this had increased to 55% (51%, 60%) of men and 83% (80%, 85%) of women.
4.3.4 Comparison of sexual behaviour trends between residents and
non-residents
Imputations and response weighting were conducted separately for residents and non-residents.
These groups represent different sampling methodologies, and also may represent different epi-
demiological risks due to the opportunity for non-residents’ to act as bridges to populations
outside the surveillance area. Figures 4.7 and 4.8 show sexual behaviour indicator estimates
by residency status for men and women, respectively, and Figure 4.9 shows estimates of HIV
prevalence and knowledge of HIV status by residency status. For both men and women, non-
residents generally reported higher levels of sexual risk behaviour than did residents, including
more partners in the last year, a higher percentage with multiple partnerships, a higher point
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Figure 4.6: Average annual change in HIV prevalence and knowledge of HIV status for residents, non-
residents, and the whole population (colours), for men (left) and women (right). The scale
represents the average percentage point change each year over the period 2005–2011 for
HIV prevalence and 2006–2011 for knowledge of HIV status. Horizontal lines indicate 95%
confidence intervals. Dotted lines indicate trends based on unadjusted annual estimates and
solid lines indicate trends based on estimates adjusted for non-response. Numerical slope
estimates and standard errors are indicated on the outside of each interval.
prevalence of concurrency, and more casual partnerships. For women, estimates suggested that
non-residents were more likely to report condom usage with their last regular partner, but for
men this was reversed. In light of previous work suggesting that migrants might be an impor-
tant population in the spread of HIV in this region [64] and the differences we found in some
reported risk behaviours, we were surprised that there was not a difference in HIV prevalence
between residents and non-residents for men or women. Resident men were more likely to report
knowing their HIV status than non-resident men, but there was not a difference for women.
There was considerably greater uncertainty in the indicator estimates for non-residents due
to the much smaller sample size and large sample weights and response weights ascribed to
some respondents. To illustrate the greater variation in the weights ascribed to non-residents
compared to residents, the coefficient of variation for the total weights (the standard deviation
of the weights divided by the mean of the weights) for non-resident men is 1.99 compared to
0.48 for resident men, and for women the coefficient of variation for non-residents is 1.65 versus
0.36 for residents. For residents, for most indicators, there is a clear and relatively consistent
trend in the point estimates year-on-year, but for non-residents there is much greater sampling
variability in the estimates from year to year, which obscures visual ascertainment of clear
trends over time.
Unsurprisingly, there was also much greater uncertainty in the estimated trends over time for
non-residents compared to residents (Figures 4.4 and 4.6). Many more trends were statistically
significant for residents than were for non-residents or the total population of both residents
and non-residents. Resident men reported changes in the proportion ever having had sex (0.8%
per year; 95% CI 0.3%, 0.9%), the percentage reporting multiple partnerships (-0.9% per year;
-1.2%, -0.7%), concurrency (-0.5% per year; -0.7%, -0.3%), average age difference with regular
partners (0.08 per year; 0.03, 0.12), and condom use with both casual (2.5% per year; 0.5%,
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Figure 4.7: Unadjusted and adjusted estimates of sexual behaviour indicators by residency sta-
tus for men aged 17–54, 2005–2011.
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Figure 4.8: Unadjusted and adjusted estimates of sexual behaviour indicators by residency sta-
tus for women aged 17–49, 2005–2011. (Condom use at last sex with casual partner
is not reported for non-residents due to very few non-resident respondents who re-
ported a casual partner.)
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Figure 4.9: Unadjusted and adjusted estimates of HIV prevalence and knowledge of HIV status
by residency status for men (top) and women (bottom), 2005–2011.
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4.5%) and regular partners (4% per year; 3.4%, 4.6%). Resident women reported significant
changes in the proportion ever having had sex (0.8% per year; 0.6%, 0.9%), the percentage with
casual partnerships (0.3% per year; 0.2%, 0.3$), average age difference with regular partners
(-0.05 per year; -0.09, -0.01), and condom usage with regular partners (3.9% per year; 2.5%,
5.4%). The only indicators for which there was significant trend for non-residents was a decline
in multiple partnerships for both men (-1.5% per year; -2.9%, 0%) and women (-0.9% per year;
-1.5%, -0.4%), and an increase in condom usage with regular partners for non-resident women
(4.6% per year; 2.6%, 6.6%). For almost all indicators, however, changes trended in the same
direction for residents and non-residents, and there were no outcomes for which there were
statistically significant trends in opposite directions for residents and non-residents.
4.3.5 The influence of adjusting for missing data and non-response
Adjusting for missing data can affect the estimates of sexual behaviour indicators in two ways.
It can change the point estimates of indicators and it can affect the uncertainty of the estimates.
Table 4.4 summarises the difference in point estimates between the adjusted and unadjusted
estimates. The table shows the absolute change in the point estimate of each indicator averaged
over all years, with proportional changes relative to the unadjusted point estimate indicated in
parentheses. Adjusting for missing data tended to have a larger effect on estimates for men than
for women, and amongst men for residents than non-residents. Indicators for which the average
level was particularly strongly affected were the percentage who ever had sex, which increased
by 5.6 percentage points for men and 1.6 percentage points for women (proportional increases
of 7% and 2%, respectively), the average number of partners in the last year which increased by
0.05 for men (a 5% increase), concurrency which increased by 1.2 percentage points for men (a
24% increase), age difference with regular partners which reduced by an average of 0.36 years
(11% decrease) for all men and half a year (17% decrease)for resident men, and condom usage
with regular partners which decreased by an average of 1.7 percentage points (5% decrease)
for all men and 3.2 percentage points (7% decrease) for resident men. The upward estimate
of the point prevalence of concurrency indicator was predicted by the analysis in section 3.5 of
chapter 3 because of increased missing data on dates of first and last sex in those that reported
more sexual partners in the past year. In most cases the adjustment for missing data increased
the standard error (Table 4.5), often my a factor of between 1.1 and 1.6, sometimes more.
The influence of adjusting for missing data on the estimated trends in sexual behaviours and
HIV status and knowledge is demonstrated in Figures 4.4 and 4.6 by comparing the unadjusted
slope estimates (indicated by dotted confidence intervals) with the adjusted slope estimate (solid
confidence intervals). In almost all cases, adjusting for missing data increased the standard er-
ror of the trend estimate, although not to the same magnitude to which it did for the indicator
estimates in Table 4.5. Often, the adjustment for missing data attenuated the trend estimates
towards zero, especially for men, although there are exceptions. Particularly surprising, for
example, are cases such as men’s reported condom usage with regular partner, where the ad-
justment slightly decreased the estimated annual change in condom usage for both residents
and non-residents, but slightly increased the estimated annual change for the total population
estimate.
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Table 4.4: Effect of adjustment for missing data on point estimates
Men, aged 17–54 Women, aged 17–49
Resident Non- All Resident Non- All
resident resident
Ever had sex 7.4% (10%) 1.7% (2%) 5.6% (7%) 1.6% (2%) 1.3% (1%)) 1.6% (2%))
Avg. annual part. 0.07 (8%) -0.02 (-1%) 0.05 (5%) 0.01 (1%) 0.01 (1%) 0.02 (2%)
Multiple partners -0.1% (-1%) -1.5% (-7%) 0% (0%) 0% (3%) -0.1% (2%) 0.2% (14%)
Concurrency 1.2% (24%) 0.2% (3%) 1.2% (15%) 0.1% (71%) 0% (NA) 0.1% (84%)
Cas. part. last year 0.2% (1%) -0.7% (-4%) 0% (0%) 0.1% (4%) 1% (33%) 0.5% (20%)
Reg. part. age diff. -0.49 (17%) -0.23 (6%) -0.36 (11%) 0.04 (1%) -0.04 (-1%) -0.02 (0%)
Cond. use cas. part. -0.9% (-1%) -0.4% (-1%) -0.3% (0%) 0.6% (1%) 1.8% (3%) 2.4% (4%)
Cond. use reg. part. -3.2% (-7%) -0.8% (-2%) -1.7% (-5%) -0.1% (1%) -0.8% (-1%) 0.4% (2%)
HIV prevalence 1.6% (9%) -3.3% (-13%) -0.3% (-1%) 1.4% (4%) -5.3% (-14%) -0.6% (-2%)
Knows HIV status 2.5% (8%) 0.9% (2%) 2.8% (8%) 1.1% (2%) 0.5% (1%) 1.5% (3%)
Average absolute (percentage point) difference between the adjusted and unadjusted point estimate
(Relative change in point estimated in parentheses)
Table 4.5: Effect of adjustment for missing data on standard error estimates
Men, aged 17–54 Women, aged 17–49
Resident Non- All Resident Non- All
resident resident
Ever had sex 1.87 0.98 1.33 2.61 0.97 1.65
Average annual partners 1.37 1.23 1.47 1.85 1.30 1.74
Multiple partners 1.09 1.13 1.36 1.08 1.64 1.70
Concurrency 1.29 1.12 1.36 1.51 4.40 3.19
Casual partner in last year 1.21 1.20 1.46 1.16 1.56 1.83
Regular part. age difference 1.29 1.42 1.58 1.10 1.27 1.48
Condom usage casual part. 1.54 1.22 1.45 1.38 0.97 1.41
Condom usage regular part. 1.58 1.23 1.45 3.22 1.12 1.81
HIV prevalence 4.32 1.25 1.78 5.81 1.20 2.68
Knows HIV status 1.18 1.18 1.45 1.34 1.07 1.50
Average ratio of standard error for adjusted estimate divided by standard error for unadjusted estimate
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4.4 Discussion
Estimated trends in population-level sexual behaviour indicators, adjusted for missing data,
showed evidence of risk reduction in some behaviours in a high HIV prevalence population in
rural KwaZulu-Natal over 2005–2011, the period of ART roll out. The most substantial change
has been a dramatic increase in reported condom usage at last sex with regular sexual partners,
for both men and women, residents and non-residents. We also found evidence of reductions in
the percentage of the population reporting more than one sexual partner in the last year and
in the point prevalence of concurrency for men. Reported condom usage with casual sexual
partners was relatively high—around three in five reported their last sex act with a casual
partner was protected—but it is less clear whether this increased over the time period.
The population of Umkhanyakude district under surveillance by the Africa Centre was one of
the first rural populations in South Africa to access antiretroviral therapy and has now achieved
high ART coverage, over 75% of those in need according to current guidelines [352, 370, 371].
The surveillance activities and other public health campaigns in the area have also probably
encouraged greater uptake of HIV testing and counselling in this population. The early provision
of services in this population make it a useful test case for understanding how sexual behaviours
might respond to the recent national expansion of HIV testing and treatment. Over the period
2005–2011 we did not find evidence of increased sexual risk behaviour that has been feared
during the ART era, but it will be important to continue to monitor this in coming years as
patients initiate treatment earlier under current treatment guidelines.
Although outside the scope of the data considered for this study, the increase in HIV preva-
lence amongst women is likely to be largely attributable to the high coverage of ART [371].
The relatively more flat trend in HIV prevalence in men could be because men have less ac-
cess to treatment [35] and poorer outcomes upon initiating ART [153], although an analysis of
the ART programme in this population through December 2008 found that amongst residents
HIV-infected men were only slightly less likely than HIV infected women to be accessing ART
(19.2% for men versus 21.8% for women) [352]. Women were much more likely to know their
HIV status than men throughout the period, even as testing increased dramatically for both
sexes. This supports the conclusion of others that special attention and innovative approaches
are needed to engage men in HIV testing and HIV care in southern Africa [372–374]. It is also
worth noting that HIV prevalence increased more amongst resident men than non-resident men,
who could face particular challenges accessing ART due to high mobility.
Men and women reported similar levels of condom usage and average age differences with
regular partners, but men reported substantially higher average numbers of partners, higher
levels of multiple partnerships, higher point prevalence of concurrency, and more casual part-
nerships. The adjustment for missing data developed here does not correct for any systematic
misreporting of individual sexual behaviour. This is not a closed population, and the high
proportion of non-resident migrant men is a mechanism which could create differentials in sex-
ual behaviour indicators between men and women. However, large differential also occurred
in residents only. Further work would need to investigate what the levels of sexual behaviour
outside of the population would have to be to create the observed differentials without mis-
reporting. Other research has persistently concluded that women tend to under-report their
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sexual risk in household-based surveys [315, 375], while studies are conflicting about whether
men over-report or under-report sexual behaviours [375–378]. If reporting is biased, but the
bias is consistent over time, then trends should still be a reliable indicator of the direction of
changes in sexual behaviour [315]. But if social norms about acceptable behaviour change in
response to the epidemic and public health messages, under-reporting of risk behaviours could
increase. In a modelling study, Johnson found that his STI-HIV interaction model fit observed
epidemic data from South Africa significantly better when he allowed for bias in the increase in
reported condom usage [33]. If true sexual risk behaviour has not changed as much as suggested
by reported trends, this could partially explain why HIV incidence remains high.
Both the multiple imputation to adjust for item nonresponse and the response weighting to
adjust for survey nonresponse relied on the assumption that the data were missing at random
(MAR), that is, that missingness may depend on the values of observed covariates, but it does
not rely on the values of the missing data themselves [379]. There has been suggestion in the
literature that refusal to participate in HIV sero-prevalence surveys may not satisfy this—that
individuals who know they are HIV infected may be more likely to refuse to participate [150,
152]. However, for sexual behaviour indicators, the MAR assumption may be less contentious.
Moreover inclusion of a large number and diversity of covariates in imputation models, as we
have here, makes the MAR assumption more plausible because observed covariates that are
correlated with any unobserved causal determinants of missingness can substitute for these
unobserved determinants [357, 380]. An exception to this is the example showed in the previous
chapter that individuals with more partners are also more likely to have missing data on the
concurrency indicator. A na¨ıve approach to imputing concurrency which did not account for
the number of sexual partners would have created missing data in which the probability of data
being missing depended on the value of the missing data (missing not at random or non-ignorable
missing data). The conditional imputation approach adopted here avoids this.
The multi-step approach of first adjusting for item nonresponse using multiple imputation
and then adjusting for survey nonresponse using response weighting is slightly dissatisfying.
The intended approach when the analysis plan was devised was to use multiple imputation to
augment missing data for the full eligible population. This proved to be challenging, however,
becuase of the very high level of non-participation in any given survey round—around 70%
in later rounds. The result of such high levels of missing data, we found, was that multiple
imputation chains tended not to converge and would yield pathological results, such as one im-
putation chain would converge on all non-respondents having casual partnerships while another
chain would impute that none of individuals missing data had casual partnerships. It was still
necessary to use the multiple imputation for partially completed survey data, rather than using
only response weighting, to ensure internally consistent data adhering to the structure of the
survey tool. Practically, it also would have been computationally intractable to impute many
datasets for the entire eligible population for many years of data due to the large population
size.
While we used multiple years of data in our analysis, we decided to conduct the multiple
imputations separately for each year, as well as for each sex, and for residents and non-residents,
instead of using longitudinal models to impute data for the same individuals over time. An
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equivalent formulation of this approach would be to consider that we imputed the longitudinal
data by including interactions with survey year and each of the variables in the imputation
models, thereby not allowing information to be shared across years. Thus, we feel that this
approach is conservative in accounting for the variance introduced by the missing data. Allowing
for information to be shared across years in longitudinal imputation models could increase the
precision of the imputations and, as a result, of the resulting point and trend estimates [381, 382].
Most of the sexual behaviour indicators that we investigated related to sexual behaviours
in the last year (since the previous survey), so conducting separate imputations for each year
does not lead to logically inconsistent imputed longitudinal data. The exception to this is the
variable ‘ever had sex’, which theoretically cannot be ‘yes’ one year and ‘no’ in the next, but
in practice this does not occur often because the proportion who have debuted sex is nearly
100% except in the 17–19 year-old age group. Model-based imputation of HIV status over
time poses unique challenges because theoretically this variable can change from ‘negative’ to
‘positive’, but cannot revert. This is not enforced in the imputation approach adopted here. As
such, this analysis can be used to estimate HIV prevalence over time, but cannot investigate
trends in or correlates of HIV incidence. Simply carrying forward the HIV status of individuals
testing positive in earlier rounds and carrying backward the HIV status of individuals testing
negative in later rounds to fill in missing data would result in biased estimates because it would
selectively add HIV infected individuals to the numerator and denominator in recent years and
only add HIV uninfected individuals to the numerator and denominator in early survey years
[383]. Instead, approaches for creating longitudinally consistent HIV estimates and estimating
HIV incidence will need to explicitly model HIV incidence events, and using this to establish
the HIV infection status at each round [384].
The most important result of adjusting for missing sexual behaviour data in ACDIS was to
increase the standard errors, both around point estimates and estimates of trends over time. For
some variables, particularly the percentage that reported ever having had sex and concurrency
for men, the adjustment changed the point estimate, and in many cases trend estimates were
slightly attenuated. However, adjusting for missing data did not change the qualitative conclu-
sions about trends in sexual behaviour that would be drawn from the unadjusted data. This
inspires some confidence in the validity of the trends that we found, particularly the sizeable
increases in reported condom usage for both sexes and reductions in multiple partners and con-
currency for men [304]. Conducting this exercise to adjust for missing data was an important
step for a comprehensive understanding of the patterns of sexual behaviour in ACDIS in order
to exclude the hypothesis that apparent changes in behaviour were attributable to changes in
the composition of respondents and non-respondents over survey rounds. The relatively consis-
tent year-on-year estimates for the sexual behaviour, HIV, and HIV testing indicators amongst
residents increase our confidence in these trends, which is reflected in the greater statistical
certainty in the trend estimates for this population. To improve the precision of estimates
about non-residents, it may be necessary to increase the size of the sample in some strata, or
undertake efforts to improve contact and participation of non-resident eligible respondents.
Assessing whether the magnitude of the changes in the estimates as a result of considering
missing data are ‘big’ is subjective. On one hand, in chapter 2 we found in a model that small
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changes of one or two percentage points in the level of concurrency, levels of changes that would
be challenging to robustly detect in surveillance data even with less missingness, could have large
effects on endemic HIV prevalence. A more relevant comparator might be how the magnitude of
changes due to adjusting for missing data compares to the amount of change in sexual behaviour
that has been observed in epidemic settings where sexual behaviour change has been associated
with declines in the HIV epidemic. In Manicaland, Zimbabwe, where between 1999 and 2002
HIV prevalence amongst those less than 20 years old declined by half, the magnitude of changes
in reported sexual behaviour that were associated with these declines in incidence were declines
in the percentage of men under 20 reporting ever had sex from 45% to 27%, declines in reporting
a casual partner in the last year from 26% to 13% [90]. The magnitude of these changes are
much larger than the effect of the adjustments in our estimates.
Common imputation software did not include facility for modelling the structural limitations
of the survey, but implementing the imputation routine was possible by extending existing
software. We hope that the success of this approach will encourage more routine consideration
of missing data in evaluating trends in population-level sexual behaviour in generalised HIV
epidemic settings.
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5 Behavioral, biological, and programmatic
factors affecting the impact of Treatment
as Prevention in generalised HIV
epidemics
5.1 Background
Recent declines in HIV incidence in several countries in southern Africa [24, 385, 386] are wel-
come news, and in chapter 4 we found evidence for recent protective behaviour changes in the
most severe epidemic in the region. However, HIV incidence remains unacceptably high in
southern Africa [25, 387–390], underscoring the need for additional HIV prevention strategies.
One strategy for which there has recently been increasing enthusiasm is expanding the provi-
sion of antiretroviral therapy (ART) in order to prevent onward transmission of infection by
those already infected—treatment as prevention [255, 391–394]. The idea of using medicines
that suppress viral concentrations to reduce the transmission of HIV is not new. It was first
considered in a mathematical model by Anderson, Gupta, and May over twenty years ago [235].
The efficacy of antivirals to reduce transmission of HIV was anticipated by the strong rela-
tionship between plasma viral load and heterosexual HIV transmission [137, 395, 396] and the
effectiveness of highly active antiretroviral therapy to reduce infected individuals HIV viral load
to low or undetectable levels [397, 398]. The strong level of protection provided by ART has
been confirmed by several observational studies of serodiscordant couples [236–238, 376] and the
HPTN 052 randomised clinical trial [105], each of which estimated levels of protection of 92%
or greater. These scientific findings have bolstered resolve to achieve universal access to ART
in low- and middle-income settings, and, with the precipitous declines in the cost of providing
HIV treatment [399, 400], some have argued that treatment for prevention is an affordable and
cost-effective prevention strategy in generalised HIV epidemics in southern Africa [185, 197].
The biological efficacy of ART for preventing HIV transmission, demonstrated by observa-
tional studies and the HPTN 052 clinical trial, is an important parameter for determining the
epidemiological impact of HIV treatment as prevention, but is only one piece of the puzzle.
Other determinants include the natural history of HIV infection and HIV transmissibility over
the course of infection, the characteristics of the sexual network over which HIV is spread, and
the success of health systems in identifying and reaching those in need of treatment, initiating
them on ART, and retaining them on treatment with suppressed viral loads [258]. Using inno-
vative research designs, new data have become available about a number of these determinants
in recent years.
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New data have improved the precision of our estimates about the natural history and trans-
missibility of HIV. Studies of HIV transmission in heterosexual serodiscordant couples in sub-
Saharan Africa have quantified the transmission rate of HIV during the period of primary
infection in the first few months after HIV is acquired [138, 260] and the relative average in-
fectiousness of individuals at different CD4 cell counts [238]. Longitudinal observation of HIV
seroconverters has improved estimates of the progression of HIV infection, including the dura-
tion until reaching need for antiretroviral therapy based on different CD4 cell count thresholds
for ART eligibility [139, 156, 157]. Clinical cohorts of patients on ART in sub-Saharan Africa
have provided data about the mortality and prognosis of patients on ART according to their
nadir CD4 cell count before initiating therapy [153].
As access to antiretroviral therapy has increased in South Africa, clinical monitoring data
have reported on the characteristics of patients initiating ART and the levels of mortality,
retention, and viral suppression of treatment facilities. In the past five years, South Africa have
surpassed the access levels set as targets in the last national strategic plan [35, 401]. This has
coincided with decreases in the proportion of individuals initiating treatment with extremely
low CD4 cell counts [402–404], but clinical surveillance data have estimated extremely high and
increasing over time rates of loss to follow-up. In analysis of patients initiating ART between
2002 and 2007 at eight public sector clinics in the four largest provinces, Cornell and colleagues
estimated that twelve month mortality had declined from 8.9% of those initiating ART in 2002
and 2003 to 5.6% of those initiating ART in 2007 [402]. However, the percentage of patients
who were lost-to-follow-up after 12 months increased from 1.1% to 23.5% over the same period.
In a retrospective analysis of records of patients starting treatment between 2004 and 2007
at 47 primary healthcare facilities, nine district hospitals, and three regional hospitals in four
provinces, Fatti and colleagues found a similar trend of decreasing mortality but increasing loss
to follow-up in Cox proportional hazards models that adjusted for baseline CD4 cell count and
WHO clinical stage, although found that treatment administered through primary health care
facilities had lower mortality and loss to follow-up than when administered through hospitals
[154]. A similar pattern of increasing rates of loss to follow-up over time was documented
in analyses of single facility cohorts of patients in Cape Town [404], Khayelitsha [405], and
Johannesburg [403]. Fatti and colleagues reported that between 80% and 90% of patients on
ART were virologically suppressed at each six-month intervals between 6 months and 36 months
on ART, with higher rates virological suppression for those receiving treatment through primary
health facilities. In data from Cape Town, Nglazi and colleagues report increasing rates of
virological failure for recent cohorts of treatment initiators [404], while Boulle and colleagues
find slightly declining rates of virological failure in Khayelisha [405].
The outcomes for individuals who are lost to treatment programmes are largely uncertain and
inherently difficult to study, but could be a crucial determinant of the success of treatment as
prevention. A systematic review and meta-analyses of studies that traced patients lost to follow-
up in ART programmes in resource-limited settings estimated that 42% of patients lost to follow-
up had died, while other reported reasons for loss to follow-up included transferring to another
ART facility, financial reasons, improved health, being too sick to attend the clinic, stigma, and
adverse effects of the drugs [406]. South Africa has a well functioning vital registration system
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and patients in the health system are linked to the death registry by national ID number. In an
ART patient cohort in Khayelitsha, Van Cutsem and colleagues found that 29% of patients who
were lost to follow-up and had an ID number available had died within three months of loss to
follow-up [407]. Correcting for mortality reduced the estimated loss to follow-up at five-years
by 4 percentage points, and after adjusting for mortality individuals with higher baseline CD4
cell counts were more likely to be lost to follow-up.
The stage of HIV infection, whether an individual is on ART is virally suppressed, and the
prognosis on ART will determine the probability that an infected individual transmits HIV
to a susceptible partner, but how HIV spreads in the population additionally relies on sexual
behaviours of the population and characteristics of the sexual network—the ‘epidemiological
context’. To a first approximation, in the short term the number of HIV infections averted by
HIV treatment might be expected to be the difference between the number of transmissions that
would have occurred had an individual not started treatment and the number of transmissions
that occur after an individual starts treatment. However, the true number could be greater
if secondary transmissions that would have occurred from an averted infection are considered,
or it could be less if individuals are infected through another route. Different ‘epidemiological
contexts’ could result in substantially different long-term impacts of the same intervention [408].
5.1.1 Contributions and dissemination
We thank Leigh Johnson of the University of Cape Town and Thomas Rehle of the University
of Cape Town and Human Sciences Research Council for advising on the interpretation of the
South African national HIV prevalence data. Leontine Alkema of the National University of
Singapore and Leigh Johnson gave advice for deriving the likelihood for the HIV epidemic data
and Le Bao of Pennsylvania State University advised and shared R code for the implementation
of the incremental mixture importance sampling (IMIS) algorithm. We thank Christophe Fraser
for helpful conversations about the interpretation of the model results.
This work has been presented as a poster at the Epidemics3 conference from 29 November to 2
December, 2011 in Boston, MA, USA (poster number P1-66). Estimates of the current impact of
ART in South Africa and projections of the current National Strategic Plan were included in the
briefing paper “The Prevention Benefits of Expanding AIDS Treatment: How Large and How
Affordable Are They?” by Robert Hecht for the Wilton Park meeting The new era in HIV/AIDS
treatment and prevention: science, implementation and finance, 27–28 June 2012 in Crozet,
Switzerland. A technical description of the mathematical model has been published on the
HIV Modelling Consortium website (http://www.hivmodelling.org/model-comparisons) in
conjunction with the model comparison study described in chapter 6 and [32].
5.2 Methods
In this chapter we use this recent data on the natural history of HIV infection, HIV transmis-
sibility, prognosis on antiretroviral therapy, and programmatic outcomes of ART programmes
in South Africa to develop a mathematical model of the potential impact of antiretroviral
treatment on HIV incidence in South Africa. The model uses a flexible representation of sex-
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ual behaviour, sexual mixing, and behaviour change over time to model heterosexual contacts
through which HIV is transmitted. It is calibrated to epidemiological data on the national
HIV epidemic in South Africa by varying parameters controlling sexual behaviour in a Bayesian
statistical framework. This results in parameter combinations representing different underlying
patterns of sexual behaviour that are consistent with the observed HIV epidemic, allowing us
to investigate how uncertainties about sexual behaviour affect the impact of HIV treatment
interventions.
Section 5.2.1 gives a non-technical description of the model, including diagrams of key model
processes. Section 5.2.2 gives a mathematical description of the model. Section 5.2.3 describes
the calibration of the model to the South African epidemic context.
5.2.1 Mathematical model
The model uses ordinary different equations to simulate heterosexual HIV transmission in a
two-sex population. The sexually active population is divided into three sexual risk groups
which mix semi-assortatively. Individuals can move between risk groups and sexual behaviour
can change over the course of the epidemic. The model includes progression through five stages
of HIV infection according to CD4 cell count, and allows for initiation of ART at any level of
CD4 cell count.
Population structure
The model simulates a two-sex adult population age 15 and older (see diagram in Figure 5.1).
The population is divided into the age groups 15 to 49, presumed to be sexually active age
group, and age 50 and older, who are assumed not to form new sexual contacts. Individuals
move from the younger to older age group at a rate ν = 1/35 per year and die from the age
50 plus population at an annual rate µ = 1/11.45 per year, calibrated to match the relative
sizes of the 15 to 49 year-old population and the age 50 plus population in the year 1990 [409].
Individuals enter the age 15–49 population at a rate α = 0.0226 per year, calibrated such that the
population growth over the period 1990 to 2010 approximately matches the population growth
estimates over that period published by Statistics South Africa [409]. All new sexual contacts,
and hence HIV transmission, occur in the 15–49 age group, but the older age group is included
in the model to assess the total ART need in the intervention scenarios. The sexually active
population is divided into three sexual risk groups (termed ‘low’, ‘medium’, and ‘high’). As a
crude means of simulating natural variability in individuals’ sexual risk behaviour, individuals
move from high risk to medium risk, high to low risk, and medium risk to low risk at a rate ψ.
This rate is varied in the model calibration (see section 5.2.3), and is the same for both sexes.
The proportion of the population in each risk group before the introduction of HIV into the
population is allowed to be different for each sex and is estimated in the model calibration.
The proportion of the new entrants into the population that enter each risk group is calculated
such that, in the absence of HIV, this proportion of the population in each risk group would
remain constant. The proportion entering each risk group remains fixed over the duration of
the simulation (meaning that the relative size of risk groups may change as a result of the
differential burden of HIV in each risk group).
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Figure 5.1: Diagram of model population structure and sexual mixing. Solid arrows indicate
flows of individuals between risk groups. Dashed light grey arrows indicate sexual
contacts between risk groups. Contacts are assortative such that individuals are
more likely to form contacts with those in the same risk group.
Sexual mixing
As described in the previous section, the population is divided into three sexual risk groups
(see Figure 5.1). The sexual contact rate in each of the risk groups is determined by the overall
population average sexual contact rate, the relative rate of new sexual contacts between the
three risk groups, and the size of the risk group. The underlying population average rate of new
unprotected sexual contacts, c(t), is allowed to vary over the course of the epidemic in order
to model potential behaviour change in response to the epidemic such as increased condom
usage [33] or reductions in the number of new sexual partners [192]. The functional form for
the reduction is a logistic function parameterised by the initial contact rate, c0, the proportion
reduction in the contact rate that will occur, ∆c, the start year of the behaviour change, tc,
and the number duration (in years) over which the behaviour change occurs, dc. Together, the
overall average contact rate at time t is given by
c(t) = c0 · (1−∆c) + c0 ·∆c · 1
1 + exp
(
t−(tc+dc)/2
dc/10
) (5.1)
Each of these parameters (the initial contact rate, the percentage reduction in the contact
rate, the timing of the start of the reduction, and the duration of the change) are estimated in
the model calibration. The relative contact rates between high and low risk females and medium
and low risk females are also estimated. The relative contact rates for males are calculated based
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on the relative contact rates for females and the sizes of each of the risk groups for males and
females so that the total number of contacts offered by males and females in the same risk group
is the same.
The number of sexual contacts formed between members of each risk group is determined by
the sexual mixing parameter ε, as proposed by Garnett and Anderson [270]. A proportion ε
(between 0 and 1) of sexual contacts are reserved exclusively to be formed with other members
of the same risk group, while the remaining (1 − ε) proportion of partnerships are formed at
random. The value of ε is estimated in the model calibration. If ε = 0, sexual mixing is
completely random, while if ε = 1, mixing is fully assortative. As HIV mortality differentially
affects males and females of each risk group, the total number of contacts offered by males may
not be equal to the number of partnerships offered by females. In this case the desired number of
contacts desired by males and females are geometrically weighted by the parameter θG ranging
between zero and one; θG = 0 indicates that the females’ preferences determines the number of
contacts while θG = 1 indicates that the males’ desired number of contacts dominates. For this
exercise, the value is fixed at θG = 0.5.
Natural history of HIV infection
HIV infection is divided into stages according to CD4 cell count progression associated with the
duration of infection (Figure 5.2). The stages are:
1. Primary infection,
2. CD4 count greater than 350 cells/µl,
3. CD4 count between 200 and 350 cells/µl,
4. CD4 count between 100 and 200 cells/µl, and
5. CD4 count below 100 cells/µl.
HIV-infected individuals progress from one stage of HIV infection to the next at a rate which
is the reciprocal of the average duration in the stage. The average duration of primary infection
is an 2.9 months, as estimated by Hollingsworth, Anderson, and Fraser [260]. The rates of
progression to subsequent CD4 cell stages and the overall duration from HIV infection to death
is based on estimates of the duration until CD4 cell count thresholds in sub-Saharan African
cohort from the eART-linc collaboration [139], which estimated mean durations of 4.8 years and
9.4 years to reaching CD4 cell counts of below 350 and 200 cells/µl, respectively. The estimate
of an average of 4.17 years between CD4 count ≤200 cells/µl and CD4 ≤100 cells/µl is based
on extrapolating the rate of decline in square-root transformed CD4 cell count between CD4
≤350 cells/µl to CD4 ≤200. The overall average duration from infection to HIV death is 14.6
years, from the eART-linc collaboration [139], and the resulting median duration from infection
to HIV death is 13.2 years.
The HIV transmission rate of an infected individual varies according to these stages of in-
fection. The overall baseline weighted average transmission rate over the period from the end
of primary HIV infection to 1.6 years before death is set to be 0.106 per year, as estimated
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Figure 5.2: Diagram depicting average duration of and relative HIV transmission rate during
each stage of HIV infection. (Note that vertical axis is not drawn to scale).
by Hollingsworth, Anderson, and Fraser [260] using data from discordant couples in Rakai,
Uganda [138]. The relative rates of transmission during the CD4 stages CD4 >350, CD4 200–
350, and CD4 ≤200 are based on the relative rates of transmission observed for these stages by
Donnell and colleagues [238], although the rate of transmission during the CD4 ≤100 stages has
been reduced in accordance with the estimate from Hollingsworth, Anderson and Fraser that no
transmission occurs during the final 9 months of infection [260], presumably because individuals
are sick and not very sexually active during this period. The transmission rate during primary
HIV infection is set at 2.76 per year, as estimated by Hollingsworth, Anderson, and Fraser [260].
ART model
Individuals may initiate ART from any of the above stages of HIV infection. Antiretroviral
therapy is divided into a multistage process (Figure 5.3). Upon treatment initiation, all indi-
viduals first enter a ‘virally suppressing’ stage during which they are on ART but their viral
load is not yet fully suppressed. This stage lasts for a mean duration of 3 months, such that
86% of patients achieve virological suppression after six months, consistent with levels of viral
suppression after six months in ART-na¨ıve patients in the United Kingdom [410]. Transmission
is assumed to be reduced by half during this stage compared to the CD4 stage from which
treatment was initiated.
After this stage, most patients enter a long period of ‘effective ART’, while a proportion of
patients for whom treatment is not successful go directly to the final stage of the ART model
of being ‘very sick’, which lasts for an average of 6.2 months before death. The probability of
immediately failing treatment depends on the CD4 cell count stage from which treatment was
initiated to allow for high early mortality when starting treatment at lower CD4 cell counts,
but then relatively similar long-term survival if treatment effectively suppresses viral load and
symptoms are controlled [153, 402, 411]. The proportion of patients who fail ART is calibrated
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Figure 5.3: Diagram of stages of antiretroviral therapy. Arrows indicate possible movements of
individuals between stages. Black arrows indicate natural progression of individuals.
Red arrows indicate dropout from ART. Individuals may only dropout from ART
once, and may return to a different CD4 stage depending on their duration on ART
(see Table 5.2).
such that mortality in the first year after initiating ART matches crude first-year mortality
rate observed for each CD4 count stratum in a collaborative analysis of ART cohorts from
sub-Saharan Africa [153].
For the majority of patients for whom ART is effective, the viral load is suppressed and
transmission is reduced by 92% compared to the HIV transmission rate in the CD4 count
between 200 to 350 cells/µl stage [238]. The period of ‘effective ART’ is divided into two
stages—first a period of ‘early effective ART’ lasting an average of 1.75 years, and then a long
period of sustained viral suppression. The reduction in transmission is assumed to be the same
in both of these stages, but this is implemented as separate ART stages so that the dropout rate
from treatment can be varied according to the duration on ART. For example, we may assume
that there is high dropout in the years following ART initiation, but patients who remain on
treatment for two years are likely to have accommodated treatment and have high retention
thereafter. In addition to the previously described higher probability for immediate treatment
failure and death for those starting ART at low CD4 cell counts, the failure rate for long-term
effective ART is assumed to be slightly lower for those who start treatment at high CD4 cell
counts (see Figure 5.3), in line with observations that mortality is modestly higher even several
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Table 5.1: Rate per year of dropping out from antiretroviral therapy
Duration on therapy
Baseline CD4 cell count Virally suppressing Early effect ART Effective ART Reinitated ART
CD4 >350 0.168 0.168 0.088 0.06
CD4 200–350 0.168 0.168 0.088 0.06
CD4 100–200 0.156 0.156 0.088 0.06
CD4 ≤100 0.120 0.120 0.088 0.06
years after treatment initiation for those who start at low CD4 cell counts [402] and to ensure
that there is no ‘survival benefit’ in the model from delaying treatment initiation.
After patients fail long-term effective ART, they enter a stage of ‘treatment-failing’ in which
they are viraemic and are assumed to have the same infectiousness as individuals in the CD4
cell count category 200 to 350 cells/µl . The average duration of this stage is 2.3 years. Finally
individuals enter a stage of being ‘very sick’ just before death, which lasts for an average duration
of 6.2 months. During this period of being ‘very sick’, transmission is reduced and assumed to
be at the same level as during the CD4 ≤100 cells/µl stage.
Dropping out from ART
Individuals may dropout from any of the first three stages of ART: ‘virally suppressing’, ‘early
effective ART’, and ‘effective ART’. The rate of dropout from treatment is permitted to vary
according to duration on ART and the CD4 cell count category from which treatment was initi-
ated, in line with data suggesting that those starting treatment at higher CD4 cell counts may
have poorer retention in treatment programmes [407], perhaps because they did not experience
AIDS-related symptoms before initiating ART and so are less motivated for treatment. The
rates of dropout from each of these stages assumed in the baseline model calibration are chosen
to represent the high rates of dropout reviewed in section 5.1. These are presented in Table 5.1.
Dropout is assumed to decline after the first two years on therapy, and individuals who reinitiate
therapy after having dropped out once (see below) are assumed to have lower rates of dropout.
After dropping out from treatment, the untreated CD4 stage category that individuals enter
depends on their pre-treatment CD4 category and the duration on treatment to simulate CD4
cell count reconstitution associated with ART. Individuals who dropout from the ‘virally sup-
pressing’ stage all return to the same CD4 stage from which they initiated treatment. For those
who dropout during the ‘early effective ART’ stage, half move one CD4 stage higher, while half
increase two CD4 stages. Those who dropout from the ‘effective ART’ stage all increase two
CD4 stages. This is summarized in Table 5.2. However, individuals who have dropped out of
treatment progress through subsequent CD4 stages twice as fast as treatment na¨ıve individuals
(rates described in Figure 5.2).
In the model, after individuals have dropped out of treatment, they are eligible to restart
treatment again once. The rate at which these individuals reinitiate treatment depends on the
CD4 cell count category, such that they are increasingly likely to reinitiate treatment at lower
CD4 count categories, when they are likely to be experiencing clinical symptoms. The rate of
reinitiating treatment for those with CD4 cell count between 200 and 350 cells/µl is 0.048 per
year, the rate for those with CD4 cell count between 100 and 200 cells/µl is 0.160, and the rate
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Table 5.2: CD4 stage after dropping out of treatment
CD4 stage at Treatment stage Percentage of droupouts returning to CD4 category
ART initiation at dropout CD4 >350 CD4: 200–350 CD4: 100–200 CD4 ≤100
CD4 >350
Virally suppressing 100%
Early effect. ART 100%
Effective ART 100%
CD4: 200–350
Virally suppressing 100%
Early effect. ART 100%
Effective ART 100%
CD4: 100–200
Virally suppressing 100%
Early effect. ART 50% 50%
Effective ART 100%
CD4 ≤100
Virally suppressing 100%
Early effect. ART 50% 50%
Effective ART 100%
for those with CD4 count below 100 cells/µl is 2.92 per year. Based on progressing through
these stages at twice the rate of treatment na¨ıve individuals, the probability that an individual
who dropped out will restart ART in each of these CD4 cell count categories before progressing
to the next CD4 stage (or dying in the case of those with CD4 count ≤100 cells/µl) is 10%,
25%, and 60%, respectively. The overall probability that an individual who has dropped out of
treatment once will reinitiate treatment before dying from HIV is 73%.
Upon restarting treatment, individuals progress through the same stages of ART as when
first initiating ART. The baseline assumption for the rate of dropping out from treatment
after reinitiating is 0.06 per year (Table 5.1, last column). Because individuals may restart
treatment, but only once, the model separately tracks treated and untreated people according
to the number of times which they have initiated ART. To summarise this, Table 5.3 lists all of
the stages of antiretroviral treatment through which infected individuals can progress, and the
subscript identifying each stages in the technical model description that follows.
Table 5.3: Stages of antiretroviral therapy.
Subscript Stage Duration Infectiousness
0 Untreated, no access to treatment
1 Untreated, access to ART
2 Virally suppressing 3 months 50% lower than prev. stage
3 Early effective ART, virally suppressed 1.75 years 92% lower than CD4 ≤350
4 Effective ART, virally suppressed (Figure 5.3) 92% lower than CD4 ≤350
5 Treatment failing, viraemic 2.3 years Same as CD4 200–350
6 Very sick 6.2 months Same as CD4 ≤100
7 Untreated, dropped out after first initiation, eligible to restart ART.
8 Re-initiated ART, virally suppressing 3 months 50% lower than prev. stage
9 Re-initiated ART, early effective ART 1.75 years 92% lower than CD4 ≤350
4 Re-iniated ART, effective ART (Figure 5.3) 92% lower than CD4 ≤350
11 Re-initated ART, treatment failing, viraemic 2.3 years Same as CD4 100–200
12 Re-initated ART, very sick 6.2 months Same as CD4 ≤100
13 Untreated, dropped out after second initiaton, not eligible to restart.
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HIV transmission
The probability of transmission in a contact between a susceptible with an infected individual
depends on the annual transmission rate βm,u in HIV stage m and treatment stage u, the
“intensity” of a contact κrM ,rF between a male in risk group rM and a female in risk group
rF . The intensity parameter accounts for factors that affect the probability of transmission in
different types of partnerships such as the partnership duration, coital frequency, and condom
usage. The per-contact transmission probability based on these parameters is 1 − e−βm·κrM ,rF
where m is the HIV stage of the infected partner.
5.2.2 Model equations
We divide the population into four categories according to their infection and treatment status:
Sg,r: HIV uninfected and sexually active (susceptible) individuals of sex g in risk
group r.
Ig,rm,u: HIV infected and sexually active individuals of sex g in risk group r and HIV
infection stage m. The subscript u = 0 indicates untreated individuals who
do not have access to treatment, u = 1 indicates untreated individuals who do
have access to treatment, u = 7 indicates individuals who have dropped out
of treatment and are eligible to restart, and u = 13 indicates those who have
dropped out from treatment a second time and are not eligible to restart.
T g,rm,u: HIV-infected and sexually active individuals on ART (treated) who began
treatment in HIV infection stage m and are in treatment stage u (see Table 5.3).
Rgm,u: Individuals removed from the sexually active population of sex g, in HIV
infection stage m, and treatment stage u. (Uninfected individuals are indicated
by m = 0 and untreated individuals by u ∈ {0, 1, 7, 13}).
In the above and throughout the following mathematical description, the superscript g ∈
{M,F} corresponds to sex; superscript r ∈ {H,M,L} corresponds to sexual risk group for the
sexually active population; subscript m ∈ {0, . . . , 5} corresponds to HIV infection stage with 0
representing uninfected and 1 to 5 corresponding to the stages of infection from primary infec-
tion to CD4 ≤100; and subscript u ∈ {0, . . . 13} corresponds to ART status with 0 indicating
untreated individuals without access to treatment, 1 indicating untreated individuals with ac-
cess to treatment, and the remaining stages indicating different stages of ART as indicated in
Table 5.3.
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The following differential equations define the dynamics of the groups:
dSg,r
dt
=
α+ ν
2
p˜ig,r
(
S·,· + I ·,·· + T
·,·
·,·
)
+
∑
r′
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∑
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ψgr,r′
)
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In the above equations, the parameter p˜ig,r is the proportion of new susceptible individuals of
sex g that should enter risk group r in order to maintain a constant proportion pig,r in risk group
r in the absence of HIV infection. Solving the above equations with fg,r(t) = 0 gives that
p˜ig,r =
∑
r′ ψ
g
r,r′pi
g,r −∑r′ ψgr′,rpig,r′
α+ ν
. (5.2)
The function fg,r(t) is the force of infection for the group Sg,r which depends on the contact
rate cg,r(t) at time t in that group, the probability that a contact is formed with an infectious
partner, and the probability of transmission in that contact.
The contact rate for a risk group depends on the average underlying contact rate c(t) which
changes over time according to equation 5.1, the size of the risk groups at the beginning of the
epidemic pig,r and the relative contact rates of the high and medium risk groups to the low risk
group ωg,r (where ωg,L := 1). The weighted average of the relative contact rate by the size of
the initial risk group yields the annual contact rate for each risk group at time t:
cg,r(t) =
c(t) · ωg,r∑
r′ pi
g,r′ωg,r′
.
The total number of contacts desired to be formed by members of risk group r of sex g is
thus
Jg,r(t) = cg,r(t)
(
Sg,r +
∑
m
Ig,rm +
∑
m
∑
u
T g,rm,u
)
(5.3)
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The number of these contacts Jg,r desired to be formed with each risk group r′ of the opposite
sex g′ depends on the value of the assortativity parameter ε. A proportion ε of the partnerships
are desired only to be formed with the members of the same risk group r = r′, while the
remaining 1− ε proportion of the partnerships are formed with each risk group of the opposite
sex proportionally to the number of partnerships Jg
′,r′ offered by those risk groups. Formally,
the proportion of contacts desired to be formed by sex g and risk group r that are formed with
the risk group r′ of the opposite sex is defined as
Qgr,r′ = ε δr,r′ + (1− ε)
Jg
′,r′∑
r˙ J
g′,r˙ (5.4)
where δr,r′ is the Kronecker delta defined as δr,r′ = 1 if r = r
′ and 0 otherwise.
In the case that males in risk group rM and females in group rF do not agree on the number
of partnerships to be formed between the risk groups, i.e. QMrM ,rF J
M,rM 6= QFrF ,rMJF,rF , the
discrepancy is balanced according to the parameter θG as
Q˜MrM ,rF = Q
M
rM ,rF
(
QMrM ,rF J
M,rM
QFrF ,rMJ
F,rF
)θG−1
Q˜FrF ,rM = Q
F
rF ,rM
(
QMrM ,rF J
M,rM
QFrF ,rMJ
F,rF
)θG (5.5)
The probability that transmission occurs in a contact between a susceptible and an infected
individual depends on the stage of infection and treatment status of the infection according to
the transmission rate parameter βm,u and on the value of the partnership intensity multiplier
κrM ,rF for a partnership between the male in risk group rM and the female in risk group rF .
The force of infection is then calculated by summing over the probability that each contact
is with an infectious individual and the probability that transmission occurs according to the
infection stage and treatment status of the partner:
fg,r(t) = cg,r(t)
∑
r′
[
Q˜gr,r′
∑
m
∑
u I
g′,r′
m p
g′,r′,r
m,u +
∑
m
∑
u T
g′,r′
m,u p
g′,r′,r
m,u
Sg′,r′ +
∑
m
∑
u I
g,r
m,u +
∑
m
∑
u T
g,r
m,u
]
(5.6)
where pg,r,r
′
m,u is the probability of transmission per contact by an infected individual of sex g
in risk group r, HIV stage m and treatment status u to a susceptible individual of the opposite
sex in risk group r′, defined as
pg,r,r
′
m,u = 1− exp {−βm,u · κrM ,rF } . (5.7)
5.2.3 Model calibration
The model is calibrated to nationally representative HIV prevalence data and ART scale-up data
from South Africa. The general strategy for model calibration is that parameters related to the
natural history of HIV infection, the effect of antiretroviral therapy on individual infection, and
patterns of access and retention in the existing ART program are fixed and informed from the
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literature as described in Section 5.2.1. Parameters relating to sexual behaviour and mixing,
the start time of the epidemic, the timing and magnitude of sexual behaviour change, and the
timing and rate of existing ART scale-up are estimated using a Bayesian approach. This yields
a joint distribution of parameter combinations representing different sexual mixing patterns
consistent with the observed epidemic.
Data
The model is calibrated using HIV prevalence data from two sources. The first is HIV prevalence
amongst 15–49 year-old pregnant women from the annual national antenatal prevalence surveys
from 1990 to 2008 [11]. The second is national HIV prevalence amongst 15–49 year-old males
and females from the three nationally representative household surveys conducted by the Human
Sciences Research Council in 2002, 2005, and 2008 [340–342]. Figure 5.4 shows the mean and
95% confidence intervals for each of these estimates. The discrepancy between the level of HIV
prevalence in the antenatal surveillance and the household survey based prevalence is reconciled
by incorporating a bias parameter in the antenatal prevalence compared to prevalence amongst
the general 15–49 year old population from the household surveys. This is described in detail
below in Section 5.2.4.
1990 1995 2000 2005 2010
South Africa HIV prevalence data
Year
H
IV
 P
re
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le
nc
e
0%
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Mean and 95% CI
Figure 5.4: Age 15–49 HIV prevalence from three nationally representative HSRC household
surveys and HIV prevalence amongst antenatal care attendees.
The model is also calibrated to the percentage of the adult population on antiretroviral
therapy. This is calculated by dividing the total number of adults reported to be on ART
according to the South Africa Department of Health in June of each year from 2005 to 2010
[412] by the annual mid-year population size estimate of those over 15 years old from Statistics
128
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Figure 5.5: Percentage of adult population (age 15+) on ART at midpoint of each year (South
Africa Department of Health)
South Africa [409]. The resulting estimates for the proportion of the adult population on ART
for 2005 to 2010 to which the model is calibrated are shown in Figure 5.5.
Estimated model parameters
A vector θ of 20 parameter values are estimated, and are either used directly or to derive a
number of the model inputs in the equations described in Section 5.2.2 and Table 5.4. The
mathematical model parameters which are estimated from fitting to HIV prevalence data from
South Africa are given in Table 5.5 along with the prior distribution from which they are
estimated. This collection of model parameters estimated from the data will be referenced
together as the parameter vector θ.
5.2.4 Statistical methods
We use a Bayesian analysis to estimate probability distributions for the unknown parameters
given the model and available HIV prevalence data, W . Let θ denote the set of parameters to
be estimated from section 5.2.3 and M denote the mathematical model and the associated fixed
parameter values. For a given set of parameter values, the model produces a corresponding set
of predicted HIV prevalence values ζ = M(θ). Then we specify a likelihood function p(W |M(θ)
for the probability of the data given the model and parameter values. If we let p(θ) denote a
prior distribution on the unknown parameters, using Bayes theorem the posterior distribution
of θ given the model and data is given by
p(θ|W ,M) ∝ p(θ)p(W |M(θ)).
Likelihood function
We now derive the combined likelihood for the national seroprevalence survey data and antenatal
clinic data. First we define the likelihood for an individual datum.
For the national household survey estimates, let WF,t and WM,t be the HIV prevalence in
the age group 15-49 reported by a survey in year t. As above, define ζg,t to be the predicted
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population HIV prevalence for sex g at time t by the model M(θ). We assume that HIV
prevalence estimates from national household surveys are an unbiased estimate of the true
population prevalence, but logit-transform the data to stabilise the error variance, so that
log
(
Wg,t
1−Wg,t
)
= log
(
ζg,t
1− ζg,t
)
+ g,t (5.8)
where g,t ∼ Normal(0, σ2g,t) and the errors are conditionally independent given ζ. Thus the
likelihood function for an estimate from a national prevalence survey is
p(Wg,t|M(θ)) = 1√
2piσ2g,t
exp
{
−1
2σ2g,t
(logit(Wg,t)− logit(ζg,t))2
}
(5.9)
In calculating the likelihood, the value of σ2g,t is replaced by an estimate σˆ
2
g,t based on the
confidence intervals reported by the HSRC survey which account for the complex sampling
design. The confidence intervals in the HSRC reports are on the inverse-logit scale, so the error
variances are estimated by
σˆ2g,t =
(
logit(CImaxg,t )− logit(CIming,t )
2 · Φ−1(.975)
)2
(5.10)
where Φ−1 is the inverse of standard normal cumulative distribution function.
For the antenatal clinic data, similar to [33, 196], we assume that HIV prevalence WC,t
amongst antenatal clinic attendees at time t is linearly related to prevalence in the general
female age 15 to 49 population on the logit scale and that this affect is fixed over time. To
model this, we introduce an additional parameter γ such that
log
(
WC,t
1−WC,t
)
= log
(
ζF,t
1− ζF,t
)
+ γ + C,t, (5.11)
where the error term C,t ∼ Normal(0, σ2C,t) and recalling that ζF,t is the HIV prevalence amongst
females aged 15 to 49 predicted by the model at time t. Thus
p(WC,t|M(θ)) = 1√
2piσ2C,t
exp
{
−1
2σ2C,t
(logit(WC,t)− (logit(ζF,t) + γ))2
}
(5.12)
Once again, when evaluating the likelihood, we replace σ2C,t with an estimate σˆ
2
C,t computed
from the confidence intervals published by the South African Department of Health. In the case
of the antenatal clinic data, the reported confidence intervals are symmetric, suggesting that
they have been estimated on the untransformed scale rather than logit-transformed prevalence.
Deriving an estimate of the sampling error variance on the logit scale involves two steps: first
estimating the untransformed error variance τˆ2C,t, and then using the delta method to approx-
imate the variance σˆ2C,t of the logit-transformed distribution, which depends on the estimated
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antenatal clinic prevalence at time t, WC,t. The equations for this are
τˆ2C,t =
(
logit(CImaxC,t )− logit(CIminC,t )
2 · Φ−1(.975)
)2
, and (5.13)
σˆ2C,t =
τˆ2C,t
WC,t
2(1−WC,t)2
(5.14)
To arrive at the likelihood for the full data W , we assume that the data points are condi-
tionally independent given the predicted prevalences ζ = M(θ) and the antenatal clinic bias
parameter γ. Defining TN to be the set of years when national survey prevalence estimate
are available and TC the set of years where antenatal clinic estimates are available, the full
likelihood is
p(W |M(θ), γ) =
∏
t∈TN
∏
g∈{M,F}
p(Wg,t|M(θ)) ·
∏
t∈TC
p(WC,t|M(θ), γ)
=
∏
t∈TN
∏
g∈{M,F}
1√
2piσ2g,t
exp
{
−1
2σ2g,t
(logit(Wg,t)− logit(ζg,t))2
}
×
∏
t∈TC
1√
2piσ2C,t
exp
{
−1
2σ2C,t
(logit(WC,t)− (logit(ζF,t) + γ))2
} (5.15)
Priors
The prior distributions for the estimated model parameters θ are given in Table 5.5. The
antenatal bias parameter γ is assumed to have Uniform(0, 1) prior distribution. This amounts
to assuming that the odds ratio of ANC prevalence to adult females prevalence is between 1 and
2.7. Restricting the prior value of γ to be positive ensures that the model does not mistakenly
interpret the ANC prevalence as the true population prevalence when fitting the model.
Estimating the posterior distribution
Multiplying the likelihood and prior distribution yields the joint posterior distribution of the
parameters θ and γ given the model and data up to a scaling constant:
p(θ, γ|W ,M) ∝ p(W |θ, γ,M)p(θ, γ) (5.16)
We are principally interested in the values of the model parameters θ. The posterior dis-
tribution for θ|W ,M can be calculated by integrating out the parameter γ. Observe that
p(θ|W ,M) ∝
∫
Ωγ
p(W |θ, γ,M)p(θ, γ) dγ
=
∫
Ωγ
p(θ)p(γ)
∏
t∈TN
∏
g∈{M,F}
p(Wg,t|M(θ)) ·
∏
t∈TC
p(WC,t|M(θ), γ) dγ
=
∏
t∈TN
∏
g∈{M,F}
p(Wg,t|M(θ))p(θ) ·
∫
Ωγ
p(γ)
∏
t∈TC
p(WC,t|M(θ), γ) dγ,
(5.17)
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so if we can efficiently evaluate the integral
∫
Ωγ
p(γ)
∏
t∈TC p(WC,t|M(θ), γ) dγ, then we can
efficiently estimate the posterior distribution of θ. Before attacking this, let us define three
useful quantities:
S2 =
∑
t∈TC
1
σ2C,t
−1 (5.18)
D = S2 ·
∑
t∈TC
WC,t − ζF,t
σ2C,t
(5.19)
D2 = S2 ·
∑
t∈TC
(WC,t − ζF,t)2
σ2C,t
(5.20)
The first can be thought of as the pooled variance of the ANC prevalence estimates, the second
as the precision-weighted mean difference between ANC data prevalence and the model predicted
female prevalence, and the third as the precision-weight mean squared distance between the
ANC data and the predicted female prevalence.
Now, again consider our integral. We will do a bit of rearranging to show that the integral can
be evaluated as a normal cumulative distribution function. For brevity, denote W˙t = logit(WC,t)
and ζ˙t = logit(ζF,t), and all sums and products are over the set TC .∫
Ωγ
p(γ)p(WC |M(θ), γ) dγ =
∫ 1
0
∏
t
1√
2piσ2C,t
exp
{
−1
2σ2C,t
(
W˙t − (ζ˙t + γ)
)2}
dγ
=
1√∏
t 2piσ
2
C,t
∫ 1
0
exp
{∑
t
−1
2σ2C,t
(
γ − (W˙t − ζ˙t)
)2}
dγ
= K ·
∫ 1
0
exp
{
−1
2
∑
t
(
γ2
σ2C,t
− 2γ W˙t − ζ˙t
σ2C,t
+
(W˙t − ζ˙t)2
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Using this expression, we can efficiently evaluate the posterior density function p(θ|W ,M)
up to a constant. We use the incremental mixture importance sampling (IMIS) algorithm to
approximate and sample from the posterior distribution [413].
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5.2.5 Analyses
After estimating the joint posterior distribution using the IMIS algorithm, we sample 1000
parameter combinations from the posterior distribution to obtain simulated epidemics with
different patterns of sexual behaviour and sexual mixing that are consistent with the observed
HIV epidemic. The model parameters that are estimated are those that control patterns of
sexual behaviour, sexual mixing, and behaviour change (Table 5.5), while parameters controlling
the natural history of HIV, prognosis on ART, and HIV transmissibility are fixed using values
from the literature, so posterior distributions and credible intervals for outcomes of interest
should be interpreted as representing the uncertainty in the outcome propagated by uncertainty
in the sexual behaviour, conditional on the fixed parameter values. They do not reflect all
sources of uncertainty in the outcome.
Using the samples from the posterior distribution, we first plot the simulated epidemics with
the HIV prevalence and ART scale-up data included in the likelihood, compare the univari-
ate posterior distribution of each parameter with its prior distribution, and estimate bivariate
correlations between the parameters. We then use the model to estimate the impact that cur-
rent ART scale-up has had on HIV incidence and prevalence in South Africa and the potential
impact if the targets defined in the current National Strategic Plan are met [414]. For each
sampled combination of parameters, the initial population size is calibrated so that the model
population size in the middle of year 2010 matches the size of the age 15+ population mid-year
population estimated by Statistics South Africa [409]. The epidemic is simulated using the
number of patients initiating ART in each year from 2003 to 2011 estimated by Johnson [35]
and the estimates of the projected number of patients that would initiate each year from 2012
through 2016 to meet the targets in the National Strategic Plan by Meyer-Rath and colleagues
[415]. For each combination of parameters, an additional counterfactual epidemic is simulated
in which no antiretroviral therapy is provided and the percentage reduction in the incidence
rate in each year attributable to ART is estimated by calculating the difference in the combined
HIV incidence rate in all adults aged 15–49 at the midpoint of each year between the ART
simulation and the counterfactual simulation and dividing this by the HIV incidence rate in the
no-ART counterfactual simulation. The change in prevalence attributable to ART is estimated
in a similar way.
Next we turn attention to investigating factors that affect the long-term impact of ART
on HIV incidence. As a base intervention, we consider an ART programme in which 80%
of HIV-infected individuals access ART at a CD4 count threshold of ≤350 cells/µl. This is
implemented such that all HIV-infected adults who are eligible for treatment initiate treatment
at a constant rate calculated so that 80% will have initiated ART before dying from HIV.
This rate is 0.23 per year. Men and women access ART at the same rate. The intervention is
implemented from the beginning of year 2012. Scale-up to the specified rate of ART initiation
is instantaneous, increasing on the baseline rates of ART initiation estimated in the model
calibration (Table 5.5). Rates of ART dropout and reinitiation are assumed to be the same as
used in the model calibration. This intervention is simulated through the year 2040 and the
primary indicator of intervention impact used is the percentage reduction in the HIV incidence
rate in the year 2040 compared to the no-ART counterfactual simulation.
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Model parameters that affect the impact of the ART intervention are assessed by calculating
the association between the parameter value and the percentage reduction in HIV incidence
in the year 2040 using correlations [33], partial correlations adjusting for the values of the
other parameters, non-parametric rank correlation coefficients, and partial rank correlation
coefficients [416]. The percentage of HIV transmissions resulting from individuals in each stage
of HIV infection is calculated over time for the no-ART counterfactual simulation and the
intervention simulation, and the percentage of transmissions in the year 2040 in the no-ART
counterfactual resulting from individuals in the primary infection stage is compared with the
percentage reduction in incidence in 2040 effected by the intervention.
Additional intervention scenarios manipulate aspects of the ART intervention program in-
cluding the CD4 cell count threshold at which infected individuals are eligible for treatment,
the percentage of the population that accesses ART, and the annual rate at which individuals
dropout from ART. Specific details of the assumptions of each of these scenarios are described
preceeding the results of each analysis in section 5.3.
5.3 Results
5.3.1 Posterior epidemic output
We first examine the epidemics simulated by sampling from the joint posterior distribution
of the calibrated model parameters. Figure 5.6 shows the epidemic curves simulated by 1000
sampled parameter combinations from the joint posterior distribution. The epidemics are pro-
jected forward to the year 2040 assuming that the rates of ART initiation estimated to fit the
scale-up through year 2010 (Figure 5.6) are continued in the future. The left panel shows that
the posterior epidemic simulations achieve a good fit to age 15–49 HIV prevalence estimates
for both men and women from the nationally representative household survey data and to the
time series of HIV prevalence amongst women attending antenatal clinics incorporating the
estimated antenatal bias parameter γ. The baseline posterior epidemic simulations project that
in this scenario prevalence will be relatively stable into the future, declining by an average of 0.9
percentage points for men and 1.8 percentage points for women. For 80% of the posterior sim-
ulations, male HIV prevalence in year 2040 is between 10.1% and 12.0% and female prevalence
is between 17.3% and 20.2%.
The panel on the right of Figure 5.6 depicts the patterns in HIV incidence that underlie these
HIV prevalence estimates. The model estimates that the HIV incidence rate peaked in 1996
for men at around 1.9 infections per 100 person-years (PYs) and in 1997 for women at around
3.2 infections per 100 PYs. After these peaks, incidence declines steeply to a posterior mean of
0.9 per 100 PYs for men and 1.8 per 100 PYs for women in 2010. That the future projection
for baseline HIV incidence is essentially constant in all of the posterior samples is an artefact
of the prior parameter restriction that the maximum end time for the logistic curve dictating
behaviour change is the year 2012, so in the absence of other interventions there are no changes
in the epidemiological context in the future projections. The 80% credible interval range for
HIV incidence in the year 2040 is 0.84 to 1.02 per 100 PYs for men and 1.52 to 1.84 per 100
PYs for women.
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Figure 5.6: Posterior model estimates and projections of HIV prevalence (left) and HIV inci-
dence (right) from 1990 to 2040. Represents scenario where the current rate of ART
scale up (estimated through 2010) is continued into the future. Model estimate for
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Figure 5.7: Posterior model calibration to percentage of adults (aged 15+) on ART. Grey lines
indicate samples from posterior distribution. Black crosses indicate midyear esti-
mates of the percentages of all adults on ART based on reported numbers on ART
from the South Africa Department of Health [412].
Included in these simulations are estimates of the rate of ART uptake for those infected with
HIV through year 2010. Those with CD4 cell counts ≤200 cells/µl are eligible for treatment, and
it is assumed that the rate of ART initiation is 1.4 times higher for women and those with CD4
cell count ≤100 cells/µl start treatment at a rate eight times higher than those with CD4 counts
between 100 and 200 cells/µl. The 80% credible interval for the treatment initiation rate in 2010
for men with CD4 counts ≤100 cells/µl is 0.99 to 1.41 per year. The percentage of the adult
population on ART each year in the posterior epidemic simulations is compared with numbers
on ART reported by the South African Department of Health in Figure 5.7. Maintaining this
rate and pattern of ART uptake in the future projection prescribes that between 67% and 76%
of men will initiate ART before HIV death and 76% to 84% of women will initiate ART before
HIV death. Fifty-one to 55% of men initiate treatment at CD4 cell count between 100 and 200
cells/µl and 55% to 61% of women initiate treatment in this range.
Figure 5.8 plots the estimated univariate posterior density of each of the parameters based on
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Table 5.6: Bivariate correlations between posterior parameter estimates
Risk Contact Partnership ART
t0 group size ψ rate ω  intensity scale up
t0 0.8 0.1 -0.0 0.8 -0.7 0.0 -0.4 -0.2 -0.3 -0.8 0.6 0.2 0.6 -0.1 -0.1 -0.3 -0.3 0.0 -0.2
1− piM,L 0.8 0.5 -0.3 0.6 -0.5 -0.1 -0.3 -0.3 -0.4 -0.8 0.7 0.3 0.6 -0.1 -0.0 -0.2 -0.2 0.1 -0.1
piM,H/(1− piM,L) 0.1 0.5 -0.1 0.2 0.4 -0.0 0.3 -0.3 0.0 -0.2 0.1 0.3 0.1 -0.0 0.1 -0.0 0.0 0.1 0.0
1− piF,L -0.0 -0.3 -0.1 0.0 0.2 -0.4 0.1 0.1 0.2 0.2 -0.0 -0.2 0.1 0.3 0.3 0.0 0.0 0.0 0.1
piF,H/(1− piF,L) 0.8 0.6 0.2 0.0 -0.5 0.1 -0.4 -0.1 -0.2 -0.7 0.3 0.4 0.3 0.0 -0.0 -0.2 -0.2 0.1 -0.1
ψ -0.7 -0.5 0.4 0.2 -0.5 -0.3 0.6 0.1 0.3 0.6 -0.5 -0.1 -0.3 0.3 0.3 0.1 0.2 0.0 0.2
c0 0.0 -0.1 -0.0 -0.4 0.1 -0.3 -0.0 0.1 0.1 -0.1 -0.1 0.1 -0.6 -0.7 -0.5 -0.0 -0.1 -0.1 -0.2
∆c -0.4 -0.3 0.3 0.1 -0.4 0.6 -0.0 0.2 0.6 0.5 -0.3 -0.2 -0.3 -0.0 0.0 0.1 0.1 -0.0 0.1
tc -0.2 -0.3 -0.3 0.1 -0.1 0.1 0.1 0.2 0.3 0.3 -0.1 -0.0 -0.3 -0.1 -0.0 -0.0 -0.0 -0.1 0.0
tc + dc -0.3 -0.4 0.0 0.2 -0.2 0.3 0.1 0.6 0.3 0.4 -0.2 -0.2 -0.4 -0.1 -0.1 0.1 0.2 0.0 0.1
ωF,M -0.8 -0.8 -0.2 0.2 -0.7 0.6 -0.1 0.5 0.3 0.4 -0.5 -0.4 -0.4 0.1 0.1 0.3 0.3 -0.1 0.2
ωF,H − ωF,M 0.6 0.7 0.1 -0.0 0.3 -0.5 -0.1 -0.3 -0.1 -0.2 -0.5 -0.1 0.4 0.1 0.1 -0.3 -0.2 0.1 -0.1
ε 0.2 0.3 0.3 -0.2 0.4 -0.1 0.1 -0.2 -0.0 -0.2 -0.4 -0.1 -0.0 -0.0 0.0 0.1 0.0 -0.1 0.1
κH 0.6 0.6 0.1 0.1 0.3 -0.3 -0.6 -0.3 -0.3 -0.4 -0.4 0.4 -0.0 0.2 0.2 -0.1 -0.1 0.0 -0.0
κM -0.1 -0.1 -0.0 0.3 0.0 0.3 -0.7 -0.0 -0.1 -0.1 0.1 0.1 -0.0 0.2 0.7 0.0 0.1 0.1 0.2
κL -0.1 -0.0 0.1 0.3 -0.0 0.3 -0.5 0.0 -0.0 -0.1 0.1 0.1 0.0 0.2 0.7 -0.0 0.0 0.2 0.3
tA0 -0.3 -0.2 -0.0 0.0 -0.2 0.1 -0.0 0.1 -0.0 0.1 0.3 -0.3 0.1 -0.1 0.0 -0.0 0.8 -0.3 0.3
λA0 -0.3 -0.2 0.0 0.0 -0.2 0.2 -0.1 0.1 -0.0 0.2 0.3 -0.2 0.0 -0.1 0.1 0.0 0.8 -0.0 0.3
tA1 − tA0 0.0 0.1 0.1 0.0 0.1 0.0 -0.1 -0.0 -0.1 0.0 -0.1 0.1 -0.1 0.0 0.1 0.2 -0.3 -0.0 0.3
λA1 -0.2 -0.1 0.0 0.1 -0.1 0.2 -0.2 0.1 0.0 0.1 0.2 -0.1 0.1 -0.0 0.2 0.3 0.3 0.3 0.3
1000 samples from the posterior distribution. The diffuse support for the posterior densities of
a number of the parameters demonstrates the range of patterns of sexual behaviour and sexual
mixing that can be consistent with the observed epidemic. For example, the 95% credible
interval for the ε parameter that controls the level of assortative mixing between the sexual risk
groups is 0.25 to 0.77 (the prior range was a uniform distribution between 0.2 and 0.8). The
posterior mean of the proportion reduction in the contact rate (∆c) is 0.27, with 95% credible
interval 0.10 to 0.37, with this behaviour change beginning (tc) in the year 1998 or 1999 in
78% of the posterior samples (the prior restriction stipulated that behaviour change begin by
the year 2000 at the latest). Thus, in most cases, the peak in HIV incidence occurred before
behaviour change began, so the peak in incidence is the result of saturation of infection in the
higher risk groups, while behaviour change extends and accelerates the behaviour change in the
2000s. The 95% credible interval for the parameter ψ which controls the rate of movement from
higher to lower risk groups is 0.002 to 0.066 with a mean of 0.030. To illustrate the implication
of this, a value of ψ = 0.03 means that 68% of individuals who start in the highest sexual risk
group will move to one of the lower sexual risk groups before ageing out of the sexually active
population, and 51% of those in the middle risk group will move to the lower risk group before
ageing out. For someone infected with HIV in the highest risk group, there is a 53% probability
he or she will move to one of the lower risk groups before death resulting from HIV infection.
This movement of individuals from higher to lower risk group also allows replenishment of new
susceptible individuals into the higher risk groups to maintain the average size of the risk group.
In order that all of the posterior epidemics be consistent with the observed HIV prevalence
data to which the model is calibrated, there are trade-offs and correlations between the pa-
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rameters. Table 5.6 presents bivariate correlations between parameters in the joint posterior
distribution. Vertical and horizontal guidelines partition parameters into logical groupings: the
epidemic start time (t0), parameters determining risk group size (1 − piM,L, piM,H/(1 − piM,L),
1−piF,L, piF,H/(1−piF,L)), the rate of movement from higher to lower risk groups (ψ), parameters
determining the average contact rate and change in contact rate (c0, ∆c, tc, tc + dc), param-
eters determining the relative contact rate between sexual risk groups (ωF,M , ωF,H − ωF,M ),
the assortativity of sexual mixing (ε), the partnership intensity parameters (κH , κM , κL), and
parameters determining the time and rate of ART scale up (tA0 , λA0 , tA1− tA0 , λA1). The abso-
lute strength of the correlation is indicated by the darkness of each cell in the table. Parameters
with moderate to high correlations are usually correlated in ways such that trade-offs occur in
order to maintain the epidemic growth rate and declines in HIV incidence that are consistent
with the epidemic data. For example, the average contact rate (c0) is negatively correlated with
the partnership intensity (the κ’s), meaning that as the contact rate increases, the probability
of transmission per contact decreases, maintaining a similar overall force of infection. The start
time of the epidemic (t0) is positively correlated with the size of the high risk groups and the
partnership intensity of contacts between members of the highest risk group, each of which
create more rapid initial growth, which is necessary if the epidemic starts later.
There are two mechanisms in the model which can effect the estimated decline in HIV in-
cidence during the late 1990s and 2000s. One is a high concentration of HIV infections high
risk groups, which become saturated and eventually shrink in size as a result of mortality. The
extent to which this occurs is partially dictated by the size of these groups and the relative
contact rates between the risk groups (the ω parameters), and partially by the rate of move-
ment from higher risk groups and lower risk groups (ψ). More movement from higher to lower
risk allows the infection to spread more broadly in the population and replenishes the high risk
groups with susceptible individuals, meaning less concentration of infections in this group. The
other mechanism that can create a reduction in incidence over time period is the amount of
reduction in the contact rate (∆c). The amount of movement from higher to lower risk groups is
positively correlated with the amount of change in sexual behaviour that occurs, so that when
the infection is spread more broadly through the population, more sexual behaviour change
throughout the population must occur to reduce incidence. Increased movement from higher
to lower risk is also positively correlated with a higher relative contact rate of the higher risk
group, indicating that when there is more movement from high to low risk the sexual risk is
more concentrated amongst those with high risk behaviour.
5.3.2 Estimated impact of current ART scale-up and projected National
Strategic Plan
In the model calibration, we incorporated data on the ART scale-up in South Africa through
the year 2010, the final year for which HIV prevalence data were available. Over this period
only those with CD4 cell counts below 200 cells/µl were eligible for ART, and ART initiation
often occurred much later than that. The projections in Figure 5.6 assumed that these rates
and patterns of ART uptake would be maintained in the future.
However, in 2010 South Africa undertook an aggressive HIV counselling and testing campaign,
139
Table 5.7: Estimated number of adults initiating ART each year under current scale-up and
projected National Strategic Plan from 1 July to 30 June of following year
Current ART scale-up∗ Projected NSP targets†
2003: 22 100 2008: 353 000 2012: 766 000
2004: 65 000 2009: 411 000 2013: 655 000
2005: 127 000 2010: 569 000 2014: 452 000
2006: 156 000 2011: 750 000 2015: 340 000
2007: 224 000 2016: 304 500
∗Based on estimates by Johnson [35].
†Based on projections by Meyer-Rath et al. [415].
and in August 2011 the South African Department of Health expanded ART eligibility to all
those with CD4 cell count below 350 cells/µl [34]. The ART scale-up accelerated dramatically
in 2011 and 2012, surpassing targets set in the previous five-year National Strategic Plan [35].
In this section, we model the actual number of individuals estimated to have initiated ART in
each year through 2012 and the number expected to start ART in each year if targets in the new
National Strategic Plan (NSP) are met [414]. We investigate the impact that the current ART
scale-up might have already had on HIV incidence and the impact that the NSP could have in
the absence of other prevention interventions or changes in risk behaviour. The annual number
of adults initiating ART from 2003 through 2011 are based on estimates by Johnson [35] and
projections of the targets under the current NSP are based on the estimates by Meyer-Rath
and colleagues [415]. Table 5.7 reports the number of adults initiating ART between 1 July of
each year until 30 June of the next. Until June 2011, only those with CD4 count below 200
cells/µl are eligible to begin ART and those with CD4 counts below 100 are eight times more
likely to start treatment. From July 2011 individuals with CD4 cell counts between 200 and
350 are eligible for treatment and initiate treatment at half the rate of untreated individuals
with CD4 cell counts between 100 and 200. Untreated women are 1.4 times more likely to start
treatment than untreated men.
Figure 5.9 compares the posterior mean estimates of adult HIV prevalence and incidence for
men and women under the current scale-up and projected NSP with what would have been
predicted to occur in a hypothetical counterfactual scenario in which no antiretroviral therapy
was provided. The projections assume no other HIV prevention interventions or changes in
sexual behaviour, and assume that rates of dropout from and reinitition on antiretroviral therapy
remain unchanged from the current assumptions described in section 5.2.3. In the absence of
ART, the model projects that HIV prevalence would have declined slightly since 2005, and
that the decline would have continued over the next five years due to the previously described
decline in incidence during the late 1990s and 2000s. Considering the current scale-up and
strategic plan, the result of increased survival of those on ART is that prevalence is expected to
remain relatively flat over the coming years, while the decline in incidence is projected to have
accelerated in 2010 and 2011 concurrently with the acceleration in ART provision and earlier
ART initiation permitted under the new guidelines.
Our model estimates that as of mid-2012, 49% of those with CD4 cell counts below 350 cells/µl
are on treatment, while 61% have ever initiated ART (Figure 5.10). Without improvements in
the retention of treatment programmes, the model predicts that if the targets set for the NSP
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Figure 5.9: Projection of HIV prevalence (left) and incidence (right) for men and women under
current ART scale-up and five-year National Strategic Plan. Compared to counter-
factual projection in which no antiretroviral therapy is provided (black lines). Lines
represent posterior means.
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Figure 5.10: Annual estimates of the percentage of adults with CD4 cell counts ≤350 cells/µl
who have ever initiated ART and are currently on ART under current scale-up
and projected National Strategic Plan, assuming no changes in ART retention.
Estimates represent posterior means.
are met, ART coverage will peak at 63% in 2015 and then decline slightly to 61% in 2017 due
to high rates of program dropout, while the percentage of those eligible who ever access ART
will continue increasing to 92% in 2017.
The overall impact of ART on adult HIV prevalence and incidence is estimated in Figure 5.11,
which shows the percentage increase in HIV prevalence and the percentage reduction in HIV
incidence relative to the HIV prevalence and incidence in the same year in the no-ART coun-
terfactual scenario. In year 2012, the HIV incidence rate is 28% lower than it would have
been without the ART programme (95% credible interval: 25%–31%), while HIV prevalence
is 9% higher (95% CI: 8%–10%), a difference of 1.4 percentage points of prevalence (95% CI:
1.2%–1.5%). The reduction in incidence is expected to peak in year 2015 at 43% (95% CI:
38%–48%), and then diminish slightly to 39% lower incidence at the end of the strategic plan
in 2017 (95% CI: 32%–45%). This reduction in intervention impact is mostly attributable to
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Figure 5.11: Estimated percentage increase in HIV prevalence and decrease in HIV incidence
associated with ART scale-up to date [35] and current National Strategic Plan [415]
compared to counterfactual in which there is no ART provided.
the accumulation of individuals who have discontinued ART and are once again infectious, as
well as some individuals experience treatment failure. Prevalence amongst 15–49 year-olds is
projected to be 2.3 percentage points higher than without ART (95% CI: 2.0, 2.5).
5.3.3 The impact of sexual behaviour and sexual mixing on long-term
intervention impact
We now turn our attention to investigating factors that affect the long-term impact of ART on
HIV incidence. We first consider how different combinations of model parameters influence the
reduction in HIV incidence in the year 2040 resulting from a generic treatment intervention in
which 80% of HIV infected individuals access ART at a CD4 count threshold of ≤350 cells/µl.
The mean reduction in the HIV incidence rate resulting from this intervention in the year
2040, compared to the counterfactual in which no ART is provided, is 26%, with interquartile
range of 23.5% to 28.0% and 95% quantile range from 16.8% to 34.7%. To assess which of the
calibrated model parameters have the greatest influence on the long-term intervention impact,
we calculated the correlation coefficient between each of the model parameters and the reduction
in incidence in 2040 using the 1000 samples from the posterior distribution. These are ranked
according to the estimated correlation coefficient in the left panel of Figure 5.12. The two
parameters most highly correlated with the reduction in incidence are ∆c and ψ, the proportion
reduction in the sexual contact rate and the rate of movement from higher to lower sexual risk
groups, respectively. These parameters are also highly correlated with each other in Table 5.6
(correlation coefficient: 0.6). In epidemics that have low rates of movement from higher to lower
risk groups and smaller amounts of behaviour change, a smaller fraction of the population will
be at high risk of infection, but the underlying reproductive number R0 at the time when the
intervention is implemented is higher, meaning that the intervention has less impact because
at risk individuals are still likely to become infected through other contacts. When there is
more movement from high to low risk, a larger proportion of the population is at risk and the
reduction in incidence is more attributable to the behaviour change, so the intervention has a
larger impact on HIV incidence. Similarly, the amount of assortative mixing between the sexual
risk groups, ε, another parameter that affects how concentrated the infection risk is, is negatively
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Figure 5.12: Correlation coefficient analysis of parameters affecting the proportion reduction in
HIV incidence in year 2040 for an intervention where 80% of individuals access
treatment at threshold of CD4 < 350 cells/µl.
correlated with the reduction in incidence. The parameter most negatively correlated with the
intervention impact is the start time of the epidemic t0. Epidemics with later start times require
more explosive transmission concentrated in the high risk groups. Epidemics where the size of
the female high risk group is larger (piFH/(1− piFL )) and the relative contact rate in the highest
risk group is larger (ωFH − ωFM ) also result in lower intervention impact.
The second panel of Figure 5.12 indicates the partial correlation between each variable and the
reduction in incidence, adjusting for the other parameters. This estimates the influence of each
parameter independent of the values of the other parameters. Here the amount of behaviour
change (∆c), the amount of movement from high to low risk (ψ), and the assortativity of
sexual mixing (ε) emerge as the most influential parameters. Two parameters that increase in
importance are the mean contact rate (c) and the partnership intensity of partnerships involving
individuals in the medium risk group (κM ). The importance of a number of the parameters
diminishes when adjusting for the other parameters, most notably the start time of the epidemic
t0. In Table 5.6 we found that some of the parameters were highly correlated with each other,
so it is not surprising that the correlations of these parameters with the outcome diminish when
controlling for the other parameters. The final two panels in Figure 5.12 plot the rank correlation
coefficient and partial rank correlation coefficient associations between each parameter and the
reduction in incidence in 2040. The magnitudes of the rank correlations and are very similar to
the correlation coefficients, suggesting that these results are relatively robust to non-linearity
of the scales of the different parameters.
5.3.4 Amount of transmission during primary infection and intervention
impact
One perceived threat to the effectiveness of treatment-as-prevention is the amount of transmis-
sion that occurs during the period of high infectiousness in the first few months after becoming
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Figure 5.13: Percentage of transmissions occurring from individuals in each stage of HIV infec-
tion for counterfactual simulation in which there is no ART (left) and intervention
treating 80% of individuals at a threshold of ≤350 cells/µl. Estimates for each
stage represent posterior mean.
infected [185, 254, 417]. The percentage of transmission that occurs from individuals in each
of the stages of infection over the course of the epidemic is illustrated in Figure 5.13. Early
in the epidemic, when the number of infected individuals is growing rapidly resulting in more
individuals in early stages than later stages of infection, primary HIV infection is responsible
for the majority of transmissions—over 80% of transmissions in the period 1990 to 1995. As
the epidemic matures, the contribution of primary infection declines sharply. In the no-ART
counterfactual simulation, the posterior mean contribution of primary infection reaches a min-
imum of 27% in mid-2008 and individuals with CD4 cell counts between 100 and 200 cells/µl
create the most new transmissions, 42%. The contribution of primary infection rebounds mod-
estly to a mean of 32% in 2040. By averting transmissions in later stages, ART increases the
relative importance of primary infection (Figure 5.13, right panel). In the intervention treating
80% of individuals at ≤350 cells/µl CD4 threshold, the mean percentage of transmission during
primary infection in 2040 is 39%.
The posterior means in Figure 5.13 conceal a large amount of variation in the contribution
of primary infection for different parameter combinations sampled from the posterior distribu-
tion. In the 1000 samples from the posterior distribution, the percentage of transmission during
primary infection in 2040 in the no-ART counterfactual simulation ranges from 24% to 41%,
with 80% of the distribution falling between 29% and 36%. The amount of transmission during
primary infection in 2040 is strongly positively correlated with the impact of the intervention—
more transmission during primary infection in the absences of ART is associated with greater
reductions in HIV incidence resulting from the treatment intervention (Figure 5.14, left panel).
This surprising finding is understood by noting that the two most influential parameters iden-
tified in section 5.3.3, the rate of movement from higher to lower risk groups and the amount
of reduction in sexual contact rate, both strongly affect the amount of transmission that occurs
during primary infection (Figure 5.14, right panel–bottom row). The ψ parameter explains 49%
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Figure 5.14: (Left) Comparison of the percentage reduction in adult HIV incidence rate in the
year 2040 with the percentage of transmission that occurs during primary HIV
infection in year 2040 when there is no ART. Points are samples from the posterior
distribution. (Right) Plots of each of these outcomes against the rate of movement
from higher to lower risk groups (ψ) and the fraction reduction in behaviour change
(∆c). The intervention scenario includes 80% access to coverage at a threshold of
CD4 < 350 cells/µl and current ART retention.
of the variation in transmission during primary infection. The ∆c parameter explains 34% of
the variation in transmission during primary infection.
Table 5.8: Reduction in incidence in 2040 regressed on transmission during primary infection,
movement from high to low risk, and amount of behaviour change.
Model
Intercept only ψ ∆c ψ + ∆c
(25.86)a
ψ (per 0.01 unit increase) 1.44 0.58 0.21 -0.15
∆c (per 0.01 unit increase) 0.60 0.51 0.57 0.52
% transm. in primary infection 1.003 0.76 0.36 0.41
% of variance explained 48% 37% 51% 82% 86% 83% 86%
Additional variance explained 48% 14% 4% 4%
aOverall mean reduction in incidence.
Table 5.8 presents the results of sequentially regressing the reduction in incidence in 2040 on
each of these factors using least-squares linear regression. Regressing the percentage reduction
in incidence on only Including only the amount of primary infection in the model estimates
that every additional percentage point of transmission during primary infection increases the
reduction in incidence in 2040 by 1.003 percentage points, explaining 48% of the variation in the
reduction in incidence. The ψ parameter alone explains 37% of the variation in the reduction in
incidence. Adding the amount of transmission during primary infection to this model explained
an additional 14% of the incidence. The ∆c parameter alone explains 82% of the variation in
the reduction in incidence. Adding the amount of transmission during primary infection only
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Table 5.9: Parameter values for model calibrations with alternate natural history assumptions
Baseline Boily primary No primary Williams CD4 No ‘very
assumptions infection infection progression sick’ stage
CD4 Stage β∗ 1/σ† β∗ 1/σ† β∗ 1/σ† β∗ 1/σ† β∗ 1/σ†
Primary infection 2.76 0.24 0.97 0.24 0.04 0.24 2.76 0.24 2.76 0.24
CD4 > 350 0.04 4.56 0.04 4.56 0.04 4.56 0.07 7.63 0.04 4.56
350 > CD4 > 200 0.07 4.60 0.07 4.60 0.07 4.60 0.11 2.16 0.07 4.60
200 > CD4 > 100 0.27 4.17 0.27 4.17 0.27 4.17 0.56 1.44 0.23 4.17
CD4 < 100 0.05 1.03 0.05 1.03 0.05 1.03 0.10 1.03 0.23 1.03
∗Baseline transmission rate per year.
†Average duration of stage in years.
an additional 4%. Both ψ and ∆c explain 83% of the variance and adding primary infection
explains an additional 4%. Nearly all of the contribution of primary infection is accounted for
by these two model parameters.
5.3.5 Assumptions about HIV infectiousness and CD4 progression over the
natural history of infection
The variation in the amount of transmission during primary infection considered in the previous
section was generated by different patterns of sexual mixing and sexual behaviour—Aall of
the simulations used the same value for the relative HIV transmissibility during primary HIV
infection based on estimates from [260] that the transmission rate is 26 times greater during
primary infection than asymptomatic infection. There is also uncertainty, however, about the
biological transmissibility of HIV during primary HIV infection [418]. To examine the influence
that different assumptions about the relative transmissibility during primary infection have on
the reduction in incidence, we conducted simulations using two alternate assumptions about the
transmissibility during primary infection: that individuals are 9.2 times more infectious than
asymptomatic individuals, as estimated in a meta-analysis by Boily and colleagues [266], and
assuming that there is no increased HIV transmission during primary infection. We also consider
two alternative assumptions about the rate of CD4 cell count progression. First we consider a
model in which CD4 cell count declines linearly, as proposed by Williams and colleagues [419] on
which the Spectrum model used by UNAIDS for estimating HIV treatment need and coverage
is based [183]. Second, our baseline model assumes that transmission is reduced at the end
of HIV infection, as noted by Hollingsworth, Anderson, and Fraser, presumably because these
individuals are very sick and having less sexual contact. In a sensitivity analysis, we assume
that infectiousness is the same for those with CD4 cell counts ≤100 cells/µl as it is for those
with CD4 cell counts between 100 and 200 cells/µl, as has been commonly assumed by other
models. Table 5.9 summarises the transmission rates and average duration in each CD4 cell
count category for these alternate natural history assumptions. For each of these assumptions
the estimated model parameters (Table 5.5) are recalibrated to the observed epidemic data
using the statistical methods described in section 5.2.4. One thousand parameter combinations
are sampled from the posterior distribution, and for each resampled combination of parameters
the intervention is simulated in which 80% of individuals with CD4 cell count ≤350 cells/µl are
treated.
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Figure 5.15: The influence of different assumptions about the infectiousness and progression
of HIV (Table 5.9) on the percentage of transmission that occurs primary HIV
infection, and after CD4 cell count falls below 350 and 200 cells/µl (top panel)
and on the reduction in incidence in the year 2040 effected by an intervention
treating 80% of individuals with ART eligibility at a CD4 threshold of 200 cells/µl
(bottom left) and 350 cells/µl (bottom right), assuming current retention rates.
The percentage of transmission during stages of HIV infection is calculated in year
2040 based on no-ART counterfactual simulation. Each point represents one out
of 1000 samples from the posterior distribution. Horizontal lines indicate posterior
means.
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As anticipated, the percentage of transmission occurring during primary infection declined
when the relative infectiousness during this stage decreased (Figure 5.15, top panel). The mean
percentage of transmission during primary infection in the year 2040 for the no-ART counter-
factual simulation was 32% using our baseline assumptions. This declined to 20% assuming
the relative infectiouness estimated by Boily and colleagues, and was 2% when there was no
increased infectiousness during primary infection. The percentage of transmission from individ-
uals with CD4 cell counts less than 200 cells/µl increased accordingly. However, the assumption
about infectiousness during primary infection did not affect the reduction in HIV incidence
effected by the ART intervention very much (Figure 5.15, bottom panel). For the intervention
treating 80% of individuals at a CD4 count threshold of ≤350 cells/µl and assuming no changes
in retention, the reduction in HIV incidence decreased slightly for the model calibrations as-
suming lower infectiousness during primary infection from a mean reduction in 2040 of 26% for
our baseline assumptions to 22% in the calibration using the Boily et al. relative infectiousness
and 23% when there is no increased infectiousness (Figure 5.15, bottom right). The results were
similar when ART eligibility was restricted to an eligibility threshold of CD4 ≤200 cells/µl. The
difference in intervention impact from different assumptions about primary infection was much
less than the variation deriving from uncertainty about the sexual behaviour and sexual mixing
parameters, as demonstrated by the amount of overlap between the posterior distributions in
the lower panel of Figure 5.15. The reason for this seemingly counterintuitive result is again
the compensatory changes that must occur in the other model parameters to replicate the rapid
epidemic growth in the early 1990s when infectiousness during primary infection is reduced.
Higher infectiousness during primary infection reduces the average generation time (the time
between when an individual becomes infected and transmits the infection), which allows the
epidemic to grow more quickly at lower R0 [418, 420, 421]. Lower R0 reduces the effort required
to control the epidemic, meaning a greater reduction in incidence for the same intervention
effort [37].
Parameterising the model using a longer duration before reaching CD4 ≤350 cells/µl as
suggested by Williams and colleagues reduced the percentage of transmission resulting from
those with CD4 cell counts ≤200 cells/µl from a mean of 40% to 27%, and accordingly increased
the relative contribution of primary infection from an average of 32% to 38%. However, this did
not change the reduction incidence: posterior mean 25.9% in the baseline assumption versus
25.5% in the Williams CD4 progression parameterisation. Omitting the low transmission for
those with CD4 cell counts ≤100 cells/µl did not affect the impact of the intervention.
5.3.6 Programme access and retention
A necessity for the success of treatment-as-prevention is to initiate and retain large fractions
of the HIV infected population on ART. Our review of clinical cohort data found that there is
currently extremely high levels of loss to follow-up of patients starting ART in South Africa.
Figure 5.18 shows contours of the posterior mean reduction in HIV incidence in the year 2040
for interventions with levels of access to treatment and decreasing annual rates of dropout from
ART. The implementation of programme access is the same as described in section 5.3.3—all
individuals with CD4 cell count below 350 cells/µl initiate treatment at a constant rate so
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Figure 5.16: Posterior mean proportion reduction in HIV incidence rate in year 2040 when
increasing the percentage of the population with access to ART and decreasing the
dropout rate for an ART initiation threshold of CD4 < 350 cells/µl. The x symbol
indicates approximately the CD4 < 350 intervention represented in Figure 5.18.
that the probability an infected individual initiates ART before HIV death matches the desired
level of access. The annual dropout rate on the vertical access is applied to all individuals
on ART (there is no gradient according to baseline CD4 cell count or duration on ART). The
x symbol on the contour denotes approximately the baseline intervention considered in the
previous section. An intervention that increased access to treatment from 80% to 95%, but
did not affect the retention on ART would increase the reduction in incidence in 2040 from
25.7% to 35.5%. This intervention also results in earlier average ART initiation, increasing the
percentage of individuals who initiate ART when their CD4 count is between 200 and 350 from
51% to 73%. Maintaining the same 80% coverage, but reducing the dropout rate from 0.11 per
year to 0.02 per year increases the reduction in HIV incidence from 25.7% to 36.6%. When
the access is 95% and the dropout rate is 0.02, the mean reduction in incidence is 50.7%—the
increase in impact is greater than the sum of the impact of either of these interventions on their
own.
5.3.7 Increasing ART eligibility threshold
Another key question has been the prevention benefit of expanding ART access to those with
higher CD4 cell counts. Our model incorporated recent data about the duration spent in each
CD4 cell count category and the HIV transmissibility by CD4 count category. Table 5.10
summarises the percentage of the sexually active (age 15–49 years) HIV-infected individuals
who are in each stage of HIV infection in year 2040 in the no-ART counterfactual simulation
and the percentage of HIV transmissions that result from individuals in each category, showing
that a disproportionate amount of transmissions result from individuals in primary infection
and with CD4 counts between 100 and 200 cells/µl.
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Table 5.10: Percentage of sexually active population in each stage of infection and transmission
from each stage in year 2040 with no ART
CD4 Stage % in stage∗ % of transmissions† ART initiation rate‡
Primary infection 2% 32% (26%, 37%)
CD4 >350 37% 12% (11%, 14%) 0.14
CD4 200–350 31% 15% (14%, 16%) 0.23
CD4 100–200 24% 38% (33%, 44%) 0.53
CD4 ≤100 6% 2% (1%, 2%)
∗Percentage of HIV-infected adult population in each risk group.
†Percentage of HIV transmissions in year 2040 resulting from each stage, mean and 95% CI.
‡ART initiation rate to achieve 80% access for ART threshold.
In this section we compare the effect on HIV prevalence and incidence of treating individuals
at different CD4 cell count thresholds. We consider interventions that reach 80% of HIV infected
individuals. In the first scenario, individuals with CD4 cell counts ≤200 cells/µl are eligible for
ART, but individuals with CD4 cell counts ≤100 cells/µl initiate ART at an 8 times higher
rate, simulating a scenario in which there is relatively good access to ART, but most HIV
diagnoses occur upon presentation with clinical symptoms (as assumed in the calibration to the
ART scale-up through 2010). To achieve 80% access in this scenario, individuals with CD4 cell
counts between 100 and 200 initiate ART at a rate of 0.21 per year and those with CD4 counts
below 100 cells/µl initiate ART at a rate of 1.65 per year. This scenario is labelled ‘current
trend’ in subsequent figures. In the next two scenarios we assume that individuals are eligible
at CD4 cell count thresholds of ≤200 cells/µl and ≤350 cells/µl, and eligible individuals initiate
ART at a constant rate such that access reaches 80% of individuals before death. The resulting
ART initiation rates are 0.53 per year and 0.23 per year for CD4 thresholds of ≤200 and ≤350,
respectively. In the final scenario, all HIV infected individuals regardless of CD4 cell count are
eligible for treatment and initiate treatment at a constant rate after the end of primary HIV
infection. This rate is 0.14 per year.
Figure 5.17 shows the impact of each of these interventions on age 15–49 HIV prevalence
and incidence through the year 2040. The interventions are implemented at the beginning of
year 2012 and assume no changes in retention and reinitiation. Treatment based on the ‘current
trend’ and only for CD4 counts ≤200 cells/µl lead to lower longer-term HIV incidence but higher
endemic HIV prevalence in 15–49 year-olds. Treating those with CD4 counts ≤350 cells/µl
reduce incidence sufficiently that endemic prevalence also falls below the no-ART counterfactual.
The reduction in incidence in the year 2040 for each of these interventions for 1000 samples
from the posterior distribution is shown in Figure 5.18, alongside the reduction incidence as-
sociated with the same intervention when the dropout rate is reduced to 0.02 per year. The
importance of improving ART retention is exacerbated when treating at earlier CD4 cell count
thresholds. When treating irrespective of CD4 count, the mean reduction in incidence was 28%
for the current levels of retention. This increased to 42% when retention was improved.
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Figure 5.17: The influence of different ART initiation thresholds on HIV prevalence (left) and
HIV incidence rate (right). Lines represent posterior mean prevalence/incidence
for each intervention scenario. All interventions begin in year 2012 and represent
80% of individuals accessing treatment and continuing current rates of dropout
from ART. Higher prevalence and incidence curves represent women aged 15–49
years and lower curves represent men aged 15–49 years.
Pe
rc
e
n
ta
ge
 re
du
ct
io
n 
in
 in
cid
en
ce
l
ll l
l
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l
l
l
l
l
l
ll
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l l
l
lll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l ll l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l l
l
l l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
lll
l
l
ll
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l
l ll
l
l
l l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l l
l
ll l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l l
l
l
l
l
l
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
0%
10%
20%
30%
40%
50%
60%
70%
Current trend CD4 < 200 CD4 < 350 All
ART eligibility
l Current ART dropout
Dropout rate 0.02 per year
Figure 5.18: Percentage reduction in the adult HIV incidence rate in the year 2040 compared
to HIV incidence rate if there were no HIV treatment. Each point represents one
combination of parameters sampled from the posterior distribution. Horizontal
lines indicate the posterior mean reduction in incidence. All interventions rep-
resent 80% of the population accessing ART. For each ART initiation threshold,
interventions are presented assuming the current rates of dropout from ART and
assuming dropout is reduced to a rate of 0.02 per year.
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5.3.8 Modelling viral suppression, treatment failure, and treatment
reinitiation
Our model of the prognosis of individuals on ART includes several stages of ART infection,
including a stage of a few months of incomplete viral suppression immediately after ART ini-
tiation and a period of viraemia before HIV-associated death for individuals on ART. This is
more complex than many of the models that have investigated the epidemiological impact of
treatment as prevention, which assume that individuals on ART have maximal suppression of
transmission from the time they initiate treatment until the die of dropout from treatment
[33, 113, 197]. To investigate the effect of including this complexity in our model, we replicated
the simulations of initiating ART at different thresholds presented in Figure 5.18 assuming that
infectiousness is immediately suppressed instead of only being partially suppressed for the first
few months on treatment, assuming that transmission is maximally suppressed until an indi-
vidual dies on ART, and finally with both of these assumptions so that the transmission rate is
fixed at constant reduced level for the duration that the individual is on ART.
Figure 5.19 shows the posterior distribution for the reduction in HIV incidence in 2040 for in-
crementally adding these assumptions. Modelling incomplete suppression of transmission during
the first few months on ART did not substantially affect the long-term impact of treatment on
HIV incidence. For all eight of the intervention scenarios, assuming immediate suppression dur-
ing this stage increased the mean reduction in incidence by a maximum of only 1.2 percentage
points. Including a period of elevated transmission for individuals on ART before experiencing
HIV-related death had a larger influence on the impact of the intervention, and the magnitude
of this increased as the interventions increased the CD4 threshold for treatment initiation and
improved retention on ART. When treating individuals at a CD4 threshold of ≤350 cells/µl,
assuming suppressed transmission until death increased the mean reduction in incidence by
3.1 percentage points. This increased to 5.8 percentage points when dropout was reduced to
0.02 per year, and a 7.4 percentage point discrepancy when treating irrespective of CD4 cell
count and assuming improved retention. For these latter two scenarios, the interquartile ranges
of the posterior reduction in incidence did not overlap between the baseline assumptions and
the results when assuming suppressed transmission until death. When programmes have early
treatment and high retention, individuals who have failed treatment will account for a higher
proportion of individuals who are viraemic, explaining why their importance increases in these
scenarios.
Finally, there is uncertainty about the subsequent ART experience of individuals who drop
out of antiretroviral therapy. Our model assumed a level of CD4 cell reconstitution depending
on the baseline CD4 count and duration on ART (Table 5.2). These individuals then progressed
through the remaining CD4 stages twice as fast as never treated individuals, but were eligible
to reinitiate treatment once. We replicated the simulations assuming the same patterns of
immune reconstitution and future progression after dropout, but that individuals could not
start treatment again. This very slightly reduced the impact of the intervention by an average
of between 0.7 and 1.8 percentage points across the scenarios.
Second, we assumed that after dropping out from ART, infected individuals returned to the
CD4 cell count category from which they initiated ART and progressed and reinitiated ART at
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Figure 5.19: Percentage reduction in the adult HIV incidence rate in the year 2040 when exclud-
ing model assumptions about viral suppression period and viraemia before death
after treatment failure. Leftmost box plot in each set represents the same scenario
as presented in Figure 5.18. Subsequent box plots sequentially omit the period
of incomplete viral suppression after treatment is initiated, the period of viraemia
before HIV death after treatment failure, and finally assuming fully reduced infec-
tiousness over the entire duration of ART. Simulations are replicated for each ART
initiation threshold and current and reduced dropout.
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Figure 5.20: Percentage reduction in the HIV incidence rate in the year 2040 when either as-
suming that individuals do not reinitate treatment again after dropping out or
assuming that individuals who dropout are indistinguishable from individuals who
have never started treatment and reinitiate ART at the same rate.
the same rate as never-treated individuals (making them indistinguishable from never-treated
individuals). This assumption also had an insubstantial effect on the reduction in incidence. It
increased the impact of the intervention by between 0.2 and 1.2 percentage points compared
to our baseline model in which those who dropped out from ART progressed faster and were
permitted to reinitiate ART once.
5.4 Discussion
This model synthesises many sources of epidemiological data about different factors affecting the
impact that antiretroviral therapy could have on HIV incidence in generalised HIV epidemics
in southern Africa. The results reinforce the conclusion that provision of antiretroviral therapy,
even in line with current clinical guidelines, could be an important tool for controlling the HIV
epidemic and may already be having a substantial impact on HIV incidence in South Africa
and other hyperendemic settings that have been successful in scaling-up ART. The model,
underpinned by the best available epidemiological data, estimated that adult HIV incidence in
mid-2012 was 28% (95% CI: 25%–31%) lower than it would have been if no ART had been
provided, resulting in an estimated 260,000 fewer infections over the past five years. Due to
the increased survival of individuals on ART, prevalence remained relatively constant while
incidence declined rapidly. Prevalence in 15–49 year-olds was flat over this five-year period at
16.4%, an estimated 1.4 percentage points higher than it would have been without treatment. In
the ART era, robust measurement of HIV incidence is essential to monitoring epidemic trends.
Data demonstrating the high biological efficacy of treatment for preventing HIV transmission
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is encouraging and essential, but uncertainty about other aspects of the epidemiology of HIV
result in a wide range of potential outcomes even for the same intervention. For the reduction
in incidence in 2040 for an intervention that reaches 80% of HIV infected individuals at a CD4
threshold of≤350 cells/µl, the 80% credible interval accounting only for uncertainty about sexual
behaviour and sexual mixing was 22% to 31%, wider than the increment in the mean reduction
in incidence from increasing the CD4 eligibility threshold from ≤200 cells/µl to ≤350 cells/µl
(20% to 26%). In principle, one approach to narrowing the uncertainty in these estimates would
be to collect additional data about unknown model input parameters. One consequence of the
abstract representation of sexual behaviour and sexual mixing in this model and many other
models is that it is challenging to directly relate model parameters to empirical measures of
sexual behaviour. This, along with concerns about biases in levels of sexual behaviour routinely
reported in population surveillance, motivated our strategy to use values from empirical data
for biological parameter values and to calibrate sexual behaviour and sexual mixing parameters
to be consistent with HIV prevalence data. However, we may have not utilised some informative
data about sexual behaviour or sexual mixing which would have excluded some combinations
of parameters and reduced the uncertainty in the outcomes.
Some factors were not as influential as we a priori expected they might be, such as the
amount of transmission that occurred during primary infection and the inclusion of a period
of incomplete suppression after ART initiation. This analysis highlights that the amount of
transmission during primary infection is an emergent property of the epidemic rather than an
underlying epidemiological determinant and is determined by a number of factors that also could
affect the impact of interventions. When considering how parameters or epidemic properties
affect interventions, it is important to recognise that these interact in non-linear ways and trade-
offs must occur to ensure that the epidemiological context being considered for future projections
is consistent with historical epidemiological data. Sensitivity analyses that in some way vary
key parameters over specified ranges and assess their influence on outcomes of interest (e.g.
[277, 416, 422]) are standard practice in epidemiological modelling, but varying parameters
independently of one another can simulate implausible or unlikely epidemics. Our Bayesian
approach to model calibration allows us to consider broad ranges for parameters, but only
selects combinations of parameters that are consistent with the epidemiological data.
In reviewing data about the effectiveness of HIV treatment programmes in South Africa, we
were surprised by the consistency of reports of high and increasing levels of loss to follow-up of
patients on ART, but one key area of uncertainty was the outcomes of individuals who stop or
fail treatment, an intrinsically challenging population to study. The survival and infectiousness
of individuals who failed treatment was one aspect to which the model results were sensitive.
Improving understanding about these populations should be a priority area for surveillance.
Our model is well calibrated to estimates of mortality on ART by baseline CD4 cell count
up to five years after ART initiation, but definitive data about long term survival and viral
suppression of patients on ART is unmeasured. One analysis from a large cohort of patients
in Uganda estimated that patients on ART had almost normal life expectancy [423], but these
estimates also necessarily rely on a model for extrapolating life expectancy from age-specific
mortality. Data were also limited about the survival, viral suppression, and retention of patients
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starting ART with CD4 cell counts above 200 cells/µl, and the data that do exist are biased
because those patients initiating above guidelines were likely experience late-stage clinical illness.
Information about these patients should become available through existing surveillance as new
guidelines are implemented studies test the feasibility of even earlier ART initiation. One
concerning hypothesis is that individuals starting ART at higher CD4 cell counts will be less
motivated due to not experiencing AIDS and will exhibit poorer adherence and retention. Our
model incorporated such a gradient in the dropout rate in the first two years on ART based
on the limited evidence for such an effect after correcting estimates of loss to follow-up for
unreported mortality using death registration data amongst patients in Khayelitsha, South
Africa [407].
In our decision to focus on the underlying epidemiological determinants of the impact of
treatment as prevention, there are many important topics which are not addressed by our
model. One common concern is the threat of treatment failure, second-line therapy, and drug
resistance to the effectiveness and cost of treatment as prevention strategies [424]. Our model did
incorporate a period of increased transmission before HIV-related mortality on ART to simulate
viraemia associated with treatment failure after treatment options have been exhausted, but
we did not explicitly model switching to second-line therapy or periods of viraemia during drug
resistance. South Africa is the only country in sub-Saharan Africa that currently conducts
routine virological monitoring of patients on ART which reduces the threat posed by drug
resistance [199, 203], but Boulle and colleagues find that there is still often a delay of several
months between the detection of virological failure and initiation of second line therapy [405].
Also not considered are the efforts required in HIV testing and linkage to care to achieve
the levels of treatment coverage and early ART initiation simulated and what interventions
and investments might achieve the improvements in retention that we simulated. Plugging the
‘treatment cascade’ [256] has become a priority area for implementation research. A systematic
review estimated heuristically that only 27% of patients who are test positive for HIV achieve
timely initiation on ART [257]. If individuals at higher risk of transmitting HIV are less likely
to access and be retained in services (for example migrant labourers [425], truck drivers, or
female sex workers [426, 427]), then these model estimates might overestimate the benefits of
treatment for HIV incidence, or if they have better access then the model might underestimate
the impact of ART. Interventions such as treatment buddies and support groups and mobile
phone text-message reminders have been found to improve adherence to therapy [428]. Distance
to the health facility has been identified as another key barrier to remaining on therapy [429],
and the finding that primary care facilities have better retention and viral suppression rates
[154] is promising for the further decentralisation of treatment services.
The model developed here studies the influence of different future trajectories for HIV treat-
ment in isolation of other factors. Our short term projections of the targets set in the current
South African National Strategic Plan only considered the objectives of the plan related to
ART provision, while the full scope of the plan outlines a broad and comprehensive response to
the epidemic and its sequelae. While the model incorporated past changes in sexual behaviour,
and this was found to be an important determinant of the epidemiological context that shaped
the impact of the intervention, it did not incorporate future changes in population sexual risk
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behaviour in response to the availability of ART or other prevention efforts. In this sense, the
projections presented here are almost surely ‘wrong’. However, isolating treatment from these
other disturbances, which cannot be disaggregated outside of models, has allowed us to metic-
ulously consider how different aspects of the system interact, identify priority areas for further
data collection to improve the precision of estimates, and inform what processes need to be
included in more comprehensive models of the epidemic response.
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6 Systematic comparison of mathematical
models of the impact of antiretroviral
therapy on HIV incidence in South Africa
6.1 Background
The mathematical model developed in chapter 5 is only one of the many mathematical models
that have been developed to evaluate the potential impact of antiretroviral therapy on HIV inci-
dence and inform public health decisions about HIV treatment as prevention in generalised HIV
epidemics. Early mathematical models of the impact of ART focused on the opposing effects of
reduced transmissibility and extended survival on new HIV infections, and whether associated
increases in sexual risk behaviour would negate the prevention benefits of ART [235, 424, 430–
439]. Since then, observational and randomised controlled trial data have demonstrated that
the biological efficacy of treatment for preventing HIV transmission is at the upper end of the
range of considered by these early models [105, 236–238, 376], and recent modelling has tended
to be more optimistic about the potential for treatment to reduce new HIV infections.
Perhaps the most provocative of these modelling efforts has been the study by Granich and
colleagues suggesting that a strategy involving annual testing and immediate treatment for
all HIV-infected individuals, combined with other interventions, could eliminate HIV by the
year 2050 [185]. Using their own implementation of the same model, Wagner and Blower con-
cluded that elimination would not be possible using different assumptions about treatment
uptake amongst asymptomatic infected individuals that they characterised as being more real-
istic [440], while Kretzschmar and colleagues highlighted how choices in model structure affect
the epidemic dynamics and intervention impact [441]. Dodd, Garnett, and Hallett showed that
the potential for treatment to eliminate HIV depends on the patterns of sexual mixing in the
population [408]. An age-structured model by Bacae¨r, Pretorius, and Auvert found that elim-
ination might be possible with less frequent testing than proposed by Granich and colleagues,
given recent epidemic trends and increases in condom usage [442]. Bendavid and colleagues
used a microsimulation model to highlight that, in addition to increasing HIV testing, improv-
ing linkage to and retention in care are essential to achieving maximal benefits of test-and-treat
interventions [422].
Other models have focused on the potential prevention benefits of providing treatment in line
with current therapeutic guidelines. Using our model from chapter 5, we estimated that 60
to 90 new infections could be averted for every 1000 additional persons treated with CD4 cell
count below 350 cells/µl (the current World Health Organization recommendation for when to
start treatment [443]), depending on how well patients on treatment are retained in care [444].
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The Goals model, used in the evaluation of the new UNAIDS Investment Framework, estimated
that a $46.5 billion incremental investment over the years 2011 to 2020, incorporating expanding
access to ART, could avert 12.2 million new infections and 7.4 million deaths globally over that
period [113]. Using a microsimulation model of the HIV epidemic in KwaZulu-Natal province,
Hontelez and colleagues found that expanding access to ART from those with CD4 cell count
≤200 cells/µl to those with ≤350 cells/µl required 28% more patients to receive treatment, but
only amounted to a 7% increase in annual investment [197]. Cumulative net costs broke even
after 16 years.
Models have also sought to understand the impact of past and current treatment policies;
Johnson and colleagues used the ASSA2003 and STI-HIV Interaction models to assess the
relative contributions of increased condom usage and ART scale-up to the declines in HIV
incidence in South Africa up to 2008 [33]. Finally, other mathematical models have been used
for short-term projections as a basis for power calculations for community randomised trials of
treatment as prevention [116].
Each of these models has predicted dramatic epidemiologic benefits of expanding access to
ART, but models appear to diverge in their estimates of the possibility of eventually eliminating
HIV using ART, the cost-effectiveness of increasing the CD4 threshold for treatment eligibility,
and the benefits of immediate treatment compared to treatment based on the current World
Health Organization (WHO) eligibility guidelines. Directly comparing the models’ predictions is
challenging because each model has been applied to a slightly different setting, in combination
with different assumptions regarding other interventions, has been used to answer different
questions, and has reported different outcome metrics.
In this study we seek to understand the extent to which diverse mathematical models agree
on the epidemiological impact of expanded access to ART by simulating the same set of inter-
vention scenarios using each model and focusing on a standardised outputs. The intervention
scenarios are designed to be simple enough to be consistently implemented across different types
of models in order to control several aspects of the treatment programme and isolate the effects
of model structure, parameters, and assumptions about the underlying epidemic on estimates
of intervention impact. The purpose of this study is not to make predictions about the im-
pact of any particular intervention in any specific setting, but rather to better characterise the
array of mathematical models being used to inform policy about treatment as prevention in
hyper-endemic settings such as South Africa.
6.1.1 Contributions and dissemination
The motivation for this study was a meeting of the HIV Modelling Consortium on The Potential
Impact of Treatment on HIV Incidence. This meeting was hosted by the South African Centre
for Epidemiological Modelling and Analysis (SACEMA) from 3–5 November 2011 in Stellen-
bosch, South Africa and funded by the Bill and Melinda Gates Foundation through the HIV
Modelling Consortium.
Tim Hallett and Leigh Johnson of the University of Cape Town contributed to the design of
this study. Model analyses were conducted by Salal Humair (Harvard School of Public Health
and Lahore University of Management Sciences), Till Ba¨rnighausen (Harvard School of Public
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Health and Africa Centre for Health and Population Studies), Eran Bendavid (Stanford Uni-
versity), John Stover (Futures Institute), Daniel Klein (Intellectual Ventures), Anna Bershteyn
(Intellectual Ventures), Edward Wenger (Intellectual Ventures), Christophe Fraser (Imperial
College London), Carel Pretorius (Futures Institute), Elisa Long (Yale University), Jan Hon-
telez (Erasmus University, Radboud University Nijmegen Medical Center, and Africa Centre for
Health and Population Studies), Leigh Johnson, and Valentina Cambiano (University College
London). David Bloom (Harvard School of Public Health), Andrew Phillips (University College
London), and Brian Williams (South African Centre for Epidemiological Modelling and Anal-
ysis) also contributed to the study. Tim Hallett and Josh Salomon (Harvard School of Public
Health) contributed to the interpretation of the results and design of figures. All mentioned
contributors edited the content of this chapter; in particular Tim Hallett and Leigh Johnson
critically revised drafts of this work. Britta Jewell coordinated the meeting for which this study
was conceived and managed subsequent dissemination and publication of the results. Partici-
pants of the HIV Modelling Consortium meeting gave helpful feedback on preliminary results
of this investigation (see [258] for a full list of participants).
This chapter appears, in its entirety, as a peer-reviewed research article in the PLoS Medicine
special collection “Investigating the Impact of Treatment on New HIV Infections” [32]. Prelimi-
nary results of this investigation were first presented at the HIV Modelling Consortium meeting.
The results were presented at the International HIV Treatment as Prevention Workshop in Van-
couver, Canada from 22–25 April 2012 (http://www.treatmentaspreventionworkshop.org/)
and as a poster presentation at the 19th Conference on Retroviruses and Opportunistic Infec-
tions in Seattle, WA, USA from 5–8 March 2012 (poster #1113).
6.2 Methods
6.2.1 Study design
Literature and reports of meetings on related topics from the previous year were reviewed
in August 2011 and researchers who had previously developed mathematical models of the
potential epidemiological impact of expanded access to ART, calibrated to the South African
epidemic setting, were invited to participate in the model comparison exercise by simulating a
standardised set of ART scale-up scenarios. Three aspects of the treatment programme were
systematically varied: the CD4 threshold for treatment eligibility, access to treatment for those
eligible, and the retention of patients on treatment. The timing of ART introduction and the rate
at which individuals start treatment after becoming eligible were also standardised. The impact
of an intervention was measured by comparing the number of new infections in the intervention
scenario with a counterfactual epidemic simulation in which no ART is provided within the
same model population. The counterfactual of no-ART was chosen so that comparison between
models would be independent of assumptions about the historic growth in ART uptake. As such,
the results should not be interpreted as estimates of the future impact of treatment compared
to current patterns of ART coverage, but can be generally taken as estimates of the overall
net impact of treatment in a hypothetical scenario which assumes rapid ART scale-up and a
homogeneous rate of ART initiation across all ART-eligible adults. Although different models
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may incidentally have been calibrated using the same data, no standardisation was imposed on
the specific epidemiologic data used for calibration or on the calibration procedure itself in this
exercise.
6.2.2 Mathematical models
Twelve groups accepted the invitation to participate in the model comparison exercise. The
collection of models encompasses a wide range of model structures, mechanisms for representing
HIV transmission and disease progression, overall levels of complexity, and detail in the char-
acterisation of treatment programmes. Table 6.1 gives the names, authors, and key references
for each of the models. Table 6.2 compares aspects of the model structures. Four of the models
are agent-based microsimulation models (i.e. models that track the behaviour and infection
status of individual people) and use random-number generators to simulate particular events
such as a new partnership formation or transmission events. The remaining eight models are
deterministic compartmental models that stratify the population into groups according to their
individual characteristics and HIV infection status and use differential or difference equations
to track the rate of movement of individuals between these groups. One of the models, the BBH
model, solves the differential equations analytically, while the others numerically evaluate the
differential equations. Ten of the models explicitly simulate both sexes and heterosexual HIV
transmission, and six of the models include some form of age-structure, although the extent
to which age affects the natural history of HIV, the risk of HIV acquisition, and the risk of
HIV transmission varies amongst these. All of the models simulate the national HIV epidemic
in South Africa except for the STDSIM model, which simulates the higher-prevalence Hlabisa
sub-district of KwaZulu-Natal province, South Africa.
Many of the models allow individuals to have different propensities for sexual risk behaviour.
Each of the microsimulation models allows individuals to have both long-term (or marital)
partnerships and short-term (or informal or casual) partnerships that are different in duration,
and individuals have heterogeneous propensities to form short-term partnerships. In the STD-
SIM model a proportion of the population engages in commercial sex work partnerships; in the
EMOD model a proportion can have transitory partnerships, a third partnership type that are
shorter than casual partnerships. Among the microsimulation models, EMOD and STDSIM
explicitly simulate the sexual partnership network, while the Bendavid and Synthesis Transmis-
sion models calculate the risk of acquiring HIV for an individual in a partnership by sampling
the distribution of viral load across the entire population or potential partners, respectively.
The deterministic models assume that sexual contacts occur instantaneously. The BBH,
Granich, and HIV Portfolio models assume that all individuals form new contacts at the same
rate and mix homogeneously. The other deterministic models stratify the population into risk
groups that form new contacts at different rates (Eaton, Fraser, Goals: three groups; STI-
HIV Interaction: two groups). The STI-HIV Interaction and Goals models additionally include
commercial sex workers, and Goals includes transmission among men who have sex with men
and injecting drug users. The STI-HIV Interaction model separates both the low- and high-risk
groups into those with short-term or long-term partnerships or both. The Eaton, Fraser, and
STI-HIV Interaction models all include a degree of ‘assortative’ mixing (preferential partnership
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Table 6.1: Model names, authors, and key references
Model name Model authors (Institution) Key reference(s)
BBH Till Ba¨rnighausen (Harvard School of Public Health/Africa
Centre for Health & Population Studies),
David Bloom (HSPH),
Salal Humair (HSPH/Lahore University of Management
Sciences)
[445]
Bendavid Eran Bendavid (Stanford University) [422]
CD4 Model of
HIV and ART
John Stover (Futures Institute),
Carel Pretorius (Futures Institute)
[446]
Eaton Jeffrey Eaton (Imperial College London),
Timothy Hallett (ICL),
Geoffrey Garnett (ICL)
Chapter 5
EMOD Daniel Klein (Intellectual Ventures), Anna Bershteyn (IV),
Edward Wenger (IV), Karima Nigmatulina (IV), Philip
Eckhoff (IV)
[201]
Fraser Christophe Fraser (Imperial College London) [447]
Goals Carel Pretorius (Futures Institute),
John Stover (Futures Institute)
[113, 448]
Granich Brian Williams (South African Centre for Epidemiological
Modelling and Analysis),
Reuben Granich (World Health Organization)
[185]
HIV Portfolio
Model
Elisa Long (Yale University),
Margaret Brandeau (Stanford University),
Douglas Owens (Stanford University)
[449]
STDSIM Jan Hontelez (Erasmus University/Africa Centre for Health
and Population Studies/Radboud University), Sake de Vlas
(Erasmus University), Frank Tanser (Africa Centre), Roel
Bakker (Erasmus University), Till Ba¨rnighausen
(HSPH/Africa Centre), Marie-Louise Newell (Africa
Centre/University College London), Rob Baltussen (Radboud
University), Mark Lurie (Brown University)
[197, 450, 451]
STI-HIV
Interaction Model
Leigh Johnson (University of Cape Town) [35, 196]
Synthesis
Transmission
Model
Valentina Cambiano (University College London), Andrew
Phillips (UCL), Deenan Pillay (UCL), Jens Lundgren (UCL),
Geoff Garnett (Imperial College London)
[199]
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formation with those in the same risk group), and all partnerships are formed in the same
risk group in the Goals model, except for low risk men and women that are married to high
risk partners. The CD4 HIV/ART model does not explicitly model sexual mixing but rather
calculates the number of new HIV infections by multiplying the current number of HIV infected
by a fixed force-of-infection calculated from the Spectrum model projection for South Africa.
All of the models except for Granich simulate different stages of HIV infection that affect
the transmissibility of an individual, including a period of elevated infectiousness during the
first few weeks of infection and increased transmission during later stage infection. Parame-
ters governing the relative transmissibility during early infection are based principally on two
sources: a meta-analysis of HIV transmission per coital act by Boily and colleagues, which
estimated a ten-fold increase in transmission relative to asymptomatic infection (BBH, CD4
HIV/ART, Goals, STI-HIV Interaction); or a reanalysis of data from Rakai, Uganda [138] by
Hollingsworth, Anderson, and Fraser [260], which estimated a 26-fold increase (Eaton, EMOD,
Fraser, Synthesis Transmission). Relative transmissibility after the early stage is according to
clinical stage (asymptomatic and AIDS: BBH, CD4 model of HIV/ART, EMOD, Goals; asymp-
tomatic, pre-AIDS, and AIDS: STDSIM, STI-HIV Interaction) or CD4 stage (Eaton, Fraser,
Portfolio). The Bendavid and Synthesis Transmission models simulate the change in viral load
for infected individuals and associate HIV transmission with this according to an empirically
described relationship [137]. Many models assume an increased risk of male-to-female transmis-
sion compared to female-to-male transmission, and attenuation in female-to-male transmission
due to male circumcision. Goals, STDSIM, and Synthesis Transmission include an increased
risk of HIV transmission in the presence of other sexually transmitted infections.
The models that simulate each individuals viral load (Bendavid and Synthesis Transmission)
mechanistically related reduction in transmission on treatment to the effect of ART on viral
load, while the other models all assume a reduction in transmission of greater than 90% for in-
dividuals on ART. The Bendavid, Eaton, and Synthesis Transmission models simulate a period
of a few months of incomplete viral suppression after ART initiation before the full reduc-
tion in infectiousness is achieved. These three models and EMOD include a return to higher
infectiousness during treatment failure. The remaining models assumed a fixed reduction in
transmissibility as soon as treatment is started until either death on ART or dropout from
treatment. The Bendavid and Synthesis Transmission models simulate switching to second line
ART upon an immunologic (Bendavid) or virologic (Synthesis Transmission) failure event. The
Synthesis Transmission model is the only model to explicitly simulate heterogeneous adherence
to treatment between patients and the emergence and impact of resistance. The models vary
in their assumptions about what happens to an individual after dropping out from treatment.
The CD4 HIV/ART, Fraser, Goals, Granich, and HIV Portfolio models return individuals who
drop out to an untreated state, allowing them to restart treatment in exactly the same manner
as those that have never been treated, while Bendavid, STDSIM, STI-HIV Interaction, and
Synthesis Transmission models do not allow individuals to start treatment again in the im-
plementation for this exercise. Eaton allows individuals to restart treatment, but only once,
and EMOD allows half of individuals to re-start treatment after they once again satisfy the
eligibility criterion.
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Eleven of the models simulated the South African national HIV epidemic, while the STDSIM
model has been calibrated specifically to the higher-prevalence Hlabisa sub-district of KwaZulu-
Natal province, South Africa. Nine models were calibrated to reproduce the historical time-series
of HIV prevalence in South Africa, while the BBH, HIV Portfolio, and Bendavid models were
initialised using the current epidemic state in the years 2009, 2011, and 2012, respectively, and
simulated forward from that point.
Most of the models were calibrated to yield a single set of model parameters and outputs.
Two of the models (Eaton, STI-HIV Interaction) were calibrated using a Bayesian framework
allowing for uncertainty in model parameters, which produces a joint posterior distribution
of parameter combinations consistent with the observed HIV epidemic [35, 196]. The STI-
HIV Interaction model allows for uncertainty in sexual behaviour, the natural history of HIV
infection, and the effect of ART, while the Eaton model only allows for uncertainty in sexual
behaviour and sexual mixing parameters.
Many of the models include facilities to simulate HIV testing and diagnosis, retention in care
prior to treatment eligibility, and other processes related to achieving successful treatment, but
these were not implemented for this exercise in order to conform to the simple intervention
scenarios. Further details of the individual models and their implementations are available in
the references given in Table 6.1.
6.2.3 Intervention scenarios
Three different CD4 cell count thresholds for treatment eligibility were considered: CD4 count
≤200 cells/µl, CD4 ≤350 cells/µl, and all HIV-infected individuals eligible for treatment. In
each eligibility scenario, treatment initiation was simulated under the assumption that all eligi-
ble individuals had equal access, without prioritisation for any subpopulations. It was further
assumed that eligible individuals with access to the intervention would initiate ART at a con-
stant rate after reaching eligibility, such that average time from eligibility to treatment initiation
would be one year.
Treatment access was defined as the proportion of eligible individuals who will eventually
initiate treatment. For example, 60% access and eligibility at CD4 ≤350 cells/µl implies that
60% of individuals will initiate treatment, on average one year after their CD4 count drops
below 350 cells/µl, while 40% will never access treatment. Seven levels of treatment access were
evaluated: 50%, 60%, 70%, 80%, 90%, 95%, and 100%.
Retention was defined as the percentage of individuals remaining on treatment after three
years, excluding from both the numerator and the denominator those who had died while on
treatment. The levels of retention were 75%, 85%, 95%, and 100% (no dropout), with indi-
viduals dropping out from treatment at a constant rate such that the desired level of retention
was achieved. The prognosis and future treatment options for individuals who drop out from
treatment were not standardised.
6.2.4 Intervention scale-up
ART was assumed to be introduced into the population from the beginning of year 2012 with
no treatment provision prior to this (in contrast to the rapid scale-up of treatment that has
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actually occurred prior to 2012 in South Africa). Intervention scale-up was immediate—a
fraction (corresponding to the specified level of ART access) of individuals already eligible
for treatment at the start of the intervention period were assumed to initiate treatment at a
constant rate from that point along with individuals who became eligible for treatment after
the start of the intervention period.
6.2.5 Output metrics
The measures of intervention impact were the percentage reduction in the HIV incidence rate
among adults (aged 15–49 years) in the ART scenario versus the no-ART counterfactual, the
cumulative number of person-years of ART provided since the introduction of ART, and the
cumulative number of person-years of ART provided per infection averted as a measure of
the efficiency with which ART prevents infections. The percentage reduction in incidence was
defined by calculating the difference in the adult HIV incidence rate between the intervention
and no-ART counterfactual in the same year and dividing this by the incidence rate in the
counterfactual scenario. The number of person-years of ART provided per infection averted was
calculated by dividing the cumulative number of person-years of ART by the difference between
the number of new adult infections since year 2012 in the intervention and the counterfactual
scenario. Each of these metrics was reported at the midpoints of the years 2020 and year 2050.
Most of the models included in this study were not designed with the intention to make realistic
projections to year 2050, but these results were included to gain some insight into the long-term
dynamics of the models.
In addition to these measures of intervention impact, each model reported the HIV prevalence
and HIV incidence rate amongst males and females ages 15 to 49 years for the no-treatment
counterfactual simulation and the total size of the adult population (age 15 and older). Each
model also produced the proportion of the HIV-infected population in each CD4 stage category
(≤200, 200–350, >350 cells/µl) and in early HIV infection in year 2012, and the proportion of
HIV transmissions from individuals in each category.
The Eaton and STI-HIV Interaction models report posterior means and 95% credible intervals
for model outcomes of interest. The Bendavid model only completed simulations for 50%, 80%,
and 100% access, and 75%, 85%, and 100% retention scenarios, and only simulated to year
2040, so results for this model are reported for the year 2040 where other model results are
reported for year 2050. The BBH model only completed simulations for the 85% and 100%
retention scenarios. The Granich model does not simulate ART for the CD4 ≤200 cells/µl
eligibility, while the STI-HIV Interaction model does not simulate ART eligibility for all HIV-
infected individuals. As a result of these models not completing all intervention scenarios and
outputs, some analyses only include a subset of the models. To maximise comparability, the
40% reduction in transmission due to combination with other preventive interventions assumed
by Granich and colleagues in [185] was not incorporated here.
6.2.6 Scenarios representing the existing ART program in South Africa
In a separate analysis, seven of the models (CD4 HIV/ART, Eaton, Fraser, Goals, Granich,
STDSIM, STI-HIV Interaction) were used to estimate the impact that the existing scale-up of
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Table 6.3: Number of adults starting ART each year in the short-term future scale-up scenarios.
Year “Low” future “Baseline” future “Medium” future “High” future
scale-up scale-up scale-up scale-up
2012 400,000 400,000 600,000 800,000
2013 200,000 400,000 600,000 900,000
2014 200,000 400,000 600,000 900,000
2015 200,000 400,000 600,000 700,000
2016 200,000 400,000 600,000 600,000
Total 1,200,000 2,000,000 3,000,000 3,900,000
Number of adults (age 15 y and older) initiating ART between midpoint of the previous year
and the midpoint of indicated year.
ART in South Africa has had on HIV incidence and prevalence by comparing model simulations
that include the ART scale-up over the past decade with the no-ART counterfactual. Models
either used an existing calibration to the number of people on ART in South Africa (Fraser,
STDSIM), or were calibrated using estimates of the number of adults starting and on ART in
each year from 2001 to 2011 [35] (CD4 HIV/ART, Eaton, Goals, Granich, STI-HIV Interaction).
Five models (Bendavid, CD4 HIV/ART, Eaton, Goals, Granich) constructed short-term pro-
jections of HIV incidence in South Africa assuming different trajectories for continued ART
scale-up from 2011 to 2016, the period covered by South Africas national strategic plan [452].
Starting from the number of patients on ART in mid-2011, the numbers of adults starting ART
in each of the years from mid-2011 through mid-2016 was specified. A baseline scenario was
considered in which 400,000 adults would start ART in each of the next five years (approxi-
mately the number who started ART in 2009), for a total of 2 million new adults initiating
ART. Three other scenarios were considered for the total numbers starting ART over the same
period: (i) ‘low’—1.2 million start ART; (ii) ‘medium’—3 million start ART; and (iii) ‘high’—
3.9 million start ART. (The exact number starting in each year is listed in Table 6.3.) The
HIV incidence rate at the midpoint of 2016 and cumulative number of new adult HIV infections
over the period 2011 to 2016 were reported for each of these scenarios. For these projections,
assumptions regarding CD4 distributions at ART initiation and rates of retention were based on
actual treatment guidelines and program experiences, but were not standardised across models.
6.3 Results
Figure 6.1 shows HIV prevalence and HIV incidence in 15 to 49 year old males and females sim-
ulated by each of the models under the counterfactual assumption of no ART provision. Other
epidemiologic statistics are presented in Table 6.4. The estimates of adult male HIV prevalence
in year 2012 ranged between 10% and 16% and estimates of female prevalence between 17% and
23%. Male HIV incidence in year 2012 ranged between 1.1 and 2.0 per 100 person-years and
female incidence ranged between 1.7 and 2.6. The STDSIM model calibrated to KwaZulu-Natal
province simulated a considerably larger burden of HIV, consistent with observation [342], with
prevalence in year 2012 of 23% and 33% in males and females respectively and incidence rates of
3.0 and 3.9 per 100 person-years respectively. All of the sex-stratified models simulated higher
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Figure 6.1: No treatment counterfactual epidemic trends. Male (left) and female (right) HIV
prevalence (top) and incidence (bottom) amongst 15-49 year olds for counterfactual
HIV epidemics with no ART. The STDSIM model is calibrated to a more severe
epidemic in the Hlabisa subdistrict of KwaZulu-Natal Province, South Africa. The
CD4 HIV/ART and Granich models do not stratify by sex and the same prevalence
and incidence curves are plotted for both sexes for these models.
HIV prevalence in adult women compared to men with sex ratios in HIV prevalence in year
2012 between 1.2 and 1.7, and all of the models except for Bendavid simulated higher incidence
in year 2012 in females than in males.
Nearly all of the models projected declines in HIV incidence after 2012 in the absence of
ART, but the magnitude of the projected natural changes between 2012 and 2050 varied widely
from almost no change (Goals, Granich) to greater than 45% reduction (Bendavid, Synthesis
Transmission).
Model projections of future national population growth in the absence of ART varied widely,
ranging from a 6% reduction to a 13% increase in the population aged 15 and older between
year 2012 and 2020. For comparison, the low and high variants for the projected total popula-
tion growth from the UN Population Division over the same period (which incorporates some
assumptions about ART provision) are between 1.5% and 6.1% [453].
171
T
a
b
le
6.
4:
S
el
ec
te
d
m
o
d
el
ou
tp
u
ts
fo
r
co
u
n
te
rf
ac
tu
al
si
m
u
la
ti
on
w
it
h
n
o
A
R
T
.
A
g
e
1
5
–
4
9
H
IV
p
re
va
le
n
ce
in
y
ea
r
2
0
1
2
(%
)
S
ex
ra
ti
o
in
p
re
va
le
n
ce
,
y
ea
r
2
0
1
2
(f
em
a
le
/
m
a
le
)
A
g
e
1
5
–
4
9
H
IV
in
ci
d
en
ce
in
y
ea
r
2
0
1
2
(p
er
1
0
0
P
Y
s)
S
ex
ra
ti
o
in
in
ci
d
en
ce
,
y
ea
r
2
0
1
2
(f
em
a
le
/
m
a
le
)
A
v
er
a
g
e
a
n
n
u
a
l
p
o
p
u
la
ti
o
n
g
ro
w
th
ra
te
,
a
g
e
1
5
+
(p
er
1
0
0
P
Y
s)
Y
ea
r
o
f
p
ea
k
H
IV
in
ci
d
en
ce
P
er
ce
n
ta
g
e
ch
a
n
g
e
fr
o
m
p
ea
k
in
ci
d
en
ce
to
y
ea
r
2
1
0
2
(%
)
P
er
ce
n
ta
g
e
ch
a
n
g
e
in
in
ci
d
en
ce
fr
o
m
2
0
1
2
to
2
0
2
0
(%
)
P
er
ce
n
ta
g
e
ch
a
n
g
e
in
in
ci
d
en
ce
fr
o
m
2
0
2
0
to
2
0
5
0
(%
)
2
0
1
2
–
2
0
1
2
–
M
a
le
F
em
a
le
M
a
le
F
em
a
le
2
0
2
0
2
0
5
0
M
a
le
F
em
a
le
M
a
le
F
em
a
le
M
a
le
F
em
a
le
M
a
le
F
em
a
le
B
B
H
10
.4
16
.8
1.
6
1.
2
2.
2
1
.8
0
.5
0
.5
-9
-1
3
-3
0
-3
0
B
en
d
av
id
13
.6
19
.4
1.
4
1.
7
1.
7
1
.0
0
.8
1
.0
*
*
-3
3
-2
9
C
D
4
H
IV
/A
R
T
14
.8
1.
3
1
.5
1
.1
1
9
9
8
-6
1
-1
5
-1
3
E
at
on
11
.1
19
.2
1.
7
1.
1
2.
0
1
.9
1
.4
1
.5
1
9
9
6
1
9
9
7
-4
5
-3
6
-4
-4
-2
-1
E
M
O
D
15
.4
19
.9
1.
3
1.
5
1.
8
1
.2
0
.6
0
.5
2
0
0
1
2
0
0
0
-2
3
-1
8
-7
-8
-2
5
-2
5
F
ra
se
r
15
.4
18
.0
1.
2
1.
4
1.
7
1
.2
-0
.2
0
.0
1
9
9
7
1
9
9
7
-4
0
-4
2
-8
-1
0
-1
9
-1
9
G
oa
ls
16
.0
20
.0
1.
3
2.
0
2.
6
1
.3
0
.3
0
.1
1
9
9
8
1
9
9
9
-3
6
-2
5
-3
-1
3
5
G
ra
n
ic
h
14
.9
1.
7
-0
.2
-0
.1
1
9
9
7
-2
2
1
0
P
or
tf
ol
io
15
.9
22
.0
1.
4
2.
3
2.
6
1
.1
-0
.8
-0
.6
-1
1
3
-1
9
-1
8
S
T
D
S
IM
*
23
.1
33
.0
1.
4
3.
0
3.
9
1
.3
-1
.3
-1
.3
1
9
9
5
2
0
0
3
-6
3
2
2
-8
-7
S
T
I-
H
IV
12
.6
20
.0
1.
6
1.
4
2.
3
1
.6
0
.4
0
.1
1
9
9
9
1
9
9
9
-2
8
-2
3
-5
-6
-6
-1
1
S
y
n
th
T
ra
n
sm
15
.2
23
.1
1.
5
1.
6
2.
4
1
.5
0
.7
0
.5
2
0
0
1
2
0
0
5
-1
8
-2
5
-4
3
-4
7
-1
2
-1
5
*
M
o
d
el
ca
li
b
ra
te
d
to
H
IV
ep
id
em
ic
in
K
w
a
Z
u
lu
-N
a
ta
l
P
ro
v
in
ce
.
*
*
A
v
er
a
g
e
a
n
n
u
a
l
g
ro
w
th
ra
te
fo
r
y
ea
rs
2
0
1
2
to
2
0
4
0
.
172
6.3.1 Impact of ART on HIV incidence
Figure 6.2 presents the outcomes of an intervention starting in year 2012 with ART eligibility
at CD4 count ≤350 cells/µl, reaching 80% of those requiring treatment, and retaining 85% of
patients on ART after three years. This scenario reflects an optimised implementation of the
current WHO treatment guidelines [443] and the UNAIDS definition for universal access of
reaching 80% of those in need [454]. Compared to the no-treatment counterfactual scenario,
ART provision reduced incidence in year 2020 by 35% to 54% across all models (Figure 6.2,
panel A). There was much greater variation, however, in the estimated long-term impact of the
intervention. In year 2050, the range of the predicted reduction in incidence was from 32% to
74%. The relative impact of the ART intervention on HIV incidence decreased between 2020
and 2050 in four models and increased in seven.
6.3.2 Number of person-years of ART per infection averted
There was considerable variation between models in estimates of the number of person-years of
treatment per infection averted. For the scenario described above, the range of estimates for
the number of person-years of ART per infection averted between 2012 and 2020 was between
6.3 and 18.7, and over the period 2012 to 2050 the range was 4.5 to 20.2 (Figure 6.2, panel B).
The four models with the greatest estimates of the number of person-years of ART provided
per infection averted (Eaton, EMOD, STI-HIV Interaction, and Synthesis Transmission) all
explicitly included variation in transmission by age (for example, allowing for reduced impact
through ART provision to older adults who are less sexually active and hence less likely to
expose susceptible individuals), whereas the other models did not assume reduced transmission
by older people. (STDSIM allows for decreased sexual activity for those older than 50 and has
the lowest estimate of ART per infection averted, but simulates a much higher HIV incidence.)
6.3.3 Determinants of program impact
The impact on incidence of increasing access from 50% to 100%, improving three-year pro-
gramme retention from 85% to 100%, and changing the CD4 threshold for treatment eligibility
is shown for each model in Figure 6.3. The reduction in incidence increases approximately
linearly with access in all models. In most models, improvements in retention in care led to
greater impact of treatment on HIV incidence. The benefit of improving retention was minimal
for the Fraser, Granich, and HIV Portfolio models. Each of these models regards individuals
who have dropped out of treatment identically to untreated eligible individuals, allowing them
to start treatment again on average within one year. In several models, improved retention
means that the impact improves more rapidly with increasing access (i.e. the slope in reduction
in incidence as access increases is steeper for higher retention).
Figure 6.4 shows how the numbers of person-years of ART per infection averted varied in
relation to the intervention programme in year 2020. There were no consistent trends across all
models. In some models, with earlier initiation of treatment, fewer years of ART were required
per infection averted (efficiency increases), whereas the opposite was predicted in others. For all
of the models except for the Granich model, which does not include increased transmissibility
173
0 20 40 60 80 100
Year 2020A
STI−HIV
STDSIM
Portfolio
Granich
Goals
Fraser
EMOD
Eaton
Bendavid
BBH
Synthesis
Transmission
CD4
HIV/ART
Percentage reduction in incidence
0 20 40 60 80 100
Year 2050
95% CI
0 5 10 15 20
Year 2020B
STI−HIV
STDSIM
Portfolio
Granich
Goals
Fraser
EMOD
Eaton
Bendavid
BBH
Synthesis
Transmission
CD4
HIV/ART
Person−years of ART per infection averted
0 5 10 15 20
95% CI
Year 2050
Figure 6.2: Impact of treatment for CD4 ≤350 cells/µl eligibility, 80% access, and 85% retention
scenario. (A) The percentage reduction in HIV incidence in the year 2020 and 2050
when eligibility for treatment is at CD4 count ≤350 cells/µl, 80% of individuals are
treated, and 85% are retained on treatment after three years. (B) The cumulative
number of person-years of ART provided per infection averted for the same scenario.
Horizontal lines indicate 95% credible intervals. For the Bendavid model, results in
year 2040 are reported in the right panel.
174
020
40
60
80
100 BBH Bendavid CD4
HIV/ART
0
20
40
60
80
100 Eaton
Pe
rc
en
ta
ge
 re
du
ct
io
n 
in
 in
ci
de
nc
e
EMOD Fraser
0
20
40
60
80
100 Goals Granich Portfolio
50 60 70 80 90 100
0
20
40
60
80
100 STDSIM
50 60 70 80 90 100
STI−HIV
Interaction
ART access
50 60 70 80 90 100
Synthesis
Transmission
ART eligibility: CD4 < 200   CD4 < 350   all
3 year retention: 85% retention 100% retention
Figure 6.3: For each model, the proportion reduction in HIV incidence in year 2020 for increas-
ing access levels from 50 to 100% (horizontal axis). ART eligibility thresholds are
indicated by lines of different colours, while 85% retention is indicated by solid lines
and perfect 100% retention is indicated by dashed lines.
175
510
15
20
25 BBH Bendavid CD4
HIV/ART
5
10
15
20
25 Eaton
Pe
rs
on
−y
ea
rs
 o
f A
RT
 p
er
 in
fe
ct
io
n 
av
er
te
d
EMOD Fraser
5
10
15
20
25 Goals Granich Portfolio
50 60 70 80 90 100
5
10
15
20
25 STDSIM
50 60 70 80 90 100
STI−HIV
Interaction
ART access
50 60 70 80 90 100
Synthesis
Transmission
ART eligibility: CD4 < 200   CD4 < 350   all
Figure 6.4: The cumulative person-years of ART provided per infection averted through year
2020 for increasing access levels from 50 to 100% (horizontal axis), assuming 85%
retention after three years. ART eligibility thresholds of are indicated lines of dif-
ferent colours. Varying retention did not affect trends between access and efficiency
for any models.
176
during late stage infection, it might be expected that treating at lower CD4 count would be
more efficient, as it targets treatment towards individuals with the highest current infectious-
ness (as in Bendavid, BBH, CD4 HIV/ART, Eaton, and Goals models). However this could
be counteracted if stage of infection interacts with other processes such as decreased propen-
sity to form new partnerships with ageing. For half the models (BBH, Eaton, EMOD, Fraser,
Goals, Granich, Portfolio), increasing the percentage of the population with access to treatment
reduced the amount of treatment per infection averted, at least at earlier CD4 initiation thresh-
olds. This increased efficiency is indicative of increasing returns due to herd immunity at high
intervention coverage levels.
6.3.4 Treatment eligibility and the theoretical impact of ‘test-and-treat’
The models varied in their predictions as to the relative benefit of increasing treatment eligi-
bility from a CD4 threshold of ≤200 cells/µl (national guidelines in some settings and close
to actual experience in many) to ≤350 cells/µl (international guidelines), compared to further
increasing eligibility to all infected individuals (Figure 6.3). The Bendavid, CD4 HIV/ART,
Goals, Portfolio and Synthesis Transmission models all predicted that there would be only a
relatively modest benefit in moving from initiation at ≤200 cells/µl to ≤350 cells/µl, and a
much greater benefit in moving from initiation below 350 to immediately. In contrast, the
BBH model simulated very little benefit in increasing from 350 cells/µl to immediate eligibility.
Eaton, Fraser, and EMOD showed similar benefits associated with each of the increments at
moderate levels of access.
One important argument that has been made for immediate ART is that commitment of a
large amount of ART now could reduce the cumulative amount of ART required in the future as
a result of averted HIV infections [258, 392]. Whether such savings could occur was evaluated by
investigating whether the cumulative person-years of treatment through year 2050 to implement
immediate treatment is less than the amount of ART required when treating after the CD4 count
falls below 350 cells/µl for the same levels of access and retention. In six (BBH, CD4 HIV/ART,
Fraser, Goals, Portfolio, STDSIM) out of eleven models (excluding STI-HIV Interaction) this
was not the case: increasing eligibility from CD4 ≤350 cells/µl to immediate initiation always
required more person-years of treatment, even with perfect ART programmes (100% access and
100% retention). However, for the EMOD model, expanding eligibility from CD4 ≤350 cells/µl
to all required fewer cumulative person-years of treatment in all intervention scenarios (including
access as low as 60% and retention in care as low as 75%). The Synthesis Transmission model
found expanding access to be ART-saving with 70% access and retention above 95%, or with
80% access and retention above 85%. The other three models that found expanding access
could be ART-saving required more demanding assumptions about programmes: according to
the Granich model, immediate initiation would be ART-saving if access were above 90% and
retention above 95%; according to Eaton, access and retention would need to exceed 95%; and
according to Bendavid, access and retention would both need to be 100%.
In an intervention treating all HIV-infected adults with 95% access and 95% retention, three
(CD4 HIV/ART, EMOD, and HIV Portfiolio) out of nine models (excluding Bendavid, BBH,
and STI-HIV Interaction) predicted that HIV incidence would fall below 0.1% per year by
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category in year 2012, in the no-ART counterfactual simulation. Panel B plots the
reduction in incidence in year 2020, for the 80% access and 85% retention scenario,
according to the cumulative proportion of transmission that occurs after eligibility
(panel A). For the all HIV+ eligible scenario, the percentage of transmission after
ART eligibility is the percentage of transmission that occurs after the end of primary
HIV infection. Colours are consistent with those used to distinguish the models in
Figures 1 and 2. The Bendavid, BBH, and STI-HIV Interaction models do not
estimate the proportion of transmission in each stage and are not included in this
figure.
2050. Notably, the Granich model, which was used to argue the case for HIV elimination using
treatment, projected that incidence in South Africa would be 0.13% under this scenario, a 92%
reduction (in the original published projections, there was an assumption that risk of infection
would fall by an additional 40% due to other interventions [185].
6.3.5 Understanding differences between model predictions.
One factor expected to influence the extent to which ART reduces HIV incidence is the fraction
of all transmission that occurs due to individuals once they reach treatment eligibility thresholds,
in the absence of any treatment [37]. Panel A of Figure 6.5 shows the percentage of transmissions
that occur from individuals in each CD4 stage in the counterfactual simulation in year 2012.
Of the models that include a period of early infection, the percentage of new infections that
occurs during this stage is between 4% and 28%, while between 20% and 51% of transmission
results from individuals with CD4 cell counts below 200 cells/µl.
These percentages of transmission after ART eligibility can be compared with the percentage
reduction in incidence in year 2020 (Figure 6.5, panel B). Here, it is assumed that access is 80%
and three-year retention in care is 85%. Although this comparison explains why, within one
model, earlier treatment initiation reduces HIV incidence more, the amount of between-model
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variation in projected impact explained by the distribution of transmission by CD4 count is
modest. R2 values for this relationship were 0.28, 0.20, and 0.40 for eligibility at CD4 less
than 200, 350, and immediate eligibility, respectively. The correlation did not improve when
considering higher access or higher retention scenarios.
Other factors hypothesised to explain the differences between the model projections are dif-
ferent assumptions about the efficacy of ART in reducing transmission between 90% and 99%
and different assumptions about the outcomes of individuals who drop out from treatment
programmes. To test this hypothesis, selected intervention scenarios were repeated under the
artificial assumption that an individual never transmits after initiating treatment (treatment
is 100% efficacious at preventing transmission and retention on treatment is 100%). This as-
sumption increased the intervention impact in every model, but, surprisingly, did not reduce
the variation in the results between models or improve the ability of factors such as different
model assumptions about CD4 progression, HIV transmission, or the future trajectory of HIV
incidence to explain the variation.
6.3.6 Estimates of the current impact of ART in South Africa
Figure 6.6 shows the estimated impact of the current ART program in South Africa on HIV
prevalence and incidence. The CD4 HIV/ART, Eaton, Goals, Granich and STI-HIV Interaction
models used estimates of the number of adults starting treatment in South Africa in each year
between 2001 and 2011 from [35], and Fraser and STDSIM used existing calibrations to ART
coverage levels in the Western Cape and KwaZulu-Natal provinces, respectively. All of the
models predicted that ART should have already had a substantial impact on the HIV epidemic,
estimating that HIV incidence in year 2011 was between 17 and 32% lower than it would have
been in the absence of ART. The increasing impact on HIV incidence over time mirrors the
steep increase every year in the number of people starting treatment during this period.
The impact on prevalence was more modest and less consistent across models. The Eaton
and STI-HIV Interaction models estimated that prevalence is around 8% higher than it would
have been without treatment (an absolute increase in prevalence of one percentage point) due to
the increased survival for those infected with HIV. The Fraser and Granich models suggest that
this effect is offset by the reductions in incidence so that there is no net change in prevalence. It
is unlikely that standard surveillance methods based on monitoring trends in prevalence would
have detected this impact, despite the significant underlying reductions in incidence.
The estimated potential impact of further ART scale-up is summarized in Table 6.5. In the
baseline scenario, where 400,000 people are started on ART each year, the models estimated
that incidence would be reduced in 2016 by between 13% and 26% compared to the incidence
rate in 2011. If 800,000 fewer people are put on ART, then between 39,000 and 186,000 more
new adult HIV infections would occur over the period 2012 to 2016 than under the baseline
scenario. If more people are put on ART—3.0 or 3.9 million over the next five years—then the
models estimated that the number of new infections over the five-year period would be reduced
by 64,000 to 327,000 and 270,000 to 521,000, respectively, compared to the baseline. The
table underscores that there are still substantial potential preventive benefits from expanding
ART coverage in South Africa. The models that tended to estimate the greatest reduction in
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Figure 6.6: The impact of the existing ART program in South Africa on HIV prevalence and
incidence. The percentage increase in HIV prevalence (top) and the percentage
reduction in HIV incidence rate (bottom) compared to what would have occurred in
the absence of any ART for years 2006 to 2011. These are estimated by comparing
HIV prevalence and incidence in a model calibrated to the existing scale-up of ART
in South Africa from 2001 to 2011 with a model simulation with no ART provision.
CD4 HIV/ART, Eaton, Goals, Granich, and STI-HIV Interaction models use the
same estimates of the number starting ART each year from [35]. Fraser uses an
existing calibration to the ART scale-up in the Western Cape province. STDSIM
is calibrated to the number of people on ART in the Hlabisa subdistrict. Vertical
lines on Eaton and STI-HIV Interaction models indicate 95% credible intervals.
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incidence in hypothetical programmes over the medium term (CD4 HIV/ART, Goals, Granich)
also tended to project greater reductions in incidence over the short-term in these more realistic
scenarios.
6.4 Discussion
The mathematical models used to simulate the impact of treatment on HIV incidence in South
Africa are diverse in their structures, level of complexity, representation of the HIV transmission
process and the ART intervention, and parameter choices. All twelve of the models compared
in this analysis predicted that treatment could substantially reduce HIV incidence—even using
past or existing treatment guidelines eligibility criteria, provided that coverage is high. Only
three (CD4 HIV/ART, EMOD, Portfolio) out of nine models (excluding Bendavid, BBH, and
STI-HIV Interaction), however, predicted that treatment could reduce HIV incidence below
0.1% by year 2050 (the definition of ‘elimination’ established by [185]), even with very high
access and retention. When simulating the historical scale-up of ART in South Africa, the
models indicated that that ART may already have reduced HIV incidence by between 17 and
32% in 2011, compared to what would have been expected in the absence of ART.
Although there have been ad hoc informal model comparison exercises [189], collections of
work using standardised assumptions for interventions [188], and thorough model comparisons
with a few research groups [455, 456], to our knowledge, this exercise was the first to bring
together such a large number of independent modelling groups to examine the same set of
interventions. We hope that this will provide a foundation for much more collaborative work.
In this study we set out to test whether different models of the potential impact of treatment
on new HIV infections in South Africa would make similar predictions when implementing the
same intervention scenarios. We found substantial consistency between the model projections
of the impact of ART interventions on HIV incidence in the short-term. However, there was
more variation in the predicted longer-term reductions in incidence, and models also produced
divergent estimates of the number of person-years of ART per infection averted. While this
represents an important scientific finding in itself, the substantial variation in the long-term
impact and efficiency of interventions demands further investigation and explanation. Based on
epidemiological theory and previous modelling studies, we hypothesised a number of model at-
tributes that might explain differences in model predictions about the impact of ART, including
the amount of transmission in different stages of HIV infection, the assumed efficacy of ART
for preventing transmission, opportunities for treatment re-initiation following drop-out from a
treatment programme, the age and sex structure of the population, future population growth
rates, the degree of heterogeneity and assortativity in sexual mixing, the future trajectory of
HIV incidence in the absence of intervention, and the inclusion of changes in sexual behaviour
over the past decade. There was indeed substantial variation between the models in their char-
acterisation of each of these aspects of the system, largely reflecting the true uncertainties that
persist even after decades of tremendous research into the epidemiology of HIV in South Africa.
We were able to show that crude differences in the proportion of transmission at each stage
of infection explained a modest amount of the variation in the short-term impact of ART, but
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less of the long-term impact. However, beyond this, findings from the models did not appear
to clearly support any of these hypotheses in univariate analyses, likely because of the large
number of processes that interact non-linearly to create the HIV epidemics and interventions.
For example, a seemingly simple quantity such as the number of person-years of ART provided
in an intervention depends on future population growth, the natural trend in the epidemic, the
proportion of HIV infected individuals qualifying for treatment, retention and survival on ART,
and the impact that ART provision will have on future HIV incidence. This contrasts with the
experiences of an earlier exercise that compared predictions of the impact of male circumcision
interventions [189], where the relationship between the established efficacy of the intervention
and population level impact was less complicated.
Having investigated the extent to which differences in ART programmes determine differences
in results, the natural focus for future model comparison studies should be to explore the con-
tribution of other hypotheses through incrementally standardising biological, behavioural and
demographic model parameters, and calibrating models to the same levels of HIV prevalence
and incidence. A systematic approach to standardising model parameters would identify which
parameters most significantly influence the results and guide priorities for future data collec-
tion. The HIV Modelling Consortium will coordinate such research efforts in coming months
to investigate the extent to which variation in model predictions is driven by differences in
underlying models of sexual mixing or different models of the natural history of infection and
epidemic trajectory.
Although our experiment and analysis has focused on how factors included in models can
affect model predictions, it is important to note that if all models exclude an important aspect
of the system, they could all be wrong. Early models of the impact of ART on HIV incidence
were very focused on the concern that increased sexual risk behaviour might offset the reduction
in transmission for those on treatment, but for this exercise all of the models assumed that pop-
ulation risk behaviour would not change in response to the introduction of ART. This may be
a reasonable assumption given consistent evidence that patients report safer sexual behaviour
after starting ART [457–461] and the relative lack of information from sub-Saharan Africa about
how the untreated and HIV negative population responds to the availability of treatment [338].
But in other epidemic settings the availability of ART has been associated with receding gains
in protective behaviour [243, 244, 462], and monitoring this in sub-Saharan African settings will
be a priority for surveillance over coming years. The models also all assumed high efficacy of
ART to reduce transmission. True effectiveness will depend on the adherence and levels of viral
suppression, which are mainly determined by adherence levels. While there are some data from
South Africa on viral suppression rates outside carefully controlled trial settings [463], further
information on this and on patterns of acquired and transmitted resistance will help calibration
of models. Only one of the models in this exercise (Synthesis Transmission) explicitly incorpo-
rated the effect of antiretroviral drug resistance on the impact of ART interventions. Models
have predicted that antiretroviral drug resistance could be widespread in sub-Saharan Africa
in coming decades [424], which could eventually lead to the spread of transmitted drug resis-
tance [199, 464]. This could affect the long-term costs and efficacy of treatment as prevention
strategies [465].
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Another finding from systematically comparing models is that often seemingly independent
modelling studies rely on the same limited data. Nearly all of the models relied on two sources to
derive parameters for elevated infectiousness during the first few weeks of infection [260, 266],
but both of these sources are based principally on data from a few retrospective couples in
Rakai, Uganda [138], which exhibit limitations and biases themselves [418]. This highlights both
how invaluable these data are and also the importance of recognising the dependencies between
seemingly independent modelling studies. However, even using the same data, models may reach
different conclusions. The Eaton, EMOD, and Fraser models all in some way used the estimates
of early HIV infectivity from [260] but estimate very different contributions of this stage to
overall HIV transmission (Figure 6.5, panel A), and the three models all reached different
conclusions from those in another recent modelling study relying on these same estimates [417].
The purpose of this exercise was not to draw conclusions or recommendations about specific
ART intervention strategies, but rather to test the hypothesis that a range of different models
would come to similar conclusions about the impact of ART on HIV incidence when the same
interventions were assumed. The simulated interventions were artificially simple and stylized to
enable comparison between models. These did not explicitly simulate the steps of HIV testing,
diagnosis, linkage to care, and adherence to ART required to achieve the access levels specified
in the intervention scenarios (although several of the models include facility for this and have
investigated this in independent analyses). Interpretation of models simulating high levels of
treatment coverage should be cautioned by data suggesting that at present fewer than one-
third of patients are continuously retained in care from HIV diagnosis to ART initiation [257],
and that barriers remain to access to and uptake of HIV testing [454]. The models assumed
that all individuals eligible for treatment were equally likely to access treatment, which might
not be true in practice (for example, women are more likely to start treatment than men
[402]). The comparison scenario (counterfactual) against which interventions were evaluated
assumed no treatment at all, which made it easier to compare models, but is clearly not the
relevant benchmark for policy makers. This study has also considered treatment in isolation
from other interventions, even as there is broad consensus that combination prevention strategies
are presently the best strategy for attacking the epidemic [113, 466].
We hope that this study will help to characterise the models that are being used to investigate
questions related to the impact of HIV treatment and enable those who rely on models for deci-
sion making to think critically about how the assumptions underlying models affect the results.
The relative consistency between models estimates of the short-term epidemiological impact of
ART, including the impact of the existing ART programme, provides some reassurance that
model projections on this time scale may be relatively robust to the substantial uncertainties
in the parameter and system. This is a significant result considering that such short-term pro-
jections are often the most relevant for policy and resource allocation questions. On the other
hand, the substantial variation in long-term epidemiological impacts and efficiency of ART,
upon which arguments of substantial epidemic reduction and cost savings hinge, suggests that
results in these areas from any single model should be extrapolated with caution. Care should
be taken to ensure that models evaluating the long-term costs, benefits, and cost-effectiveness of
treatment programmes adequately communicate the degree and myriad sources of uncertainty
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that influence these outputs.
A common question when faced with a diversity of model results is whether some models
are better or worse. Without data against which to test the predictions of models, it is not
possible to answer this question in a study such as this, nor is this the correct question to
be asking. Rather, users of model outputs should ask whether models include the necessary
components to capably answer the specific questions at hand, and whether the models make
credible assumptions in light of the information available, and choose models accordingly. This
will vary between applications so there is no single best model. However, in this exercise, the
models that tended to project more pessimistic outcomes for the interventions seemed to do
so for important reasons. For example, models that estimated poorer efficiency of ART for
averting infections tended to be those that simulated ART provision for those at older ages
who might be at lower risk of transmitting or included the elevated risk of transmission for
those failing treatment, whereas models with more optimistic predictions assumed that risk
behaviour did not vary by age or that transmission was fully suppressed immediately upon
beginning treatment until death on ART or dropout. Artificial convergence of models should
be avoided when true uncertainties persist about the system. It is incumbent upon modellers to
incorporate and communicate uncertainty in projections, and identify which components of the
system account for the uncertainty. For this exercise, only one model (STI-HIV Interaction)
included a comprehensive analysis accounting for uncertainty about basic epidemiology and
intervention efficacy. While the focus of the study was on variation between models, it is
interesting to observe that the 95% credible interval representing parameter uncertainty for this
model encompassed the point-estimates of the other eleven models.
Fortunately there will be important new opportunities in the near future to test, validate,
and improve epidemiological models of HIV treatment. These include comparing projections to
the experience of expanded ART in industrialised countries [244, 462], the observed impact of
ART in well characterised communities [344], and results of a number of community randomised
trials of treatment as prevention that will soon be underway [116]. As new data are reported,
the accuracy of models projecting the impact of treatment as prevention should improve, and
we expect that validated and scientifically-based model projections will continue to be central
in understanding how ART can have the greatest impact in mitigating the global HIV epidemic.
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7 Conclusion
At the start of this investigation, four years ago, enthusiasm was low for biomedical approaches
to controlling the HIV epidemics in southern Africa [21, 76]. Post-mortems had been completed
[467, 468] on the failure of clinical trials endeavoring to reduce HIV incidence by treating or
suppressing other sexually transmitted infections [80–83, 93]. Numerous formulations of vaginal
microbicide gels had failed to prevent HIV infection, with indication that some might even
increase the risk of acquisition [469–471]. The outcome of almost one billion dollars invested
and 99 clinical trials conducted on vaccine development was the then head of the US National
Institute for Allergy and Infectious Disease Anthony Fauci wondering whether we would ever
get a vaccine [472]. Efficacy had been demonstrated for male circumcision [48, 86–88], and
antiretroviral-based prevention of mother-to-child transmission [473, 474], but the scale-up of
these was frustratingly slow [475, 476].
The leading conclusion of a comprehensive high-level review of HIV prevention was that
expansion of behavioural prevention services could avert more than half of new HIV infections
that would occur between 2008 and 2015 [21]. The UNAIDS ‘Know your epidemic—know your
response’ initiative and the modes of transmission model had refocused thinking about HIV
prevention on the specific behaviours that put one at risk of acquiring and transmitting HIV
[477, 478], and most countries were developing behaviour change communication campaigns
consisting of billboards, radio spots, and dramatic skits with support from the United States
Agency for International Development. Interventions to reduce multiple sexual partnerships
along with massive scale-up of male circumcision represented the best evidence-based allocation
of HIV prevention resources [479].
Now, at the time of the conclusion of this body of work, it feels in many ways as if the pendu-
lum has swung to the opposite extreme. Male circumcision remains a priority, and financing and
political will have increasingly lined up behind this [480], but this has been small in comparison
to the momentum behind antiretroviral based prevention—the transition from ‘treatment or
prevention’ to ‘treatment as prevention’. Early phase vaccine and even HIV cure research high-
lighted the return of the International AIDS Conference to the United States in 2012. Behaviour
change communication campaigns in southern Africa have largely been de-funded.
This shift is not unjustified. Almost immediately after the despair about HIV prevention
trials at the end of the last decade [85], the sequence of well-conducted and successful HIV
prevention trials using antiretrovirals has precipitated a narrative that we now have the tools
in hand to conquer the epidemic, if only they are brought to scale. Perhaps it is an honest
appraisal of evidence, or maybe a long memory of successive frustrations and disappointments
for HIV prevention in southern Africa, but, to many, declarations of ‘the end of AIDS’ [481]
and an ‘AIDS free generation’ [394] feel premature [482]. Even if prevention interventions are
swiftly and effectively scaled-up, the life-long provision of ART for those already infected means
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substantial liabilities from HIV and AIDS for southern African countries for decades to come
[483]. Nevertheless, the new narrative has acknowledged the point that, while development
of new prevention technologies remains worthwhile, the greatest gains maybe be from making
better use of existing tools [114, 484]. The greatest challenges ahead may not be in choosing
what components comprise the best mix of ‘combination prevention’, but rather in determining
how to deliver comprehensive HIV prevention strategies that are relevant and responsive to
local social context [485, 486]. This has motivated increased investment in implementation
research [114, 487], social science research on the barriers to HIV services in specific populations
[374, 429], and stepped-up surveillance to see where current systems are failing.
The perceived shift towards exclusively biomedical HIV prevention also may not match the
scientific reality. Scientific progress does not move as quickly as media or political interests, and
the successful efficacy trials that have reported over the past three years were being planned
as many as ten years ago. Even while overall enthusiasm about biomedical prevention was
lower four years ago, plans for the next steps contingent on the outcomes of these trials were
being made [76]. Similarly today, even with the amount of discourse about antiretrovirals, a
cluster-randomised trial finding that monthly cash transfers encouraging adolescent women to
remain in school reduced HIV and HSV-2 prevalence has reinvigorated enthusiasm for struc-
tural HIV interventions [160], with results eagerly awaited for two other cash transfer trials to
adolescent women in South Africa [488, 489]. For behavioural interventions, Project Accept
(HPTN 043) testing the impact of interventions to increase HIV testing and counselling on HIV
incidence will likely report results before the end of this year [490]. The label on the consen-
sus HIV prevention prescription today remains the same as it did four years ago: combination
prevention—consisting of biomedical, behavioural, and structural interventions [21, 113, 114].
The combination approach to prevention is supported by the work in this thesis. In chapters 5
and 6 we found that while antiretroviral therapy has the potential to dramatically reduce HIV
incidence, they are unlikely to eliminate new infections completely hyperendemic settings such
as South Africa. On the other hand, in chapter 4, we found that decreases in reported sexual
risk behaviour are possible. However, in other generalised epidemic settings where declines in
the burden of HIV have been associated with changes in sexual behaviour, such as Uganda
and Zimbabwe [89, 491], HIV has continued to spread at lower levels, suggesting the need for
alternative prevention strategies. As experience accumulates and new data become available,
the ingredients of evidence-based combination prevention packages continue to change and ap-
propriate dosings remain debated and to be determined. Understanding how independently
efficacious interventions will combine to achieve population effectiveness is a question ideally
suited for mathematical modelling, and mathematical modelling has been central to the devel-
opment and design of three cluster-randomised trials testing different combination prevention
packages [116].
The focus of this thesis on topics in isolation—concurrency, sexual behaviour trends, and HIV
treatment—has allowed us to gain a deeper understanding of individual epidemiological deter-
minants than would be possible from data alone. The capability of models to perturb one aspect
of a system without affecting the other parts, when the real world is rarely so well behaved,
has been particularly important for the development of the concurrency hypothesis, and will
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hopefully also help to disentangle the effectiveness of different component parts of combination
intervention packages. Because of the complex interactions between behavioural and biological
aspects of HIV transmission, the different topics examined in this thesis are inextricably linked.
For example, the slow epidemic growth in the model of concurrency and primary HIV infection
in chapter 2 suggested the need to include additional structural heterogeneity in sexual mixing
when developing a model required to replicate observed epidemic data in chapter 5. At the
same time, we note that the amount of transmission that occurs during primary HIV infec-
tion at endemic equilibrium in the model in chapter 5, where partnerships are instantaneous,
is similar to the upper range for the amount of transmission during primary infection in the
concurrency model in chapter 2, which corresponded to a situation in which concurrency was
created by random partner selection in the population. Intuitively, this makes sense because the
instantaneous contact model represents the limit of when partnership selection is random and
the duration of partnerships goes to zero. We interpret this finding to suggest that the instan-
taneous partnership model is relatively conservative regarding the effect that concurrency and
primary infection interaction might have on treatment as prevention strategies; lower levels of
concurrency created because individuals with a partner are less likely to acquire a new partner
would reduce transmission during primary infection compared to the instantaneous partnership
model. Time trends in sexual risk behaviours estimated in chapter 4 may be compared with the
patterns of sexual behaviour required to replicate the observed HIV prevalence data in chap-
ter 5, in which we found strong evidence that a decline in numbers of new unprotected sexual
contacts is most consistent with the observed epidemic data.
The inclusion of empirically grounded and well calibrated biological and behavioural determi-
nants of the spread of HIV in model developed in chapter 5 make it well suited for consideration
of combination prevention strategies, and this is a logical next step for this work. Moreover,
the Bayesian framework for identifying combinations of parameters that are consistent with
observed data allows us to evaluate uncertainty ranges for outcomes of interest, such as the
impact of an intervention. Having quantified such a range allows us to determine whether new
empirical information, for example the outcome of a trial, falls within our expectation or rejects
our previous understanding which would prompt reconsideration of the model structure and
parameter values. Continuing to expand and improve the ways in which models incorporate
data into their estimates and validating the predictions of models against data will increase
confidence in the reliance on models for public health decision making.
7.1 A way forward for concurrency
Recent empirical research has reinforced the conclusion of the Four Cities study that levels of
concurrency alone are not a straightforward first-order explanation to distinguish different levels
of HIV infection between populations [212, 213, 219, 304]. Nevertheless, the theoretical argu-
ment that concurrency increases the potential spread of HIV and other STIs is strong, and, as
we found in chapter 2, the high levels of HIV infectiousness during primary HIV infection could
enhance the theoretical importance of concurrency [267]. HIV infections in sero-concordant
negative couples [138] and unlinked transmissions from outside partners sero-discordant couple
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Key conclusions for HIV prevention programming
• Biological and behavioural factors, such as primary HIV infection and concurrent sexual
partnerships, interact in complex ways to permit more rapid spread of HIV in southern
Africa (chapter 2). These factors alone do not appear sufficient to explain the speed or
severity of HIV epidemics, suggesting that other heterogeneities in sexual risk behaviours,
HIV infectiousness, and HIV susceptibility also contribute to the epidemics (chapter 2,
chapter 5), but primary infection and concurrency may still be worthwhile targets for
averting new HIV infections. HIV prevention programmes may be more efficient and
effective if heterogeneities can be leveraged by identifying individuals during periods in
which they are at high risk of transmitting or acquiring HIV infection. Mathematical
modelling can be used to help design such strategies.
• There was no evidence of increases in sexual risk behaviour during the period of an-
tiretroviral scale-up from 2005 to 2011 in rural KwaZulu-Natal, South Africa. Trends
suggested protective changes in sexual behaviour including small reductions in concur-
rency and multiple sexual partnerships and large increases in reported condom usage
with regular sexual partners (chapter 4). This finding provides some reassurance that
the positive impacts of HIV treatment and prevention programmes may not be counter-
acted by commensurate increases in other risk behaviours, but continuing surveillance
of sexual behaviour will be essential for understanding the success or failure of future
prevention efforts.
• The amount of HIV transmission that occurs during primary HIV infection depends on
both biological factors and characteristics of the sexual network (chapter 2, chapter 5).
The amount changes over the natural course of the epidemic, and in response to HIV
prevention efforts or other changes in the epidemic context (chapter 5). However, the
specific value of this quantity in a given epidemic setting may be less consequential for
the long-term impact of HIV treatment as prevention strategies than has been presumed
(chapter 5, chapter 6). Measurement of this quantity, interpreted in the context of its
transience illustrated by this modelling, nonetheless may be useful for understanding the
short-term impact of intervention programmes or trials and extrapolating the results of
studies to longer time-horizons.
• There is broad consensus amongst mathematical models that, based on current epidemi-
ological evidence, large expansions in eligibility for and access to antiretroviral therapy
has the potential to dramatically reduce HIV incidence in generalised epidemics, but
ART alone may be unlikely to eliminate HIV in the next 30 years (chapter 6).
• The mathematical model developed in this thesis estimated a relatively small additional
reduction in HIV incidence resulting from immediate ART eligibility compared to ef-
fective implementation of 2010 WHO eligibility guidelines recommending ART for HIV-
infected adults with CD4 count ≤350 cells/µl, especially when modelling interventions
that did not improve retention on HIV treatment (chapter 5). Not all mathematical
models reached the same conclusion on this point though (chapter 6), and this is a key
question to test in upcoming community-randomised HIV prevention trials.
• The current scale-up of antiretroviral therapy in South Africa may have already be
effecting substantial reductions on adult HIV incidence rates, and models agreed that
these reductions would not likely be reflected yet by a decline in adult HIV prevalence
due to the life-prolonging benefits of ART (chapter 5, chapter 6). Going forward, this
underscores the importance of reliably measuring HIV incidence to effectively evaluate
the success of HIV prevention programmes and predicting the course of the epidemic.
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HIV prevention studies [84, 105] are infections that either would not have occurred or would
have been delayed if there had not been concurrency. Taken together, this suggests that con-
currency remains a relevant concept through which to understand and communicate HIV risk
in these generalised epidemics.
Epidemiological and modelling literature has expanded to consider different typologies of con-
currency and concurrency in the context of more complex patterns of sexual network formation
[492, 493]. Simple models of long-term concurrency, such as our model in chapter 2, demon-
strated the theoretical impact of concurrency, but did not create an HIV epidemic that spread
on a realistic time-scale, suggesting that other forms of assortativity and heterogeneity in sex-
ual mixing, which might also interact with factors that increase HIV transmission probabilities
[292], are also required to explain the explosive HIV epidemics in southern Africa. Models that
use mechanistic partnership formation rules to simulate sexual partnerships that match ob-
served patterns of sexual mixing necessarily include some amount of concurrency, even if this is
not the focus of the model development or analysis [197, 198, 201, 202]. Others have developed
novel stochastic and deterministic approaches to parameterising and simulating sexual networks
that allow direct manipulation of multiple network characteristics [194, 290, 494, 495]. In the
context of the multifaceted perspective of sexual mixing and sexual behaviour required to ex-
plain the patterns of HIV spread in southern Africa, the establishment of a consensus indicator
for concurrency provides another metric with which to compare and monitor HIV epidemics for
decades to come [496].
There has been a refocusing in the literature on the most relevant question about concurrency:
what is the role for concurrency in the prevention of HIV [331, 492, 497]? Stylised mathematical
models that conserve other characteristics of sexual behaviour and networks while manipulating
concurrency, such as that considered in chapter 2, have been crucial for understanding the
hypothesis, but are probably less useful for making predictions about the potential impact of
interventions that aim to reduce concurrency [295], which would likely affect a number of other
correlated sexual behaviour indicators [498]. Some sceptics have suggested that campaigns
about the risks associated with concurrency could have unintended epidemiological and social
consequences such as dissolution of stable partnerships just so that new partners can be acquired
in serial monogamy [304, 497]. This seems unlikely to occur in reality. A more relevant question
is whether behaviour change campaigns that use imagery of concurrency and sexual networks to
communicate the risk of having even one or two additional partners and that HIV risk does not
depend solely on one’s own behaviour will be more effective at encouraging protective sexual
behaviours than have previous behaviour change communication strategies [327]. Unfortunately,
evaluation of behaviour change communication strategies based on concurrency programmes has
been limited and none have been rigorously evaluated using biological endpoints. The upcoming
combination prevention trial in Iringa, Tanzania includes behaviour change communication as
a component of the intervention package [116], but it is not yet clear how the impact of that
component will be assessed.
Mathematical models, such as that by Enns and colleagues [296], are useful to investigate
the potential benefits of reductions of sexual risk in different population groups and to advise
what levers to push given different options, but until data about the efficacy of behaviour
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change strategies are available, including media campaigns that use imagery of concurrency
and sexual networks, such models are purely speculative and cannot confidently inform policy.
Mathematical models could play a role in designing and interpreting the complex studies that
will be needed to obtain this information. The spatial study by Tanser and colleagues in the
Africa Centre Demographic Information System did not find that levels concurrency in men
in 2004 affected the risk of HIV incidence in women over the next six years, which has been
interpreted as lack of support for the concurrency hypothesis [304]. However, it was also not
demonstrated that the study, as designed, would have had the power to detect an effect of
concurrency. Given the methodological concerns that were raised in response to the study,
including high levels of migration, possible poor correlations between geographic structure and
sexual network structure, suspected levels of underreporting of concurrency, and non-linearities
of HIV transmission [327–330], would we have expected for the regression analysis to find a
statistically significant effect of concurrency even if it did exist? A mathematical model could
simulate the empirical study design and assess under what conditions with regards to these
factors the study would and would not be powered to detect an effect of concurrency. This
would greatly enhance the interpretation of Tanser and colleagues’ empirical findings and inform
future experimental designs. This is precisely one of the roles that mathematical models are
fulfilling in the design of community-randomise combination HIV prevention trials [116].
7.2 Measurement of sexual behaviour data and its use in
mathematical models
We addressed two major concerns surrounding sexual behaviour surveillance in generalised HIV
epidemics in this thesis: the selection of metrics of sexual behaviour that balance theoreti-
cal importance and feasibility of measurement (chapter 3) and analysis of sexual behaviour
surveillance data in general populations in the context of high levels of non-participation and
non-response (chapter 4). The establishment of a consensus indicator has proved an effective
cornerstone against which to orient further investigations of concurrency and measurement of
sexual behaviour [496], and several researchers using different data sources have investigated
the properties of the indicator and an coordinated way that did not exist previously in the
concurrency literature [264, 303, 319, 320]. Whilst the existence of the consensus indicator
efficiently motivated and focused research on the topic that had been fragmented, in retrospect
it is unfortunate that the subsequent research evaluating the properties of the indicator could
not have been conducted alongside, and used to inform, the stipulation of the indicator. There
were other key questions which it was determined could not be answered with existing data,
and a strength of the consensus building process was the creation of a research agenda around
the indicator, which has influenced specific data collection projects to answer priority questions
about the indicator. This challenge is an example of a common conflict in HIV and public
health research, including modelling questions, in which the need to respond urgently must
be balanced with the potential ability to make more informed decisions were one to wait for
additional data.
The trends in sexual behaviour presented in chapter 4 are interesting their own right. One of
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Key conclusions for mathematical modelling
• As often predicted, concurrency increases the amount of transmission that occurs during
primary HIV infection, and together these dramatically affect the endemic equilibrium.
However, a model that simulates only long-term partner concurrency with staged infec-
tiousness does not create the rapid epidemic growth that has been observed, suggesting
that other forms of heterogeneity in sexual mixing need to be included in models to
create realistic representations of epidemics (chapter 2).
• The amount of HIV transmission during primary HIV infection predicted by a mass-
action model with instantaneous sexual contacts is similar to the upper range of trans-
mission during primary infection predicted by a classical model in which concurrency is
varied from serial monogamy to random partner selection (chapter 2, chapter 5). Other
models of concurrency, for example in which some individuals with a current partner are
more likely to obtain an additional partner, might produce different results.
• A broad array of sexual mixing and sexual behaviour patterns can be consistent with ob-
served HIV epidemic patterns, and these can affect the predicted course of the epidemic
and the impact of interventions (chapter 5). Although an abstract representation of sex-
ual networks in mathematical models make it challenging to relate uncertain parameters
to data, limiting the ability to reduce uncertainties.
• Mathematical models of the impact of ART in southern Africa, answering the same ques-
tion, exhibit some relative agreement in short-term predictions but substantial variation
in longer-term predictions. Because of the many interacting processes, it is difficult to
determine with certainty the main reasons for differences between models. Model un-
certainty is at least as important as parameter uncertainty, and, when possible, multiple
models should be used to address the same policy decisions to determine if they reach
the same high-level conclusions (chapter 6).
the focuses of ‘second generation surveillance’ was the production of trends in risk behaviours
to serve as an early warning for the direction of the epidemic. Our estimates are even more
important when it is considered the other ways in which these sexual behavioural data are
used. Since their establishment, population based cohort studies such as the Africa Centre have
been used for observational studies that exploit the longitudinal nature of the data and other
variation in the population to attempt to suggest causal associations, as the case with the study
on the effect of concurrency on HIV incidence. Sexual behaviour data enter these analyses as a
crucial covariate to control for confounding due to different levels of HIV risk.
However, after two decades of research, experience, and innovation, probably the greatest
obstacle for interpreting sexual behaviour data and using it in mathematical models remains
concerns about systematic biases in reporting [315]. A number of approaches have been demon-
strated to elicit increased reporting of sexual risk behaviour by women in low- and middle-
income countries, including anonymous self-interview [499], long-form in depth interviews using
calendars [500], informal confidential voting interviews [65, 501], ‘best-friend’ reports [502], and
‘randomised response’ in which the respondents are randomly instructed to answer each ques-
tion truthfully or supply a randomly generated answer [501]. Which of these, or combination
of these, is optimal is an open question, and without a ‘gold standard’ against which to com-
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pare sexual behaviour reporting, it is impossible to quantify the amount of bias that remains
when using novel interview methods. Most of these approaches are based on the assumption
that the source of misreporting is social desirability bias, and seek to mitigate this either by
ensuring anonymity and the perception of anonymity to the respondent (informal confidential
voting interviews, audio computer-assisted self-interview, ‘best-friend’, random response), or
by ensuring the respondent feels comfortable and builds a good rapport with the interviewer
(in-depth calendar interview). Using calendars and having a discussion also helps to improve
recall of dates. However, if these reasons are not the only or primary reasons for reporting
bias, these methods may not eliminate bias. For example, respondents may not wish to admit
to themselves their level of risk behaviour or remember unpleasant events or experiences. In
a study attempting to reconcile adolescent HIV prevalence with reported numbers of sexual
partners, Pettifor and colleagues found strong statistical evidence of underreporting of sexual
behaviour and still estimated that the probability of HIV acquisition per sexual partnership for
young women must be nearly 100% [503]. In a study in urban Zimbabwe using a biomarker
testing for PSA protein in vaginal fluid, which indicates recent unprotected sexual activity, only
52% of women testing PSA positive reported unprotected sexual intercourse in the past two
days [504].
These concerns could make one despondent about the prospect of sexual behaviour surveil-
lance, but it should be remembered that measureable changes in reported sexual behaviour
have foretold both declines [89, 90, 332, 333] and increases [335–337, 505] in HIV and STI in-
cidence. This provides some level of validation for the theoretical application of these data,
and measures of sexual risk exposure will remain critical to understanding trends in epidemics
and interpreting the impact of other interventions and changes in epidemiological determinants.
Additional work to improve self-reporting of behaviour will increase the precision and power of
sexual behaviour trends to predict changes in the epidemic sooner. We should also be creative in
supplementing self-reported behavioural data with other correlates or proxies that might be less
precise measures of sexual risk but less susceptible to measurement error, for example volumes
of condom distribution and trends in STIs, pregnancy, and contracepting behaviour.
As HIV surveillance continues to evolve, phylogenetic analyses that reconstruct the sequence
and timings of HIV transmissions in a population will provide another mode of inquiry to di-
rectly address questions about the interaction between behavioural and biological determinants
of transmission. A recurring theme for both concurrency and HIV treatment as prevention is
the amount of HIV transmission that occurs at different stages of HIV infection. To date, all
estimates of this distribution have relied on mathematical models that combine information
about sexual behaviour and biological infectiousness [506], propagating model assumptions and
measurement bias about each of these. Phylogenetic analyses offer an opportunity to estimate
the amount of transmission that comes from primary infection and other stages of HIV infec-
tion more directly [507]. Such analyses may also provide alternative approaches to measuring
characteristics of the sexual networks underlying HIV transmission that have been challeng-
ing to estimate from ego-centric sexual behaviour surveys such as assortativity and clustering
[508, 509]. New biological and genetic surveillance should not be viewed as a panacea or a
replacement for behavioural surveillance. A major limitation of phylogenetic analyses is that
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they only recover the portions of the sexual network where transmissions occurred, lacking the
‘denominator’ information about parts of the sexual network where HIV transmission did not
occur. Nonetheless, an important area of methodological development for statisticians and mod-
ellers in coming years will be the creation of analytical methods and mathematical modelling
that appropriately exploit these data while acknowledging their limitations in order to make
richer epidemiological inferences.
The challenges for using reported sexual behaviour to directly inform mathematical models
are at least three-fold. The first is the suspected reporting bias already described. For sig-
nalling trends in sexual behaviour that may lead to changes in incidence, reporting bias may
be acceptable as long as it does not change too substantially over time [315], but mathemati-
cal models must reconcile these biases and inconsistencies in order to simulate population-level
sexual networks that underlie HIV epidemics. Every modeller of heterosexual HIV epidemics
has lost sleep over how to resolve the classic problem of balancing the number of sexual part-
nerships had by males with the number had by females in light of the substantial discrepancies
in reported number of partnerships between men and women, as exemplified in our findings in
chapter 4.
Second is that traditional epidemiological surveillance collects information about individuals,
but for the transmission of HIV what is most important is who has sex with whom. Instruments
have improved their collection of data about sexual mixing over the years by adding sexual
partner histories that ask specific questions about each partner, but respondents might be
systematically more uncertain regarding information about some partners than others. The
most impressive advance has been the execution of a sexual network census on Likoma Island
in Lake Malawi [325, 326], but analyses still require assumptions about missing individuals and
unreported partnerships [377], with the qualm that partnerships outside of the census could be
of particular epidemiological importance [510].
Finally, it is often not straightforward to relate model parameters to observed sexual behaviour
indicators. Models are necessarily and intentionally abstractions of reality. Classical infectious
disease models like ours in chapter 5 use differential equations that mathematically conflate the
duration, sexual acts, and transmission probability of a sexual contact into a single instant.
Some models have made approximations that match well to aggregate indicators of sexual
behaviour, sexual mixing, and burden of infection, and confidence in these models would be
increased through further investigation of their internal consistency [511, 512]. The models
reviewed in section 2.2 illustrate a number of approaches to more realistic representations of
sexual partnerships, but still are not directly comparable to behavioural data.
The same challenges found with comparing model representations of sexual behaviour to data
apply to comparing sexual behaviour assumptions from one model to another. In chapter 5 we
were able to relate patterns in sexual behaviour and sexual mixing to the impact of an HIV
treatment intervention when varying parameters in an individual model. However, in chapter 6
we were not able to identify determinants of the impact of interventions across models. We
hypothesised that this was because of our inability to compare or even rank models according to
dimensions of sexual behaviour anticipated to be important such as hetergeneity, assortativity,
or even levels of sexual contact, and the trade-offs that have to occur in these parameters
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to create observed epidemics. Developing new methods and metrics for characterising sexual
mixing across models would provide modellers and decision makers using models way in which
to characterise models and could help to inform more considered selection of appropriate models
for specific questions being asked. For example, maybe some models will be ideally suited to
answer short-term estimates but have less credibility for long-term projections, or vice versa.
Devising metrics that are calculable for all models and reflect meaningful differences in sexual
mixing is challenging. Instead, as a first attempt to isolate the effect of sexual behaviour in the
models, we plan to incrementally standardise as many other aspects of the models as possible,
including the natural history of infection, population demography, and the HIV prevalence and
incidence, so that any remaining differences in the impact of an intervention must be due to
the sexual mixing as other differences will have been excluded.
7.3 Using data, modelling, and collaboration to strengthen HIV
policy making
The ultimate goal of epidemiological modelling is to improve our understanding of how infections
spread, and to use this information to inform policy to mitigate the human consequences of
infectious disease. New theories, methods, and knowledge improve our ability to achieve this
goal and are the focus of most academic research, but innovations in the research process also
constitute progress. The global response to HIV and AIDS has pioneered new collaborative
models for conducting and disseminating scientific research, including epidemiological modelling
and analysis. The UNAIDS Reference Group on Estimates, Modelling, and Projections has been
a successful venture for over a decade to advise UNAIDS and the World Health Organization
on methods and data for estimates of the burden of HIV [173].
Successful collaboration with large groups has strengthened much of the work in this thesis.
The process through which the consensus indicator for concurrency was developed in chapter 3
brought together a broad group of researchers, data scientists, and programme implementers
to ensure that a broad set of considerations were balanced in the establishment of a consensus
indicator. The systematic comparison of mathematical models in chapter 6 brought together
the largest group of mathematical modellers to date of which we are aware. Benefits of these
collaborative processes include that they enable more systematic and robust decision making,
they accelerate both scientific advancement and the dissemination of scientific results, and
they encourage trust, open exchange of ideas, and buy-in to the conclusions and policy rec-
ommendations. Work in this thesis that has followed a more traditional research process has
also demonstrated how openness and transparent research paradigm can accelerate scientific
progress and elevate scientific discourse. The publication of computer code alongside the re-
sults of the investigation in chapter 2 [267] allowed the rapid reproduction and extension of
the results by Sawers and colleagues [293] (although the failure to have yet published computer
code for the model in chapter 5 acknowledges practical challenges when faced with the decision
to tidy already completed analyses or move on to the next policy-relevant and time-sensitive
question).
The HIV Modelling Consortium, through which the systematic model comparison in chapter 6
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was conducted, is an innovative new institutional framework that streamlines collaborative
modelling research and communication between scientists and decision makers. This comes at a
time of maturation for mathematical modelling in the public health community. As an example,
for the first time in 2013, the World Health Organization will include mathematical modelling
results in their strategic guidance for the provision of antiretroviral therapy. Those with longer
experience recall times when mathematical modellers were treated with extreme scepticism or
were dismissed outright by the broader medical and public health community [172]. Model
results are still consumed critically, as they should be, but modellers just as often now find
themselves cautioning about the limitations of what can be answered by models. Model results
are not ‘data’ nor can they serve as replacement for data. Rather mathematical models are
powerful tools to enhance the synthesis and interpretation of data, much like statistical models
help us to know how we should change our beliefs when confronted with new information. In
an area where almost all data are candidates for measurement error or systematic bias, whether
it be misreporting of sexual behaviour, incomplete patient records in clinic surveillance, or
selection bias in study populations relied upon to estimate HIV incidence, mathematical models,
sometimes as simple as multiplying two carefully chosen numbers, are crucial for reconciling
and interpreting data. If a model suggests that many data sources point towards the same
qualitative conclusions, confidence in the data and decisions based on them should be increased,
but a model can also suggest reexamination of data, caution in decision making, and generate
new hypotheses when different streams of data are inconsistent. The mathematical modelling
approach in chapter 5, alongside several of the models contributing to chapter 6, represent
another step in the continuing transition in epidemiological modelling from heuristic models
that examine general phenomena to modelling approaches that are able incorporate many data
sources simultaneously and consider the uncertainties in each. This leads to greater precision
about the overall system than would be possible from a single data source and, as we found,
can lead to different conclusions.
Mathematical models are most interesting when they produce unanticipated results, and
they are the most useful when they allow us to explain complicated phenomena in terms of
fundamental theory or more general principles. This was the case of both of the mathematical
models developed in this thesis. In chapter 2 we found that even with high levels of concurrency
the size of the HIV epidemic was greater when infectiousness was constant over the duration of
infection than when it varied according to stage of infection, an initially surprising result, but
we were able to relate this to an analytical result about the relationship between R0 and the
variation in infectivity from almost 20 years ago [178]. In chapter 5, the surprising finding that
the intervention impact was not substantially affected by the level of increased infectiousness
in primary infection is explained by the fundamental relationship between the generation time
and epidemic growth rate [420].
The challenges facing the southern African region due to HIV and the consequences of AIDS
are formidable, and shifts the global power dynamics and global fiscal priorities necessitate
efficiency gains and strategic transitions in the response to HIV and AIDS. But, the creativity,
energy, and coordination of the response, along with recent positive epidemiologic indications
[33, 192], give reasons for optimism about the fourth decade of the epidemic.
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